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ABSTRACT 
The over-expression of C-FABP plays an important role in promoting tumorigenicity of 
prostate cancer. It has been hypothesized that the overexpressed C-FABP may transport an 
excessive amount of intracellular fatty acids into cancer cells to activate their nuclear receptor 
PPARγ to trigger a chain of molecular events that may lead to a facilitated malignant 
progression of the cancer cells. 
To investigate whether PPARγ involved in activities exerted by C-FABP in prostate cancer, 
their expression status was assessed in prostate cell lines and tissues. Results showed that 
their expression levels in malignant cell lines and tissues (cytoplasm and nucleus) were 
significantly higher than those expressed in benign cells and in BPH and it appeared that their 
expression levels were increased as the increasing malignancies of the cell lines and tissues. 
The increased expression of both C-FABP and PPARγ were significantly correlated to a 
reduced survival time. Suppression of PPARγ in highly malignant prostate cancer cells 
produced a significant reduction in growth rate (up to 53%), invasiveness (up to 89%) and 
anchorage-independent growth (up to 94%) in vitro. Suppression of PPARγ in PC3-M cells 
could significantly reduce the sizes of tumours formed in nude mice by 99%. Tumour 
incidence was reduced to 10% and the latent period was significantly increased by 3.5 fold.   
The results in this study also showed that C-FABP promoted VEGF expression and 
angiogenesis by PPARγ (through the stimulation of the fatty acids transported by C-FABP). 
When PPARγ was blocked with its antagonists, cells did not respond to stimulation signal 
produced by fatty acids, even when high level of fatty acids was available. Further study 
showed that the activated PPARγ regulated VEGF expression through acting with the PPREs 
in the promoter region of VEGF in prostate cancer. Although androgen can modulate VEGF 
expression through Sp1/Sp3 binding site on VEGF promoter in androgen-dependent prostate 
cancer cells, this route was disappeared and gradually replcaced by the C-FABP-PPARγ 
route as the cells gradually lost their androgen dependency. 
The results of this study suggested that C-FABP, together with fatty acids, PPARγ and VEGF 
should be considered as key factors in the fatty acids-initiated signalling pathway that 
promoted the malignant progression. Therefore, the C-FABP-PPARγ-VEGF axis may be a 
novel therapeutic target for prostatic cancer.  
Acknowledgments 
 
 
4 
ACKNOWLEDGMENTS 
 
I would like to express my deepest gratitude to Professor Youqiang Ke and Professor 
Christopher Foster, my research supervisors, for providing me the invaluable opportunity to 
undertake the PhD study in this department and for their patient guidance, enthusiastic 
encouragement and useful critiques of this research work. Also I take this opportunity to 
express my profound appreciation and deep regards to my sister, Dr Shiva S. Forootan for her 
exemplary guidance, monitoring and constant encouragement throughout the program of 
PhD. The blessing, help and guidance given by them time to time shall carry me a long way 
in the journey of life on which I am about to embark. 
 
I own a big appreciation to my family and friends for their endless love. I thank my parents 
for giving me the strength to overcome all the difficulties. The hard working spirits and 
intelligence inherited from them made me coming through all the way here. Special thanks 
must go to my beloved wife, Helen and my children, Faraz and Hasti for their love, 
understanding and confidence in me. Appreciation should also give to my sister and her 
family, for all their supports which made my life in Liverpool enjoyable. 
 
Last but not least, I would like to thank all the technical staffs in Molecular Pathology 
department, especially Mrs. Carol Beesley, Mr. Gregor Govan, Mr. Timothy Dickinson, Mrs. 
Patricia Gerald, Mrs. Sharon Forest and Mr. Andrew Dodson. They helped me with their 
experience and insightful feedbacks on the most experimental aspects of this research. 
 
 
Declaration 
 
 
5 
DECLARATION 
 
No portion of the work referred to in the thesis has been submitted in support of an 
application for another degree or qualification of this or other university or other institute of 
learning. 
 
 
 
DECLARATION OF ORIGINALITY 
 
This thesis is a product of my own work which has been carried out during my PhD study in 
the Department of Molecular and Clinical Cancer Medicine (Pathology), University of 
Liverpool, between September 2011 and January 2014. All the experiments presented in the 
result chapter were performed by me under the supervision of my supervisor, Professor 
Youqiang Ke and Dr Shiva S. Forootan, senior research associate in molecular Pathology 
department. The thesis was written by me with their guidance. 
 
 
 
 
 
 
 
 
Publications 
 
 
6 
Publications 
 Farzad S. Forootan, Shiva S. Forootan, Mohamad I. Malki, Danqing Chen, Gandi 
Li, Ke Lin, Philip S. Rudland, Christopher S. Foster and Youqiang Ke. The expression of 
C-FABP and PPARγ and their prognostic significance in prostate cancer, International 
Journal of Oncology, 44: 265-275, 2014. 
 
 Farzad S. Forootan, Shiva S. Forootan, Syed A Hussain, Youqiang Ke. Inter-action 
of C-FABP and PPARs in prostate cancer. 23rd Biennial Congress of the European 
Association for Cancer Research (EACR), Munich, Germany, 5-8 July 2014 and North 
West Cancer Research (NWCR) annual meeting, March 24st 2014, Liverpool, UK (Poster 
presentation). 
 
 Farzad S. Forootan, Shiva S. Forootan, Ke Lin, Christopher S Foster, Youqiang Ke. 
Evaluation the expression of C-FABP and PPARs in Prostate cancer, North West Cancer 
Research (NWCR) annual meeting, May 21st 2013, Liverpool, UK and NCRI 
conference, 3-6 Nov. 2013, Liverpool, UK (Poster presentation). 
 
 Danqing Chen, Shiva S. Forootan, John R. Gosney, Farzad S. Forootan and 
Youqiang Ke. Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing 
angiogenesis and suppressing apoptosis in small cell lung cancer, Genes & Cancer, 
published on July 6, 2014. 
 
 Zhengzheng Bao, Mohammad I. Malki, Shiva S. Forootan, Janet Adamson, Farzad S. 
Forootan, Danqing Chen, Christopher S. Foster, Philip S. Rudland and Youqiang Ke. 
Binding Protein-Related Signalling Pathway Leading to Malignant -A Novel Cutaneous 
Fatty Acid Progression in Prostate Cancer Cells, Genes & Cancer, published on 
September 18, 2013 as doi: 10.1177/1947601913499155. 
 
 S.S. Forootan, Z.Z. Bao, F. S. Forootan, L. Kamalian, Y. Zhang, C. Foster, A. Bee, 
Y. Ke. Atelocollagen-delivered small interference RNA targeting C-FABP gene as 
experimental prostate cancer therapeutics in nude mice, International Journal of 
Oncology, 36:69-76, 2010. 
Table of Contents 
 
 
7 
Table of Contents 
ABSTRACT ............................................................................................................................... 3 
ACKNOWLEDGMENTS ......................................................................................................... 4 
DECLARATION ....................................................................................................................... 5 
Publications ................................................................................................................................ 6 
Table of Contents ....................................................................................................................... 7 
List of Figures .......................................................................................................................... 14 
List of Tables ........................................................................................................................... 17 
List of Abbreviations ............................................................................................................... 18 
1 Introduction ...................................................................................................................... 22 
1.1 Epidemiology of prostate cancer ............................................................................... 22 
1.1.1 Cancer epidemiology ......................................................................................... 22 
1.1.2 Prostate cancer epidemiology ............................................................................ 24 
1.1.2.1 Incidence ........................................................................................................ 24 
1.1.2.1.1 By age of diagnosis................................................................................... 25 
1.1.2.1.2 Trends by the time .................................................................................... 26 
1.1.2.1.3 Life time risk ............................................................................................ 27 
1.1.2.1.4 Geographic variation worldwide .............................................................. 27 
1.1.2.1.5 Socio-economic factors ............................................................................ 27 
1.1.2.2 Mortality ......................................................................................................... 28 
1.1.2.2.1 Age of death .............................................................................................. 29 
1.1.2.2.2 Trend over time ........................................................................................ 29 
1.1.2.2.3 Geographic variation worldwide .............................................................. 29 
1.1.2.3 Survival .......................................................................................................... 31 
1.1.2.4 Risk factors ..................................................................................................... 33 
1.1.2.4.1 Family history ........................................................................................... 33 
1.1.2.4.2 Ethnicity.................................................................................................... 33 
1.1.2.4.3 Other cancers ............................................................................................ 33 
1.1.2.4.4 Radiation ................................................................................................... 34 
1.1.2.4.5 Insulin-like growth factor-1 ...................................................................... 34 
1.1.2.4.6 Factors associated with lower prostate cancer risk ................................... 34 
1.2 Pathology of prostate cancer ..................................................................................... 35 
1.2.1 Prostate anatomy ................................................................................................ 35 
1.2.2 Normal prostate cells ......................................................................................... 36 
Table of Contents 
 
 
8 
1.2.3 Prostate cancer ................................................................................................... 38 
1.2.3.1 Benign prostatic hyperplasia (BPH) ............................................................... 38 
1.2.3.2 Prostatic Intraepithelial Neoplasia (PIN) ....................................................... 38 
1.2.3.3 Prostate cancer grading by Gleason scores .................................................... 39 
1.2.4 Prostate cancer cell lines .................................................................................... 40 
1.2.4.1 PNT2 .............................................................................................................. 40 
1.2.4.2 LNCaP ............................................................................................................ 41 
1.2.4.3 22RV1 ............................................................................................................ 41 
1.2.4.4 DU145 ............................................................................................................ 41 
1.2.4.5 PC3 & PC3-M ................................................................................................ 42 
1.2.5 Biomarkers and Oncogenes in prostate cancer .................................................. 42 
1.2.5.1 Prostatic Acid Phosphatase and Prostatic Specific Antigen ........................... 42 
1.2.5.2 Over-detection and over-treatment of prostate cancer ................................... 44 
1.2.5.3 Potential biomarkers ....................................................................................... 45 
1.2.5.3.1 BRCA1/2 gene mutation ........................................................................... 46 
1.2.5.3.2 Prostate cancer antigen 3 .......................................................................... 46 
1.2.5.3.3 TMPRSS2-ERG gene fusion ..................................................................... 47 
1.2.5.3.4 Early prostate cancer antigen 2 (EPCA2) ................................................. 47 
1.2.5.3.5 Interleukin-6 (IL-6) ................................................................................... 47 
1.2.5.3.6 S100 Protein family (Calcium-binding protein family) ........................... 48 
1.2.5.3.7 Transforming growth factor β1 (TGF β1) ................................................ 49 
1.2.5.3.8 Prostate Stem Cell Antigen (PSCA) ......................................................... 49 
1.2.5.3.9 Cutaneous fatty acid binding protein (C-FABP) ...................................... 49 
1.2.5.3.9.1 C-FABP and prostate cancer .............................................................. 51 
1.2.5.3.10 Peroxisome proliferator activated receptors (PPARs) ............................ 52 
1.2.5.3.10.1 Intracellular PPARs regulatory pathway .......................................... 53 
1.2.5.3.10.2 PPARs and cancer ............................................................................ 54 
1.2.5.3.11 Vascular endothelial growth factor (VEGF) ........................................... 56 
1.2.5.3.11.1 VEGF and prostate cancer ................................................................ 57 
1.2.5.3.11.2 PPARs and angiogenesis .................................................................. 58 
1.3 Aims and scope ......................................................................................................... 59 
1.3.1 Research Plan ..................................................................................................... 60 
2 Materials and Methods ..................................................................................................... 62 
2.1 Materials .................................................................................................................... 62 
Table of Contents 
 
 
9 
2.2 Methodology ............................................................................................................. 62 
2.2.1 Cell culture ......................................................................................................... 62 
2.2.1.1 Routine cell culture ........................................................................................ 62 
2.2.1.2 Cell counts ...................................................................................................... 62 
2.2.1.3 Cryopreservation/Cell Freezing ..................................................................... 63 
2.2.1.4 Cell Thawing .................................................................................................. 63 
2.2.2 Culturing of transfected cells ............................................................................. 63 
2.2.3 Evaluating protein expressions in cell lines ....................................................... 63 
2.2.3.1 Protein extraction from cultured cells ............................................................ 64 
2.2.3.2 Bradford assay ................................................................................................ 64 
2.2.3.3 Western Blotting ............................................................................................ 64 
2.2.3.3.1 Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis (SDS-
PAGE)……… ........................................................................................................... 64 
2.2.3.3.2 Transfer proteins from SDS gel to PVDF membrane ............................... 65 
2.2.3.3.3 Immunoblotting to detect protein expression ........................................... 65 
2.2.3.3.4 Correcting loading variations ................................................................... 66 
2.2.4 Evaluating protein expression in tissues ............................................................ 67 
2.2.4.1 Human tissue samples .................................................................................... 67 
2.2.4.2 Preparing tissue sections ................................................................................ 68 
2.2.4.3 Immunohistochemistry ................................................................................... 68 
2.2.4.4 Controls for immunohistochemistry............................................................... 70 
2.2.4.5 IHC scoring .................................................................................................... 70 
2.2.5 Evaluating RNA expressions in cell lines .......................................................... 70 
2.2.5.1 Total RNA isolation ....................................................................................... 70 
2.2.5.2 Reverse transcriptional polymerase chain reaction (RT-PCR) ...................... 71 
2.2.5.2.1 PCR primer design.................................................................................... 71 
2.2.5.2.2 Complementary DNA (cDNA) synthesis ................................................. 72 
2.2.5.2.3 RT-PCR .................................................................................................... 73 
2.2.6 Molecular biology .............................................................................................. 73 
2.2.6.1 Small interfering RNA ................................................................................... 73 
2.2.6.2 Designing siRNA sequences .......................................................................... 74 
2.2.6.3 Transient transfection ..................................................................................... 75 
2.2.6.4 Designing short hairpin RNA (shRNA) sequences ........................................ 75 
2.2.6.5 Cloning silencing sequences into vector ........................................................ 76 
Table of Contents 
 
 
10 
2.2.6.5.1 Vector selection ........................................................................................ 76 
2.2.6.5.2 Annealing sense and anti-sense oligos ..................................................... 77 
2.2.6.5.3 Competent cell preparation ....................................................................... 78 
2.2.6.5.4 Double digestion of plasmid DNA ........................................................... 79 
2.2.6.5.5 Ligation of shRNA insert into psiRNA .................................................... 80 
2.2.6.5.6 Transformation ......................................................................................... 80 
2.2.6.5.6.1 Transformation efficiency .................................................................. 81 
2.2.6.5.7 Plasmid DNA preparation ........................................................................ 81 
2.2.6.5.7.1 Miniprep DNA extraction .................................................................. 82 
2.2.6.5.7.2 Midiprep DNA extraction .................................................................. 82 
2.2.6.5.7.3 Agarose gel analysis ........................................................................... 83 
2.2.6.5.7.4 Sequencing analysis ........................................................................... 83 
2.2.6.6 Stable transfection .......................................................................................... 84 
2.2.6.6.1 Ring cloning of transfected cells .............................................................. 84 
2.2.7 In vitro assays .................................................................................................... 85 
2.2.7.1 Proliferation assay .......................................................................................... 85 
2.2.7.1.1 Growth curve preparation ......................................................................... 85 
2.2.7.1.2 Cell number determination by MTT assay ............................................... 86 
2.2.7.2 Invasion assay ................................................................................................ 86 
2.2.7.3 Soft agar assay ................................................................................................ 88 
2.2.7.4 Angiogenesis assays ....................................................................................... 89 
2.2.7.4.1 Enzyme-linked immunosorbent assay for evaluating VEGF ................... 90 
2.2.7.4.1.1 Standard curve preparation ................................................................ 90 
2.2.7.4.1.2 Human VEGF ELISA ........................................................................ 91 
2.2.7.4.2 In vitro angiogenesis assay ....................................................................... 92 
2.2.7.4.2.1 Preparation of ECMatrix coated plate ................................................ 92 
2.2.7.4.2.2 Angiogenesis assay ............................................................................ 92 
2.2.7.4.2.3 Quantitation of tube formation ........................................................... 93 
2.2.7.5 Dual-Luciferase
®
Reporter (DLR
TM
) Assay ................................................... 93 
2.2.7.5.1 Luciferase Reporter Vector (pGL3-Promoter Vector) ............................. 94 
2.2.7.5.2 Reporter constructs ................................................................................... 95 
2.2.7.5.3 Cell culture and transfection ..................................................................... 96 
2.2.7.5.4 DLR
TM
 Assay Protocol ............................................................................. 96 
2.2.8 In vivo tumorigenicity assay .............................................................................. 97 
Table of Contents 
 
 
11 
2.2.8.1 Mice and cell lines.......................................................................................... 97 
2.2.8.2 Mice inoculation ............................................................................................. 98 
2.2.8.3 Processing of primary tumour tissues ............................................................ 98 
2.2.8.4 Immunohistochemistry ................................................................................... 98 
2.2.9 Statistical analysis .............................................................................................. 99 
2.2.9.1 Two-sided Fisher’s exact test & Chi-square (χ2) ........................................... 99 
2.2.9.2 Survival analysis ............................................................................................ 99 
2.2.9.2.1 Kaplan-Meier curve .................................................................................. 99 
2.2.9.2.2 Cox regression test.................................................................................... 99 
2.2.9.2.3 Log Rank test .......................................................................................... 100 
2.2.9.3 Mann-Whitney U test ................................................................................... 100 
2.2.9.4 Student’s t-test .............................................................................................. 100 
3 Results ............................................................................................................................ 102 
3.1 Expression of PPARβ/δ, PPARγ and C-FABP at protein level in prostate cell 
lines………… .................................................................................................................... 102 
3.1.1 Expression of PPARβ/δ protein ....................................................................... 102 
3.1.2 Expression of PPARγ protein .......................................................................... 102 
3.1.3 Expression of C-FABP protein ........................................................................ 102 
3.2 Expressions of PPARβ/δ and PPARγ at mRNA levels in prostate cell lines .......... 104 
3.3 Expression of PPARβ/δ, PPARγ and C-FABP in prostate tissues .......................... 105 
3.4 Correlations between PPARβ/δ, PPARγ and C-FABP ........................................... 109 
3.5 Correlation with Gleason score ............................................................................... 109 
3.5.1 Correlation of PPARβ/δ and Gleason score ..................................................... 109 
3.5.2 Correlation of PPARγ and Gleason score ........................................................ 109 
3.5.3 Correlation of C-FABP and Gleason score ...................................................... 110 
3.6 Correlations with patient survival ........................................................................... 110 
3.6.1 PPARβ/δ expression and patient survival ........................................................ 110 
3.6.2 PPARγ expression and patient survival ........................................................... 111 
3.6.3 C-FABP expression and patient survival ......................................................... 111 
3.6.4 Gleason scores and patient survival ................................................................. 114 
3.6.5 Androgen receptor and patient survival ........................................................... 114 
3.6.6 Prostatic specific antigen and patient survival ................................................. 114 
3.6.7 Inter-relationship of C-FABP and PPARγ in predicting patient survival ........ 116 
3.7 Correlations between PPARβ/δ, PPARγ and PSA level and AR index .................. 119 
Table of Contents 
 
 
12 
3.7.1 Correlation of PPARβ/δ and PSA level ........................................................... 119 
3.7.2 Correlation of PPARγ and PSA level .............................................................. 119 
3.7.3 Correlation of PPARβ/δ and AR index ............................................................ 121 
3.7.4 Correlation of PPARγ and AR index ............................................................... 121 
3.8 Suppression of PPARγ expressions by siRNA ....................................................... 124 
3.8.1 Selection of most efficient siRNA for PPARγ suppression ............................. 124 
3.9 Establishment of stably PPARγ-suppressed PC3-M cell lines................................ 127 
3.9.1 Stable transfection ............................................................................................ 130 
3.10 Effect of PPARγ suppression on tumour cells in vitro ............................................ 132 
3.10.1 Effect of PPARγ suppression on cellular proliferation .................................... 132 
3.10.2 Effect of PPARγ suppression on invasiveness of prostate cancer cell ............ 135 
3.10.3 Effect of PPARγ suppression on anchorage-independent growth of prostate 
cancer cells ..................................................................................................................... 137 
3.11 Effect of PPARγ suppression on tumorigenicity of prostate cancer cells in vivo ... 139 
3.12 Interaction of C-FABP and PPARγ and its effects on regulation of ....................... 144 
3.12.1 C-FABP and PPARγ up-regulated VEGF expression ..................................... 146 
3.12.2 Suppression of C-FABP or PPARγ down-regulated VEGF expression .......... 152 
3.12.3 Suppression of PPARγ neutralized up-regulatory effect of C-FABP on                                                                                                                                                                                              
VEGF expression ............................................................................................................ 154 
3.12.4 Effects of C-FABP and PPARγ on VEGF activity through PPREs ................. 156 
3.12.4.1 PPARγ regulated VEGF-promoter activity ............................................... 159 
3.12.4.2 C-FABP regulated VEGF-promoter activity ............................................ 161 
3.12.4.3 Combined effects of C-FABP and PPARγ on VEGF-promoter activity ... 163 
3.12.5 Effects of Sp1 (Androgen binding site) on VEGF-promoter activity .............. 165 
3.12.5.1 Combined effects of Sp1 and PPARγ on VEGF-promoter activity........... 167 
4 Discussion ....................................................................................................................... 170 
4.1 C-FABP and PPARγ were overexpressed in prostate cancer cells and tissues ....... 171 
4.2 Increased expression levels of C-FABP and PPARγ were associated with poor   
patient survival ................................................................................................................... 172 
4.3 Suppression of PPARγ reduced the tumorigenicity of prostate cancer cells ........... 173 
4.4 C-FABP promoted biological activity of VEGF through PPARγ in ...................... 175 
4.5 C-FABP-PPARγ up-regulated VEGF expression in prostate cancer cells via acting 
with the PPREs in the promoter region of VEGF gene ..................................................... 178 
4.6 Androgen regulated VEGF activity in androgen-dependant prostate cancer cells .. 183 
Table of Contents 
 
 
13 
4.7 Conclusion ............................................................................................................... 188 
5 References ...................................................................................................................... 191 
6 APPENDIXES ................................................................................................................ 208 
6.1 APPENDIX A: REAGENTS .................................................................................. 209 
6.1.1 Reagents for cell culture .................................................................................. 209 
6.1.2 Reagents for Western blot ................................................................................ 209 
6.1.3 Reagents for Immunohistochemistry ............................................................... 210 
6.1.4 Reagents for RT-PCR ...................................................................................... 210 
6.1.5 Reagents for general molecular biology .......................................................... 211 
6.1.6 Reagents for cell proliferation assay ................................................................ 212 
6.1.7 Reagents for cell invasion assay ...................................................................... 212 
6.1.8 Reagents for soft agar assay ............................................................................. 212 
6.1.9 Reagents for measurement of VEGF ............................................................... 212 
6.1.10 Reagents for in vitro angiogenesis assay ......................................................... 212 
6.1.11 Reagents for dual luciferase reporter assay ..................................................... 212 
6.2 APPENDIX B: BUFFERS ...................................................................................... 213 
6.2.1 Cell Culture ...................................................................................................... 213 
6.2.2 Western Blot .................................................................................................... 214 
6.2.3 Immunohistochemistry .................................................................................... 216 
6.2.4 Molecular Biology ........................................................................................... 217 
6.3 APPENDIX C: EQUIPMENTS .............................................................................. 220 
6.4 APPENDIX D: LUCIFERASE CONSTRUCTS SEQUENCES ............................ 224 
        
 
 
List of Figures 
 
 
14 
List of Figures 
Chapter 1 
Figure 1.1: Cancer incidence, UK, 2011 . ................................................................................ 22 
Figure 1.2: Average numbers of new cases for all cancers (excluding non-melanoma skin 
cancer) per year and age-specific incidence rate, UK, 2009-2011 . ........................................ 23 
Figure 1.3: All cancers (excluding non-melanoma skin cancer), European Age Standardised 
Incidence Rates, Great Britain, 1975-2011 . ............................................................................ 23 
Figure 1.4: Ten most common cancers among men (excluding non-melanoma skin cancer) in 
the UK, 2010 . .......................................................................................................................... 24 
Figure 1.5: Prostate cancer, average number of cases per age of diagnosis, UK, 2008-10 . ... 25 
Figure 1.6: Prostate cancer, European age related incidence rates, males, Great Britain, 1975-
2010.......................................................................................................................................... 26 
Figure 1.7: Prostate Cancer (C61), World Age-Standardised Incidence Rates, World ........... 28 
Figure 1.8: Prostate cancer mortality rate in age-specific groups, UK, 2010 . ........................ 30 
Figure 1.9: Prostate cancer mortality rate, UK, 1970-2010. .................................................... 30 
Figure 1.10: Prostate cancer mortality rate worldwide, 2011 . ................................................ 31 
Figure 1.11: Prostate cancer relative survival rates, England and Wales 1971-1995, England 
1996-2009 . .............................................................................................................................. 32 
Figure 1.12: Schematic illustration of Prostate gland zones . .................................................. 35 
Figure 1.13: Schematic illustration of cells in human prostate epithelium ............................. 37 
Figure 1.14: Schematic diagram of Gleason grading system . ................................................ 40 
Figure 1.15:  Putative intracellular functions of FABP. .......................................................... 51 
 
Chapter 2 
Figure 2.1: psiRNA-h7SK-GFPzeo vector map. ..................................................................... 76 
Figure 2.2: Invasion assay; performed in chambers with 8µm pore size which coated with 
Matrigel matrix. ....................................................................................................................... 88 
Figure 2.3: Serial dilutions for VEGF ELISA standard curve. ................................................ 91 
Figure 2.4: pGL3-Promoter Vector circle map. ....................................................................... 95 
 
Chapter 3 
Figure 3.1: Measurement of levels of C-FABP and its possible nuclear receptors (PPARβ/δ 
and PPARγ) in prostate cell lines........................................................................................... 103 
List of Figures 
 
 
15 
Figure 3.2: Detection of PPARβ/δ, PPARγ and β-actin mRNA in prostate cell lines. ........... 104 
Figure 3.3: Immunohistochemical staining of BPH and prostatic carcinoma tissues with 
antibodies against PPARβ/δ, PPARγ, and C-FABP. ............................................................. 107 
Figure 3.4: Kaplan-Meier survival curves of prostate cancer patients with different levels of 
staining for PPARβ/δ and PPARγ. ......................................................................................... 112 
Figure 3.5: Kaplan-Meier survival curves of prostate cancer patients with different levels of 
staining for C-FABP. ............................................................................................................. 113 
Figure 3.6: Kaplan-Meier survival curves of patients with prostatic cancer with different 
Gleason scores, AR indices and PSA levels. ......................................................................... 115 
Figure 3.7: Kaplan-Meier survival curves of patients with prostatic cancer with Different 
levels of joint staining for PPARγ and for C-FABP. ............................................................. 117 
Figure 3.8: Box plot analysis of correlation between different levels of PSA with cytoplasmic 
and nuclear PPARβ/δ and PPARγ staining. ........................................................................... 120 
Figure 3.9: Box plot analysis of correlation between different AR indexes with cytoplasmic 
and nuclear PPARβ/δ staining. ............................................................................................... 122 
Figure 3.10: Box plot analysis of correlation between different AR indexes with cytoplasmic 
and nuclear PPARγ staining. .................................................................................................. 123 
Figure 3.11: Expression levels of PPARγ in PC3-M cells after transient transfection with 
different siRNAs. ................................................................................................................... 125 
Figure 3.12: PC3-M cells, after transient transfection with different siRNAs. ..................... 126 
Figure 3.13: Digestion of psiRNA-h7SKGFPzeo plasmid. ................................................... 127 
Figure 3.14: Confirmation of the correct DNA insertion. ..................................................... 128 
Figure 3.15: Effect of shRNA on levels of PPARγ expression in PC3-M-derived 
transfectants. .......................................................................................................................... 131 
Figure 3.16: Standard curves of parental PC3-M and different transfected cell lines. .......... 132 
Figure 3.17: The impact of PPARγ silencing on the proliferation rate of transfectant cells.. 134 
Figure 3.18: The impact of PPARγ silencing on invasiveness of transfectants. .................... 136 
Figure 3.19: The impact of PPARγ silencing on the anchorage-independent growth of 
tranfectant cells. ..................................................................................................................... 138 
Figure 3.20: Average tumour volume of each test group. ..................................................... 142 
Figure 3.21: Representative mice and corresponding tumour mass of each test group. ........ 143 
Figure 3.22: Levels of C-FABP and PPARγ in PC3-M and 22RV1 cells. ............................ 145 
Figure 3.23: Levels of VEGF protein in 22RV1 cells exposed to different treatments. ........ 148 
List of Figures 
 
 
16 
Figure 3.24: Levels of secreted VEGF in conditional media of 22RV1 cells exposed to 
different treatments. ............................................................................................................... 149 
Figure 3.25: HUVEC cells network formation on ECMatrix, exposed to conditional media of 
22RV1 cells with different treatments. .................................................................................. 150 
Figure 3.26: Relative values of HUVEC cells network formation under 22RV1 cells’ 
conditional media exposed to different treatments. ............................................................... 151 
Figure 3.27: Luciferase activity in different prostate cancer cell lines transfected with 
different luciferase reporter gene constructs. ......................................................................... 158 
Figure 3.28: Effects of PPARγ on VEGF-promoter activity in prostate cancer cells. ............ 160 
Figure 3.29: Effects of C-FABP on VEGF-promoter activity in prostate cancer cells. ......... 162 
Figure 3.30: Combined effects of C-FABP and PPARγ on VEGF-promoter activity in prostate 
cancer cells. ............................................................................................................................ 164 
Figure 3.31: Effects of Sp1 binding site on VEGF-promoter activity in prostate cancer cells.
................................................................................................................................................ 166 
Figure 3.32: Combined effects of Sp1 binding site and PPARγ on VEGF-promoter activity in 
prostate cancer cells.. ............................................................................................................. 168 
 
Chapter 4 
Figure 4.1: Schematic illustration of “C-FABP (fatty acids)-PPARγ-VEGF” axis. .............. 182 
Figure 4.2: Schematic illustration of inter-relationship between androgen-Sp1/Sp3 and C-
FABP (fatty acids)-PPARγ signalling route in up-regulating VEGF in androgen-dependant 
and androgen-independent prostate cancer cells.................................................................... 186 
 
 
 
 
 
 
 
 
List of Tables 
 
 
17 
List of Tables 
Chapter 1 
Table 1.1: Prostate Cancer (C61), number of new cases, Crude and European Age-
Standardised (AS) Incidence Rates per 100,000 people, UK, 2011. ....................................... 25 
Table 1.2: Prostate cancer mortality rate, UK, 2011. ............................................................... 29 
Table 1.3: Prostate cancer one, five and ten year survival rates in England 2005-2009 and 
Wales 2007 .............................................................................................................................. 32 
Chapter 2 
Table 2.1: Primary and secondary antibodies used for Western blotting. ............................... 67 
Table 2.2: Primary antibodies used for immunohistochemical staining. ................................. 69 
Table 2.3: RT-PCR primer’s sequences. .................................................................................. 72 
Table 2.4: PCR Mixture. .......................................................................................................... 73 
Table 2.5: PPARγ target and siRNA sequences. ..................................................................... 74 
Table 2.6: PPARγ and negative control shRNA sequences. .................................................... 76 
Table 2.7:  Annealing reaction. ................................................................................................ 78 
Table 2.8: Double digestion reaction. ...................................................................................... 79 
Table 2.9: Ligation reaction. .................................................................................................... 80 
Table 2.10: Numerical values for degree of angiogenesis progression. .................................. 93 
Chapter 3 
Table 3.1: Cytoplasmic and nuclear expression of different PPARs and C-FABP in benign and 
malignant human prostate tissues. ......................................................................................... 108 
Table 3.2: Multiple Cox regression test between levels of C-FABP and PPARs with patients’ 
survival. .................................................................................................................................. 118 
Table 3.3: A part of psiRNA-h7SKGFPzeo plasmid sequence map. .................................... 129 
Table 3.4: Cell counts of parental and transfected PC3-M cells at the 5
th
 day of proliferation 
assay. Using Student’s t-test, p values were obtained by comparing data from test groups to 
parental group. ....................................................................................................................... 133 
Table 3.5: Number of invaded cells per field in invasion assay. ........................................... 135 
Table 3.6: Colony counts of transfected cells at 4
th
 week of soft agar assay. ........................ 137 
Table 3.7: Incidence, latent period and weight of tumours developed by parental and 
transfectant cells in nude mice. .............................................................................................. 141 
Table 3.8: Nuclear expression of PPARγ in different primary tumours resected from nude 
mice. ....................................................................................................................................... 141
List of Abbreviations 
 
 
18 
List of Abbreviations 
Abbreviation                       Full name 
………………………………………………………………………………………….. 
AICR American Institute for Cancer Research 
APC Adenomatous Polyposis Coli 
AR Androgen Receptor 
BCL gene                                    B-cell lymphoma–leukemia gene 
BPH Benign Prostatic Hyperplasia 
BRCA   BReast Cancer 
BSA Bovine Serum Albumin 
cDNA Complementary DNA 
CFU    Colony Forming Unit 
CK Cytokeratin 
C-FABP Cutaneous fatty acid binding protein    
CRPC Castration resistant prostate cancer 
DHT 5-alpha-Dihydrotestostron 
DLR assay Dual-Luciferase
®
Reporter Assay 
DMSO Dimethyl sulfoxide  
DR Direct Repeat 
DRE Digital Rectal Examination 
E coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
E-FABP Epidemic-FABP 
EL Expression Level 
ELISA Enzyme-Linked Immunosorbent Assay 
ENOS Endothelial Nitric Oxide Synthase     
EPCA Early Prostate Cancer Antigen 
ER Esterogen Receptor 
ERSPC European Randomized Study of Screening for Prostate Cancer 
FASN Fatty Acid Synthase 
FAT Fatty Acid Translocase 
FATP  Fatty Acid Transport Protein 
FGF Fibroblast Growth Factor 
List of Abbreviations 
 
 
19 
Abbreviation                       Full name 
…………………………………………………………………………………………………..  
GS Gleason scores 
HIF Hypoxia Inducible Factor 
HK Human glandular Kallikrein 
HUVEC Human Umbilical Vein Endothelial Cells 
IGF Insulin-like Growth Factor 
IHC Immunohistochemistry 
IL Interleukin 
IMS Industrial Methylated Spirits 
kDa    kilo Dalton 
K-FABP Keratinocyte-FABP 
LAR II  Luciferase Assay Reagent II 
LB medium Lysogeny broth medium 
L-FABP Liver Cytosolic Fatty Acid-Binding Protein 
LUTS Lower Urinary Tract Symptoms 
mRNA Messenger RNA 
MTT   3-(4, 5-dimethylthiazl-2-yl)-2, 5-diphenylterazolium bromide 
MVD Micro Vessel Density      
NF-KappaB Nuclear Factor-KappaB 
NSCLC Non-small cell lung cancer 
OD Optical density 
PA-FABP Psoriasis Associated-FABP 
PAGE Poly Acrylamide Gel Electrophoresis 
PAP Prostatic Acid Phosphatase 
PCA Prostate Cancer Antigen 
PI-3K Phosphatidylinositol-3 Kinase 
PIN Prostatic Intraepithelial Neoplasia 
PKB Protein Kinase-B 
PlGF Placental Growth Factor 
PPAR Peroxisome proliferator-activated receptors 
PPRE Peroxisome Proliferator Response Elements 
PSA Prostate-Specific Antigen 
PSCA Prostate Stem Cell Antigen 
PVDF PolyVinylidene DiFluoride 
List of Abbreviations 
 
 
20 
Abbreviation                        Full name 
…………………………………………………………………………………………………..  
PZ Peripheral Zone 
RM Routine Medium 
RNAi    RNA interference 
RSM Routine Selective Medium 
RT-PCR Reverse transcriptional polymerase chain reaction 
RXR Retinoic X Receptor 
SDS Sodium Dodecyl Sulphate 
SE Standard error 
shRNA short hairpin RNA 
siRNA small interfering RNA                         
SLB Sample Loading Buffer 
SOB medium Super Optimal Broth  
SOC medium Super Optimal broth with Catabolic repressor 
Sp Specificity protein 
SPSS Statistical Package for Social Sciences 
STAT1 Signal Transducer and Activator of Transcription-1 
SV Simian virus 
TAE buffer Tris-Acetate EDTA buffer 
TBE buffer Tris-Borate-EDTA buffer 
TBS-T   Tris Base Salt-Tween 
TCF-4 T-Cell Factor-4 
TGF β1 Transforming growth factor β1 
tPSA total PSA 
TURP Trans Urethral Resection of Prostate 
TZ Transitional Zone 
UCP   Uncoupling Proteins   
VEGF Vascular endothelial growth factor 
VSMC Vascular Smooth Muscle Cell 
WCRF World Cancer Research Fund 
WHO World Health Organization 
χ2 test Chi square test 
Chapter 1: Introduction 
 
 
21 
 
 
 
 
 
CHAPTER ONE: 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 
 
22 
1 Introduction 
1.1 Epidemiology of prostate cancer  
1.1.1 Cancer epidemiology 
In the UK, it was estimated that one in three people develop cancer in their lifetime, and it is 
predicted to rise by more than 3% each year 
1
. In 2011, 331,487 new malignant cases 
(excluding non-melanoma skin cancer) were diagnosed in the UK; 164,000 cases in females 
and 167,487 cases in males. Breast, lung, colorectal and prostate cancer account more than 
half (54%) of all new cases 
2-5
 (Fig. 1.1). Cancer is primarily an old people’s disease and risk 
of cancer generally increases with age. About 63% of cancers are diagnosed in people with 
the age of 65 and over and more than 36% are diagnosed in elderly (aged 75 and over) 
2-5
 
(Fig. 1.2). The European Age Standardised Incidence Rates for all cancers in the Great 
Britain shows an increase by 22% in males from 1975 to 2011 (from 351.8 to 429.8 per 
100,000 people) and by 42% in females with an entire rise before the late 1990s (from 263.3 
to 375.1 per 100,000) 
2-4
 (Fig. 1.3). 
                                         
                                         
Figure  1.1: Cancer incidence, UK, 2011 6. 
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Figure  1.2: Average numbers of new cases for all cancers (excluding non-melanoma skin cancer) 
per year and age-specific incidence rate, UK, 2009-2011 
7
. 
 
 
 
Figure  1.3: All cancers (excluding non-melanoma skin cancer), European Age Standardised 
Incidence Rates, Great Britain, 1975-2011 
8
. 
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1.1.2 Prostate cancer epidemiology 
1.1.2.1 Incidence 
Prostate cancer is the most common cancer among men in the UK (2010) which accounting 
for 25% of all new cases of men cancer 
2-5
 (Fig. 1.4). In 1990, both lung and colorectal 
cancers were more common in males than prostate cancer but from 1998, prostate cancer 
became the most common in UK. In 2011, prostate cancer is the 6
th
 most common cancer in 
whole population and the second common diagnosed cancer among men, worldwide 
9
. Also it 
is the second leading cause of male cancer death (after lung cancer) in the Western countries 
10
. In 2011, there were 41,736 new diagnosed cases of prostate cancer in the UK (Table 1.1). 
Figure  1.4: Ten most common cancers among men (excluding non-melanoma skin cancer) in 
the UK, 2010 
11
; Prostate cancer accounted for 25% of cancers following by lung cancer 
(14.1%), Bowel cancer (13.9%), Bladder cancer (4.5%), Non-HodgkinLymphoma (4%), 
Malignant Melanoma (3.8%), Kindney cancer (3.6%), Oesophagus cancer (3.4%), Leukemia 
(2.9%), Stomach cancer (2.8%) and other organ cancer (21.8%). 
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England Wales Scotland 
Northern 
Ireland 
United 
Kingdom 
Cases 35,567 2,346 2,817 1,006 41,736 
Crude Rate 136.1 155.9 110.5 113.1 134.3 
AS Rate 106.7 107.0 84.8 100.7 104.7 
AS Rate - 95% LCL* 105.6 102.7 81.7 94.5 103.7 
AS Rate - 95% UCL* 107.8 111.3 88.0 106.9 105.7 
 
 
Table  1.1: Prostate Cancer (C61), number of new cases, Crude and European Age-
Standardised (AS) Incidence Rates per 100,000 people, UK, 2011
12-15
. 
 
1.1.2.1.1 By age of diagnosis 
Incidence of prostate cancer is strongly age-related, with a higher incidence rate in older 
people. In the UK between 2008 and 2010, about 75% of new diagnosed cases were from 
men by age of 65 or more and only 1% were diagnosed in the under 50s 
2-5
 (Fig. 1.5). 
 
Figure  1.5: Prostate cancer, average number of cases per age of diagnosis, UK, 2008-10 10. 
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1.1.2.1.2 Trends by the time  
Incidence rate of prostate cancer has increased substantially during recent decades in many 
countries including Great Britain 
16, 17
. Majority of this increase both in the UK and most 
other countries worldwide can be related to improved detection of prostate cancer during 
TURP (Trans Urethral Resection of Prostate) or PSA (Prostate Specific Antigen) testing 
17, 
18
. Prostate cancer incidence rate has increased overall in Great Britain from 1970s which 
shows a 218% rise between 1975-77 and 2008-2010 
3, 4
 (Fig. 1.6).Two rapid increase can 
be seen in this chart: during early 1990s (44% increase between 1989-91 and 1994-96) and 
early 2000s (34% increase between 1997-99 and 2002-04); these periods related to 
introduction of PSA testing from the late 1980s 
19-21
  and increasing PSA testing rate 
around the late 1990s 
22, 23
. During the last decade (between 1999-2001 and 2008-2010), 
incidence rates of prostate cancer have increased by 22% which may be related to increase 
detection rate through TURP 
24-26
. 
 
 
Figure  1.6: Prostate cancer, European age related incidence rates, males, Great Britain, 1975-
2010 
10
. 
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1.1.2.1.3 Life time risk 
Life time risk is an estimation of risk which a new born child may be diagnosed with a type 
of cancer during his or her life-time. It is a summary of risk in the population. Genetic and 
lifestyle factors affect the risk of cancer. The life time risk of developing prostate cancer in 
the UK  in 2010 was 1 in 8 
27
.  
1.1.2.1.4 Geographic variation worldwide 
Prostate cancer is the 6
th
 most common overall cancer with an estimated 900,000 new 
diagnosed cases in 2011. Rates of prostate cancer vary widely around the world; it is the least 
common cancer in South-central Asia, more common cancer in Europe and the most common 
cancer in Australia and New Zealand with around 25-fold variation around the world 
10, 28
 
(Fig. 1.7). High risk of developing prostate cancer in black Caribbean and African American 
men and low risk in Asian men suggest that there may be ethnicity difference 
29, 30
. 
1.1.2.1.5 Socio-economic factors  
Incidence rate of prostate cancer is lower in more deprived men, so its incidence rate is 
strongly inversely correlated with deprivation and poverty 
31
. These results are not 
unexpected, as levels of PSA are generally higher in wealthy people 
32
. 
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Figure  1.7: Prostate Cancer (C61), World Age-Standardised Incidence Rates, World 
Regions, 2011 Estimates 
33
. 
 
1.1.2.2 Mortality 
Prostate cancer is the 4
th
 common cause of  cancer death in the UK (2010) , accounting for 
7% of all cancer death and the second leading cause of cancer death, after lung cancer in UK 
males (13% of male cancer death) 
34-36
. In 2011, there were 10,793 deaths from prostate 
cancer in the UK (around 35 in every 100,000 men) 
34-36
 (Table 1.2). 
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England Scotland Wales 
Northern 
Ireland UK 
Deaths 9,123 900 537 233 10,793 
Crude Rate 34.9 35.3 35.7 26.2 34.7 
AS Rate 23.8 21.9 21.9 21.7 23.7 
AS Rate - 95% LCL* 23.4 20.0 20.0 18.9 23.3 
AS Rate - 95% UCL* 24.3 23.8 23.8 24.5 24.2 
 
Table  1.2: Prostate cancer mortality rate, UK, 201112-15. 
1.1.2.2.1 Age of death 
Prostate cancer mortality is strongly related to age, with higher death rate in older men. In the 
UK between 2008 and 2010, around 93% of prostate cancer deaths were in men aged 65 and 
over and more than half (54%) were in 80s and over 
34-36
 (Fig. 1.8). Prostate cancer became 
the most common cause of cancer death in men aged 85 and over, with 31% of all prostate 
cancer deaths between 2008 and 2010, UK 
34-36
. 
1.1.2.2.2 Trend over time     
Like incidence rate, prostate cancer mortality rate has also increased in the UK from 1970s 
34-
36
. Mortality rate has risen from 20 deaths per 100,000 men in 1970s to a peak of 30 deaths 
per 100,000 men in 1990s; since then mortality rate has gradually fallen to 24 deaths per 
100,000 men in 2008-2010 (Fig. 1.9). PSA test and improvement in cancer treatment may 
attribute the recent mortality reduction. 
1.1.2.2.3 Geographic variation worldwide 
Worldwide cancer mortality data was collected and distributed by WHO (World Health 
Organization) 
37
. Prostate cancer is the 6
th
 common cause of male cancer death worldwide (9
th
 
in both sexes). Mortality rate is the highest in the Caribbean men and the lowest in eastern 
and south-central Asian men by a variation of ten-fold 
38
 (Fig. 1.10).  
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Figure  1.8: Prostate cancer mortality rate in age-specific groups, UK, 2010 39. 
 
Figure  1.9: Prostate cancer mortality rate, UK, 1970-2010 39. 
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Figure  1.10: Prostate cancer mortality rate worldwide, 2011 37. 
1.1.2.3 Survival 
Latest prostate cancer age-standardized relative survival rate in England and Wales between 
2005 and 2009 revealed that 93.5% of men were expected to survive from prostate cancer in 
the first year of diagnosis which fell to 81.4% in the 5
th
 year (Table 1.3) 
40-42
. High survival 
rate was related to early detection of greater proportion of latent and slow growing tumours 
by TURP and PSA testing. Like most other cancers, relative survival for prostate cancer 
improves due to screening (PSA test), although some improvement may come from 
treatment. Five year survival rate increased from 31% in England and Wales during 1971-75 
to 81.4% in England during 2005-9 
40, 43-45
 (Fig. 1.11). Prostate cancer relative survival rate 
also strongly related to stage of the disease at the time of diagnosis. For cases without 
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metastasis, five year survival rate in England during 1999-2002 was 90% or higher but 
reduced to around 30% for metastatic cancers 
46
.   
 
Table  1.3: Prostate cancer one, five and ten year survival rates in England 2005-2009 and 
Wales 2007 
40, 47
.
 
Figure  1.11: Prostate cancer relative survival rates, England and Wales 1971-1995, England 
1996-2009 
48
. 
 
 
 
  
Relative Survival (%) 
1 Year 5 Year 10 Year 
Sex 2005-2009 2005-2009 2007* 
Male 93.5 81.4 68.5 
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1.1.2.4 Risk factors 
1.1.2.4.1 Family history  
Past history of prostate cancer in first-degree relatives increases the risk of cancer by 120-
150% 
49-51
. Risk will increase in a man with affected father by 120-140% and with affected 
brother by 187-230%. The risk increase is higher when more than one first-degree relative is 
affected. Risk increase also reported in man with a second-degree affected relative by 90-
150% 
49-51
. Risk increase has been reported in men with mothers affected from breast cancer 
by 19-24%, but risk did not increase in men with sister diagnosed by breast cancer 
52, 53
. 
Germ line mutation in BRCA2, breast cancer gene, can increase the overall risk of 
developing prostate cancer in men, up to five-fold and in men below 65 years old, by seven-
fold 
54
. It has been estimated that, about 5-9% of prostate cancer cases are associated with 
genes and family history 
55
.  
1.1.2.4.2 Ethnicity 
The latest England-wide data show that the black men have the highest  prostate cancer risk , 
followed by the white ones, while Asian men (especially Chinese ethnicity) have the lowest 
risk 
56
. A cohort study showed that risk increase related to black ethnicity is higher in 
younger ages, and black men may be diagnosed 3-5 years sooner than white men 
30, 57, 58
. 
1.1.2.4.3 Other cancers 
It has been shown that previous renal cell (kidney) carcinoma increase the risk of prostate 
cancer up to 69% 
59, 60
. This associated risk was  reported to be higher in cases with positive 
family history of prostate cancer 
61
. Previous history of bladder cancer, melanoma and lung 
adenocarcinoma have been shown to increase prostate cancer risk by 14-151%, 15-50% and 
Chapter 1: Introduction 
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56%, respectively 
62-65
. Past history of thyroid cancer has also been shown to be related with 
increased prostate cancer risk 
66
. 
1.1.2.4.4 Radiation 
There were some evidences that exposure to gamma, x-ray and thorium-232 increased 
prostate cancer risk 
67
. 
1.1.2.4.5 Insulin-like growth factor-1 
High levels of insulin-like growth factor-1 (IGF-1) have been shown to be related to the 
increased risk of prostate cancer (38-83%) 
68, 69
. Levels of IGF-2, IGFBP-1 and IGFBP-2 
have not been shown to be related to prostate cancer 
69, 70
. 
1.1.2.4.6 Factors associated with lower prostate cancer risk 
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 
reported that food containing higher level of lycopene (type of plant vitamin A) or selenium 
(a trace mineral) may protect against prostate cancer 
71
. Men with high body levels of 
selenium and lycopene have shown to have a reduced prostate cancer risk by 26-71% and by 
16-24%, respectively 
72-75
.  Some limited study in Asian population revealed that high intake 
of soy reduced risk of prostate cancer by 26-31% 
76, 77
. Case-control and cohort studies 
showed that the exposure to warfarin (a vitamin K antagonist) was associated with a 17-31% 
reduction in prostate cancer risk 
78-80
. Previous studies also showed that men, who were 
diagnosed by diabetes mellitus at least five to ten years earlier, had a 21% reduction in the 
risk of prostate cancer 
81
. However it is still controversial that pathological events happening 
during the diabetes mellitus is the main reason or for example anti-cancer effects of anti-
diabetes drugs 
82
. 
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1.2 Pathology of prostate cancer 
1.2.1 Prostate anatomy 
Prostate, an oval-shaped gland is a part of male reproductive and urinary system. Prostate 
surrounds the neck (base) of the bladder 
83
. It is covered by a fibro muscular layer called 
prostate capsule which divide prostate to three different zones (Fig. 1.12); the peripheral zone 
(PZ) which consists about 70% of prostate volume, is the commonest location for prostatic 
intraepithelial neoplasia (PIN) and adenocarcinoma. The central zone makes up 25% of the 
total prostate mass, surrounds the ejaculatory ducts and accounts for only 2.5% of prostate 
cancers although these cancers tend to be more aggressive 
84
. The transitional zone (TZ), 
which accounts for 5% of the prostate volume, is the primary site of benign prostatic 
hyperplasia (BPH).  
                      
 
Figure  1.12: Schematic illustration of Prostate gland zones 85. 
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1.2.2 Normal prostate cells 
Mainly, three different types of cells can be detected in prostate epithelium: Luminal cells, 
basal cells and neuroendocrine cells (Fig. 1.13). Basal lamina contains a series of stem cells 
which potentially work as a reservoir to generate all these three cell types 
86
.  
Luminal cells have the highest population in prostate and secret prostatic proteins including 
PSA and prostatic acid phosphatase (PAP), two important prostate cancer biomarkers. 
Luminal cells are androgen dependent cells which express high level of androgen receptor 
(AR) 
87
. Luminal cells are distinguished by the expression of cytokeratin (CK) 8 and 18, 
filament high molecular weight proteins. As 95% of prostate adenocarcinomas  are originated 
from luminal cells, the levels of biomarkers such as PSA, CK8 and CK18 are expected to be 
increased in the cancer cells 
88
. 
Basal cells, the second large population in prostate epithelial cells are located between 
luminal cells and basement membrane and express high molecular weight proteins like CK5 
and CK14. Unlike luminal cells, basal cells neither secret any prostatic protein nor are 
dependent on androgen; so they do not go to apoptosis in androgen ablation situations 
89, 90
. 
However, they express anti-apoptotic gene Bcl-2 and free-radical scavenger GST-π which 
protect against DNA damage 
91
. 
Neuroendocrine cells spread in all acini epithelium and ducts which can produce serotonin, 
thyroid stimulating hormone and Chromogranin A. They produce neuropeptides which are 
supportive factors in vitality and proliferation of luminal cell 
91
. Neuroendocrine cells finally 
differentiate to androgen independent post-mitotic cells, which express neuropeptide Y 
92
. 
Because of the immune-reactivity to neuropeptide Y in up to 75% of prostate cancers, it is 
supposed to have a main role in prostate cancer growth and expansion 
93
. It has been proved 
in some studies that levels of neuroendocrine factors have a positive correlation with the 
advanced stage of prostate adenocarcinomas 
94, 95
. 
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Using specific biomarker such as α2β1-integrin and α2β1
hi
/CD133
+
, some research groups 
have confirmed the presence of the prostate stem cells within basal layer (about 1% of human 
prostate basal cells) 
96
 which have high potential to generate fully differentiated prostate 
epithelium in vivo 
97, 98
. 
 
 
                  
 
Figure  1.13: Schematic illustration of cells in human prostate epithelium 99; three different 
types of cells can be detected in prostate epithelium: Luminal cells, basal cells and 
neuroendocrine cells. Basal lamina contains a series of stem cells with potential capability to 
generate all these three cell types. 
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Chapter 1: Introduction 
 
 
38 
1.2.3 Prostate cancer 
1.2.3.1 Benign prostatic hyperplasia (BPH)  
Non-malignant overgrowth of prostate cells is defined as BPH. Both BPH and prostate cancer 
are age-related and require androgen stimulation, so they are often found concurrently. 
However, BPH is not a precursor for prostate cancer 
100
. BPH develops in transition zone, a 
ring of tissue around the urethra and its growth is inward toward the prostate’s core, 
constantly tighten around the urethra and associate with lower urinary tract symptoms 
(LUTS). On the other hand, most of prostate carcinomas initiate from outer peripheral zone 
then invade to surrounding tissue. Although the pathogenesis of BPH is still poorly 
understood, some studies indicate that BPH relates to hormonal changes occurring in aged 
men 
101
. Testis produces testosterone hormone which derives to 5-alpha-dihydrotestostron 
(DHT) and estrogen in target organs. It has been hypothesized that high level of DHT, which 
is involved in prostate growth, may trigger BPH initiation 
102
. 
1.2.3.2 Prostatic Intraepithelial Neoplasia (PIN) 
PIN is the earliest identifiable stage of prostate carcinogenesis and identified by abnormal 
proliferation of luminal epithelium cell with pre-existing of acini and ducts without any 
invasion to surrounding stroma 
86
. It co-exists with cancer in more than 85% cases and unlike 
cancer which lacks of basal layer, PIN remains intact or fragmented 
103
. PIN can be divided 
into two subgroups: low-grade and high-grade, according to their cellular crowding features, 
nuclear enlargement, chromatin patterns and nucleolar appearance 
103
. Also basal layer shows 
frequent interruption in high-grade PIN but remain intact or rare interrupted in low-grades 
104
. 
From the architectural point of view, high-grade PIN can be divided into four different 
groups: Tufting, Micropapillary, Cribriform and Flat 
105
. Tufting is the most common pattern 
(97%), although multiple patterns can be found in most of the cases. Currently, the World 
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Health Organization (WHO) recommended using PIN term as a representative of high-grade 
PIN. Many studies described common properties of PIN and prostate cancer 
(epidemiologically, histologically and cytogenetically) and the importance of high-grade PIN 
as a biomarker or precursor for detection of potential prostate cancer 
106
. 
1.2.3.3 Prostate cancer grading by Gleason scores 
Combined Gleason scores are a grading system for prostate cancer proposed by Dr. David 
Gleason in 1960s which use to describe the degree of morphological changes in prostate 
cancer 
107
. Nowadays, it is the most widely used method to evaluate the prognosis of men 
with prostate cancer. 
In the Gleason grading, histological patterns were categorized at low magnification according 
to the extension of glandular differentiation and growth pattern of tumour in prostate stroma.  
Glandular patterns were classified from well-differentiated (grade 1) to anaplastic (grade 5) 
according to their morphological appearance (Fig. 1.14). Combined Gleason scores are the 
sum of the score of the major lesion and the score of the secondary lesion.  Each lesion is 
measured by 5 different scores and thus the highest combined Gleason scores are 10 and the 
lowest are 2.  The Gleason grading system has been simplified by compressing the scores into 
three groups: well differentiated (Gleason scores <6), moderately differentiated (Gleason 
scores 6-7) and poorly differentiated (Gleason scores 8-10). Combined Gleason scores were 
commonly used as prognostic indicator in prostate carcinomas and in correlation with all 
important pathologic parameter and clinical outcomes 
103
. 
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Figure  1.14: Schematic diagram of Gleason grading system 2. 
 
 
1.2.4 Prostate cancer cell lines  
To show the pathogenesis and malignant progression of prostate cancer a wide range of 
prostate cell lines have been studied, varied from benign PNT2, through less malignant 
LNCaP and moderately malignant 22RV1, to highly malignant DU145, PC3 and PC3-M.  
1.2.4.1 PNT2 
Normal human prostate cell line, initially derived from prostate epithelial cells of a dead 33 
year old man and immortalized by transfecting with Simian virus 40 (SV40) 
4, 5
. Their 
population doubling time is about 40 hours. They are androgen-dependent and express PSA, 
PAP, CK 8, 18 and 19 which are markers of differentiated luminal cells of prostate glands. 
There is no tumorigenic ability when inoculated in nude mice 
108
. 
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1.2.4.2 LNCaP 
The LNCaP cells are derived from moderately-differentiated lymph node metastasis of 
prostate cancer 
5
. Their population doubling time is 60 hours. They express high level of 
androgen receptor in nucleus and their growth rate increase in response to androgen. Animal 
studies show earlier tumour growth in male animals compare to females, due to possible 
higher sensitivity to androgen 
3
, however no metastatic spread detected in inoculated animals 
109
. LNCaP cells express CK8, 18 and wild type TP53. In culture medium, they grow in 
clusters.  
1.2.4.3 22RV1 
22RV1 is a human prostate carcinoma epithelial cell line derived from a xenograft that was 
serially propagated in mice after castration-induced regression and relapse of the parental, 
androgen-dependent CWR22 xenograft. Their population doubling time is about 49-56 hours. 
22RV1 cells express PSA, their growth is weakly stimulated by DHT and androgen receptor 
can be detected in its lysate by western blotting 
110
. 
1.2.4.4 DU145 
Moderately-differentiated prostate cancer cell line derived from brain metastasis 
5
. Their 
population doubling time is about 34 hours. They are not hormone sensitive and express low 
level of PAP and do not express PSA, AR and human glandular kallikrein (hK2) 
111
. DU145 
cells express filament proteins, CK5, 8 and 18 which confirms its derivation from epithelial 
cells 
112, 113
 . Animal studies show metastasis in liver, spleen, lung, adrenal, kidney, lymph 
node and diaphragm when tumour cells inoculated in nude mice 
114
. 
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1.2.4.5 PC3 & PC3-M  
PC3 and PC3-M cell lines initially derived from a poorly-differentiated bone marrow 
metastasis of prostate cancer 
5, 115
. Their population doubling time is about 33 hours. They are 
androgen-independent, do not express PSA and show high rate of tumorigenicity and 
metastasis when they are inoculated in nude mice 
116
. PC3-M cell line was established from 
the selection of the most aggressive sub-population from the parental PC3 cells 
117
. 
1.2.5  Biomarkers and Oncogenes in prostate cancer 
Current diagnosis and informed treatment decisions for prostate cancer are based on digital 
rectal examination (DRE), PSA and subsequent biopsies for histopathological staging 
118
. In 
practice, each procedure has its shortcomings and, has led to the over-treatment of low-risk 
patients 
119
, unnecessary biopsies and non-essential radical prostatectomies 
120, 121
. Major 
biomarkers can be used to assist decision-making on designing appropriate treatment strategy 
for individual patients, to detect advanced disease at an earlier stage, and to predict metastatic 
cancer and re-occurring disease following prostatectomy. A biomarker is defined by The 
National Cancer Institute as “a biological molecule found in the blood, other body fluids, or 
tissues that is a sign of a normal or abnormal process or of a condition or disease” 122. So the 
ideal biomarker should be used to screen the disease and its progression, to identify high-risk 
individuals, to predict recurrence and to monitor response to treatments. It should be 
economical, consistent, non-invasive, easily accessible, and quickly quantifiable 
123
. 
1.2.5.1 Prostatic Acid Phosphatase and Prostatic Specific Antigen   
Prostatic acid phosphatase (PAP) is a dimer glycoprotein, produced predominately by 
prostate and was used as a serum biomarker to detect prostate cancer metastasis 
124
, but after 
development of  PSA test, PAP replaced by PSA  because of its low sensitivity in detecting 
localized disease 
125
.  
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PSA, a 33 kDa serine protease (human kallikrein-3), is secreted by the epithelial cells of the 
prostate. The 6 kb PSA gene is located in chromosome 19 and codes for a single chain 33 
kDa glycoprotein 
126
. It is secreted from the prostatic epithelium into the secretory ducts to 
contribute to the seminal fluid and to liquefy seminal coagulum by cleaving the protein 
semenogelin into small peptides hence increasing sperm motility 
86
. However, the basal-cell 
layer disruption in prostate cancer, allows PSA to leak into the circulation resulting in 
elevated serum levels of PSA. Serum levels of PSA may be increased by non-cancerous BPH, 
prostatitis, diet alterations, some medications and certain environmental factors but rarely by 
other human malignancies 
127, 128
.  PSA levels cannot be used to clearly distinguish the 
difference between benign and malignant diseases; it cannot reflect different stages of the 
cancer; thus PSA test is not a very sensitive or specific method which may not be reliably 
used as foundations for making accurate therapeutic decisions 
129
. Using the traditional cut-
off point of PSA in screening studies (≥4 ng/mL) as an indicator for prostate biopsy, the 
sensitivity and specificity of PSA for detecting cancer have been estimated about 40-50% and 
60-70%, respectively 
130-132
. Other studies suggested that using a cut-off point ≥ 10 ng/ml to 
increase its sensitivity and specificity in prostate cancer detection to 72% and 95%, 
respectively 
132
. Although, PSA is currently used as diagnostic and prognostic biomarkers for 
prostate cancer worldwide, some large clinical trials have casted some doubts on the 
effectiveness of screening the general population with PSA detection to identify the cancer 
patients 
133, 134
. To increase the diagnostic accuracy of PSA test, it has been refined by 
measuring different molecular forms of PSA and rate of PSA increase as total PSA (tPSA). 
tPSA refers to the sum of free PSA (unbound) and bound PSA (complexed predominantly to 
α-1-antichymotrypsin) 135. Whilst the level of tPSA is largely influenced by the level of free 
PSA, it still produces high false negatives or positives 
136
. Although refinement of the tPSA 
assay can improve its diagnostic efficiency, tPSA still fail to fulfil the necessary standard of 
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an appropriate biomarker. These issues have highlighted the need of more accurate diagnostic 
and prognostic biomarkers for prostate cancer. 
1.2.5.2 Over-detection and over-treatment of prostate cancer 
With the widespread screening and aggressive diagnostic practices in recent years, more 
prostate cancer cases have been diagnosed and prostate cancer has now become the most 
commonly diagnosed solid male cancer in the developed countries. However prostate cancer 
autopsy studies showed that men with high prevalence rates of small, indolent tumours 
usually died from other causes which led to increased concern for the over-detection and 
over-treatment of prostate cancer 
137
. Over-detection cannot only cause the cost burden to the 
patients; it can also lead to over-treatment and cause significant patient anxiety when facing 
the difficulty in choosing the alternative modalities. Over-treatment can cause considerably 
unnecessary decrements in quality of life, especially with regard to urinary incontinence and 
sexual dysfunction 
138
. The recent results from the European Randomized Study of Screening 
for Prostate Cancer (ERSPC) revealed that among the 1,068 men in the screening program 
for PSA, it was estimated that for one life saved, 48 men were required to be treated 
119
. 
Currently published results described the institutional experiences in active surveillance. 
Postponing selective therapy was suggested as a way to deal with men with low-grade, early-
stage prostate cancer 
139-144
. D’Amico defined low-risk prostate cancer as "Gleason score of ≤ 
6 or ≤ 7 (3+4), PSA < 10 ng/ml and a tumour that is either non-palpable or only palpable in 
less than half of one lobe of the prostate (clinical stage T1c or T2a)" 
145
. In those "active 
surveillance" studies, men were followed carefully with serial PSA assessments (every three 
months for two years at first; and then every six months), repeated biopsies (every six months 
for first year and then every 3-4 years) and in some cases other tests were employed to 
identify early signs of progression (such as MRI). Although active surveillance is becoming 
widely accepted 
146
, this strategy still relies on serial PSA assessments  and repeat biopsies. In 
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addition to the invasive nature, repeated biopsies also carry other significant risks such as 
subsequent infection and short-term disturbances on quality of life 
147, 148
. As the 
effectiveness of PSA screening is still under question, it is urgently needed to search for more 
sensitive and specific biomarkers. 
1.2.5.3 Potential biomarkers 
Blood, urine, semen and prostate tissue are the biomaterial sources that could be used to 
identify prostate cancer biomarkers. Serum proteomics analysis is a useful method for 
searching for biomarkers, but this method is facing the challenges presented by the wide 
range of protein concentrations. Another difficulty for using this method is to find low-
abundance proteins due to the masking effects of high-abundance proteins. Other problems 
for serum proteomics include the interference produced by high levels of salts and other 
compounds, extreme variations among individuals and lack of reproducibility 
149
. Semen is a 
relatively non-invasive material for analysing prostate biomarkers, in which proteins 
originated from prostate can be directly accessed; but it varies among different patients. Urine 
has become a popular source for identifying proteomic biomarker, due to its non-invasive 
nature. The problem for using urine is that the urine generally contains low concentration of 
biomolecules 
123
. Genomic analysis is widely used for studying disease biomarkers. Genome 
wide analysis can stratify those people who have high cancer risk. Germ line genetic markers 
are widely used markers, their levels do not fluctuate over time and they are available for 
assay at any age 
150
. Identifying biomarkers and understanding the key cancer-related 
pathways are essential for the development of new and improved diagnostic and predictive 
tools. A number of potential biomarkers have been identified and their predictive values for 
prostate cancer were studied. Apart from PSA, many other biomarkers have been reported 
and their diagnostic and prognostic significances were studied for prostate cancer 
151
. These 
markers include, but not limited to: breast cancer mutated gene (BRCA1/BRCA2) (Tumour 
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suppressor) 
152, 153
, prostate cancer antigen 3 (PCA3) (non-coding RNA) 
154, 155
, TMPRSS2-
ERG fusion gene (Transcription factor) 
156, 157
, early prostate cancer antigen 2 (EPCA2) 
(nuclear matrix protein) 
158, 159
, Interleukin-6 (IL-6) (Cytokine) 
160
, S100 family proteins 
(Calcium-binding protein family) 
161, 162, Transforming growth factor β1 (TGF β1) (cytokine) 
163, 164
, Prostate Stem Cell Antigen (PSCA) (glycoprotein) 
165, 166
 and Cutaneous fatty acid 
binding protein (C-FABP) (cytoplasmic lipoprotein) 
167, 168
.  
1.2.5.3.1 BRCA1/2 gene mutation 
BRCA1 and BRCA2 are tumour suppressor genes. Germ-line BRCA2/BRCA1 mutations 
produce a hereditary breast-ovarian cancer syndrome in affected families which also 
associated with higher prostate cancer risk (8.6-fold and 3.4-fold, respectively) in men ≤ 65 
years 
169, 170
. Studies revealed that a wide spectrum of pathogenic mutations in BRCA2/1 
conferred a more aggressive prostate cancer phenotype with a higher probability of locally 
advanced metastatic diseases. Furthermore BRCA2 mutation was detected as a prognostic 
factor associated to poorer survival 
153
. Mutation of germ-line BRCA2/BRCA1 presented in 
1.2% and 0.4% of prostate cancer cases 
169, 170
. 
1.2.5.3.2 Prostate cancer antigen 3 
Prostate cancer antigen 3 (PCA3) is a commercially available diagnostic marker. This non-
coding RNA is only expressed in the prostate, and can be detected in urine and prostatic fluid. 
Since PCA3 test requires digital massage of the prostate prior to urine collection, it is 
considered more invasive than blood-based tests. It is over expressed in 95% of biopsies from 
prostate cancer patients compared to healthy or BPH patients with a high specificity 
154
.  A 
PCA3 level of >35 units in urine has been recorded with an average sensitivity of 66% and 
specificity of 76% for the diagnosis of prostate cancer compared to serum PSA (specificity of 
47% and 65% sensitivity) 
155
. Reliability of this test is depended on a full prostate massage 
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through DRE just before taking the urine sample, so it is not pleasure and varies due to 
examiner.  
1.2.5.3.3 TMPRSS2-ERG gene fusion   
 
TMPRSS2-ERG is the most frequent gene fusion present in prostate cancer, which has been 
greater than 90% specificity and 94% positive predictive value 
156
. Unfortunately, a clinical 
diagnostic test is still not available for this marker and current evidence did not support the 
prognostic significance of TMPRSS2-ERG analysis with equivocal findings regarding 
outcomes 
156
. TMPRSS2-ERG gene fusion has been found in patients with good prognosis 
157
, 
with no association to prostate cancer incidence or Gleason score 
171
. 
1.2.5.3.4 Early prostate cancer antigen 2 (EPCA2) 
Prostate cancer associated nuclear structural protein is expressed in prostate 
adenocarcinomas, can be detected in serum and its increased measurement in blood is 
correlated with tumour progression and poor prognosis 
159
. Some studies implied that EPCA2 
expression might occur early during the development of cancer so it may be used as a 
potential predictive marker for the onset of incidental prostate cancer. However tissue 
EPCA2 staining and plasma EPCA absorbance were not found to be correlated with tumour 
stage and Gleason scores in patients with prostate cancer 
158
. 
1.2.5.3.5 Interleukin-6 (IL-6) 
IL-6 is involved in the host immune defence mechanism (mediates B cell differentiation) as 
well as the modulation of growth and differentiation in various malignancies 
172
. 
Overexpression of IL-6 was shown in relation with tumour progression through inhibition of 
cancer cell apoptosis, stimulation of angiogenesis, and promotion of drug resistance. 
Increased serum IL-6 concentration has been reported in association with advanced tumour 
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stages of various cancers (e.g., multiple myeloma, non-small cell lung carcinoma, colorectal 
cancer, renal cell carcinoma, prostate cancer, breast cancer and ovarian cancer) and short 
survival of the patients. In patients with high levels of IL-6, the response to treatment with 
chemotherapy and hormone therapy was worse than those with low levels of IL-6 
173
. 
Therefore, blocking IL-6 signalling may be considered as a potential therapeutic strategy (i.e., 
anti-IL-6 therapy) in those who have been characterized by pathological IL-6 overproduction. 
Further investigations in xenograft tumour models are needed to establish the therapeutic 
efficacy of anti-IL-6 therapy in human cancer 
160
. 
1.2.5.3.6 S100 Protein family (Calcium-binding protein family) 
The multi-gene calcium binding proteins, more commonly known as the S100 protein family, 
are involved in protein phosphorylation, enzyme activity and calcium homeostasis of cells.  
They are also involved in regulation of transcription factors, macrophage activators and 
modulators of cell proliferation 
174
. Recently, it has been shown that they were involved in a 
variety of intracellular and extracellular functions including cell growth, cell-cell 
communication, energy metabolism and intracellular signal transduction 
175
. Furthermore 
their different expression in neoplastic tissues was compared to normal tissue and their 
involvement in the metastasis process has been revealed 
162
. At least seventeen S100 genes 
were recognized on human chromosome 1q21, a region frequently rearranged in several types 
of cancer 
176
. Several proteins from this family, including S100A2, S100A4, S100A8, 
S100A9 and S100A11, are associated with prostate cancer recurrence and progression to 
higher pathological stages 
161, 177
. Although S100A4 overexpression was detected in prostate 
cancer cell lines and tissues, it was not significantly  associated with poor patient survival 
178
.   
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1.2.5.3.7 Transforming growth factor β1 (TGF β1) 
TGF β1 involves in the regulation of cellular proliferation, chemotaxis, immune response, 
differentiation and angiogenesis. Increased expression of TGF β1 in prostate cancer was 
correlated with severe tumour grade, invasion, metastasis (to regional lymph nodes and bone) 
and biochemical recurrence 
164
. More validation is needed before TGF β1 can be used as a 
prostate cancer biomarker 
179
. 
1.2.5.3.8 Prostate Stem Cell Antigen (PSCA) 
Prostate Stem Cell Antigen (PSCA) is a member of the Thy-1yLy-6 family of glycosyl-
phosphatidyl-inositol, involved in regulation of cell proliferation. Its’ up-regulation   has been 
detected in both androgen-dependent and independent prostate cancer xenografts and is 
correlated with Gleason scores, advanced stage and metastatic progression 
180, 181
. Exact 
biological function of PSCA is unknown; but its cell surface location makes it a putative 
target for therapy and diagnosis 
123
. The expression of PSCA in prostate cancer supports the 
concept that cancers arise from transformation of basal cells 
182
. But using PSCA as a serum 
marker need to develop better methods for detection and measurement 
181
. 
1.2.5.3.9 Cutaneous fatty acid binding protein (C-FABP) 
Cutaneous fatty acid protein (C-FABP) is also known as epidemic-FABP (E-FABP), psoriasis 
associated-FABP (PA-FABP), keratinocyte-FABP (K-FABP) or FABP5.Gene coding for C-
FABP is located at chromosome 8q21.13. FABP5 is a 15 kDa cytosolic protein from fatty 
acid binding protein family with high affinity to bind with long chain fatty acids and other 
lipophilic substances like eicosanoid and retinoid 
183
. C-FABP is expressed most abundantly 
in epidermal cells of the skin. However its wide expression has been detected in endothelial 
cell of placenta, skin, tongue, adipocyte, brain, intestine, kidney, liver, Clara and Goblet cells 
of lung, heart, skeletal muscle, testis, retina, lens, spleen, mammary gland, dendritic cell and 
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macrophage 
184
. FABPs are involved in fatty-acid import, storage and export as well as 
cholesterol and phospholipid metabolism 
185
. They have also been proposed to sequester 
and/or distribute ligands to regulate signalling processes and enzyme activities. Intracellular 
FABPs increase the solubility of fatty acids and facilitate the transport to organelles such as 
mitochondria or endoplasmic reticulum (Fig. 1.15) 
184
.  Presence of FABPs in the nucleus of 
some cell lines such as heart myocyte, hepatocyte, cancer cells and the cell lines transfected 
with FABP gene, leaded to the discovery of the interaction between the nuclear receptors and 
FABPs 
186
. Overexpression of FABPs was reported to act in concert with PPARs and this 
activity is highly selective for particular FABP-PPAR pairs 
187
, which may indicate that 
individual FABPs initiate unique signalling pathway in nucleus and trigger specific gene 
expression, as shown in Figure 1.15. 
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Figure  1.15:  Putative intracellular functions of FABP 184; FABPs involve in fatty-acid 
import, storage and export, oxidation (Perixosome), β-oxidation (Mitochondria), transcription 
(PPARs), enzyme activity (Cytosol) and signalling and membrane synthesis (Endoplasmic 
reticulum). 
 
 
1.2.5.3.9.1  C-FABP and prostate cancer 
Previous studies demonstrated that C-FABP is overexpressed in malignant prostate and breast 
cell lines and when transfected into the benign rat Rama 37 model cells, C-FABP induced 
metastasis of the DNA recipient cells, in vivo 
188
. Further investigations revealed that over-
expression of the C-FABP gene induced metastasis through up-regulation of the VEGF and 
thus VEGF might play a crucial role in this particular metastatic cascade 
189
. Furthermore, it 
has been shown that suppression of C-FABP expression in highly malignant PC3-M cells 
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significantly reduced invasive capacity, in vitro 
190
 and inhibit the tumorigenicity, in vivo 
(nude mice model) 
191
 by decreasing VEGF and microvessel densities. On the other hand, 
inducing the C-FABP gene in less malignant, androgen-dependent LNCaP cells raised cell 
invasiveness and proliferation ability, in vitro and increased the tumorigenicity, in vivo (nude 
mice model) 
167
. Higher levels of both nuclear and cytoplasmic C-FABP were detected in 
carcinoma tissues than those in normal and BPH tissues and the increased expression of C-
FABP was significantly associated with a reduced patient survival time, thus it has been 
suggested as a prognostic biomarker to predict patients’ outcome 168. Recent studies showed 
that cancer promoting activity of C-FABP in prostate cancer is closely related to its ability to 
bind and transport extracellular fatty acids into the cancer cells 
167
. It has been established 
that there is a fatty acid-initiated signalling pathway which may lead to malignant progression 
of prostatic cancer cells.  
1.2.5.3.10    Peroxisome proliferator activated receptors (PPARs) 
PPARs were originally identified in Xenopus frogs as receptors that induced the proliferation 
of peroxisomes in cells 
192
.  PPARs belong to the nuclear hormone receptor superfamily of 
ligand-inducible transcription factors 
193
. They play essential roles in the regulation 
of cellular differentiation, development,  metabolism (carbohydrate, lipid and protein) 
and tumorigenesis . PPARs regulate target gene expression by translocation from cytoplasm 
to nucleus and hetero-dimerization with retinoic X receptor (RXR) which binds to specific 
DNA binding domain known as peroxisome proliferator (hormone) response elements 
(PPREs) within enhancer sites of regulated genes (promoters) 
194
. PPREs composed of direct 
repeat (DR) elements consisting of two hexanucleotides with a consensus sequence 
AGGTCA separated by a single nucleotide spacer and named DR1 (AGGTCA-A- 
AGGTCA). Alternatively, in DR2 motifs two hexanucleotides are separated by two 
nucleotide spacer and can also be recognized by PPARs 
195
.  Endogenous ligands for the 
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PPARs include free fatty acids and their derivations including eicosanoids and prostaglandins 
196
. Three main isotypes of PPARs have been identified: PPARα (alpha) (NR1C1) (on 
chromosome 22q12-13.1) 
197
, PPARγ (gamma) (NR1C3) (on chromosome 3p25) 198, and 
PPARβ/δ (beta-delta) (NUC1) (on chromosome 6p21.1–p21.2) 199. PPARα  is highly 
expressed in tissues with high rates of mitochondrial fatty acid oxidation, such 
as liver, kidney, heart, muscle , adipose tissue and cells of arterial wall. It reduces triglyceride 
level and is involved in regulation of energy homeostasis. PPARβ/δ  expresses in many 
tissues, particularly in brain, adipose tissue and skin, to enhance fatty acids metabolism. 
PPARγ  is expressed on all major cells of the vasculature, including endothelial cells, VSMCs 
(Vascular Smooth Muscle Cells) and monocytes/macrophages, human coronary artery 
smooth muscle cells, umbilical artery smooth muscle cells, umbilical endothelial cells and 
aortic smooth muscle cells. It is predominately seen in adipose tissues where it plays a critical 
role in the regulation of adipocyte differentiation 
200
. PPARγ  causes insulin sensitization and 
enhances glucose metabolism. Three forms of PPARγ  are transcribed by the same gene : γ1 
expresses in virtually all tissues, including heart, muscle, colon, kidney, pancreas and spleen; 
γ2 expresses mainly in adipose tissue (30 amino acids longer) ; γ3 expresses 
in macrophages, large intestine and white adipose tissue 
201
. 
1.2.5.3.10.1   Intracellular PPARs regulatory pathway 
All three isotypes of PPARs have been shown to modulate lipid metabolism. 
PPARα regulates the expression of genes involved in the peroxisomal and mitochondrial β-
oxidation pathways such as Acyl-CoA oxidase, Enoyl-CoA hydratase/dehydrogenase 
multifunctional enzyme, Keto-Acyl-CoA thiolase, Malic enzyme, medium chain Acyl-CoA 
dehydrogenase and mitochondrial hydroxy methylglutaryl-CoA synthase. It also is regulated 
by FATP (Fatty Acid Transport Protein), FAT/CD36 (Fatty Acid Translocase), L-FABP 
(Liver Cytosolic Fatty Acid-Binding Protein) and UCP2 and UCP3 (Uncoupling Proteins-2 
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and 3). Hence activated PPARα leads to increased breakdown of triglycerides and fatty acids, 
increased cellular fatty acid uptake and reduced triglyceride and fatty acid synthesis 
202
. 
PPARβ/δ is a potential downstream target of APC (Adenomatous Polyposis Coli), Beta-
Catenin and  TCF4 (T-Cell Factor-4) tumour suppressor pathway, which is involved in the 
regulation of growth promoting genes such as c-Myc and Cyclin-D1. PPARβ/δ plays an anti-
apoptotic role in keratinocytes via transcriptional control of the Akt/PKB (Protein Kinase-B) 
signalling pathway. Both PI3K (Phosphatidylinositol-3 Kinase) and Integrin-linked kinase are 
target genes of PPARβ/δ 203. Both PPARγ and PPARα are regulated by phosphorylation 
events. Activation of PPARγ inhibits monocyte and macrophage inflammatory responses by 
preventing the activation of nuclear transcription factors, such as NF-KappaB (Nuclear 
Factor-KappaB), AP-1 (Activating Protein-1) and STAT1 (Signal Transducer and Activator 
of Transcription-1) 
204
. 
1.2.5.3.10.2   PPARs and cancer 
Wide expression of PPARγ in many tumours and the ability of its ligands to inhibit cellular 
proliferation, promote differentiation, induce apoptosis and inhibit angiogenesis, highlight the 
importance the role of PPARγ in carcinogenesis. High expression levels of PPARγ have been 
detected in human mammary adenocarcinomas. PPARγ agonists have been reported to reduce 
growth and induce differentiation of malignant breast epithelial cells 
205
. It has been shown 
that survival of patients with colorectal cancer was significantly longer in those with high 
level of PPARγ 206. On the other hand, PPARγ has shown to have an important role in 
bladder tumorogenesis 
207
. Inhibition of proliferation in lung carcinoma cells and non-small 
cell lung cancer (NSCLC) has been reported in association with PPARγ-dependent signals 208, 
209
. It has been demonstrated that PPARγ ligands induced cell cycle arrest in pancreatic 
tumour cell lines 
210
. 
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Enhanced expression of PPARα has been reported in human hepatocellular carcinoma 211. 
Previous studies revealed that PPARα expression correlated with a shorter survival time and 
poor chemo-response in patients with ovarian carcinoma 
212
. Moreover, up-regulation of 
PPARα and its related proteins has been detected in human glioblastoma cells 213. 
 
 
Figure  1.16: PPARs  regulatory pathway 214. 
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PPARβ/δ has been identiﬁed as a target of the tumour suppressor APC in colorectal cancer 
cells 
215
. Furthermore it has been showed that PPARβ/δ has regulatory effects on the genes 
which may increase cell proliferation and promote colon carcinogenesis 
215
. Higher levels of 
PPARβ/δ have been detected in ovarian carcinomas, squamous cell carcinomas, breast 
tumours and endometrial carcinomas 
212, 216-218
. Increased proliferation or inhibited apoptosis 
in presence of high PPARβ/δ has been shown in variety of human lung, breast, liver and 
prostate cancer cell lines 
219
. Indeed, PPARβ/δ ligands have been reported to inhibit the 
proliferation of mouse and human keratinocytes 
220
. 
1.2.5.3.11    Vascular endothelial growth factor (VEGF) 
Process of new vascular network formation from pre-existent capillaries is called 
angiogenesis, which is one of the essential component of the tumour growth and the 
metastatic pathway 
221
. During the process of vascularisation endothelial cells initially 
respond to changes in the local environment and migrate toward the growing tumour. The 
endothelial cells then migrate together to form tubular structures which are ultimately 
encapsulated by recruiting periendothelial support cells to establish a vascular network that 
facilitates tumour growth and metastasis 
222
. Tumour angiogenesis is regulated by the 
production of angiogenic stimulators including the vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (FGF-2), acidic FGF (FGF-1), matrix 
metalloproteinases, insulin-like growth factor I, and angiopoietin-1 
223
. VEGF is a signalling 
protein being produced by cells to stimulate vasculogenesis and angiogenesis. VEGF belongs 
to a sub-family of growth factors (the platelet-derived growth factor family of cystine-
knot growth factors). It has been divided to several sub- groups: VEGF-A (involve in 
angiogenesis by increasing endothelial cells mitosis and migration, creation of blood 
vessel lumen and creation fenestrations), VEGF-B (involved in embryonic angiogenesis), 
VEGF-C (involved in lymphangiogenesis), VEGF-D (involved in the development of 
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lymphatic vasculature surrounding lung bronchioles), VEGF-E (encoded by viruses and in 
the venom of some snakes) and a structurally related molecule named placental growth factor 
(PlGF) (important for vasculogenesis) 
224
. Human VEGF is a 45 kDa homodimeric-binding 
glycoprotein which was firstly identified by Senger et al. at 1983. VEGF gene is located at 
chromosome 6p21.3 and consists of 8 exons separated by 7 introns 
225
. As a key mediator of 
angiogenesis, VEGF is tightly regulated at both the transcriptional and post-transcriptional 
levels. VEGF regulation is complex as it is up-regulated by hypoxia, growth factors, steroid 
hormones and transcription factors 
226
. 
1.2.5.3.11.1   VEGF and prostate cancer 
There are some controversies regarding the relationship between VEGF expression and 
degree of malignancy of prostate cancer. It has been reported that expression of VEGF 
mRNA was significantly higher in PIN and poorly differentiated prostate carcinomas 
comparing to BPH and normal prostate tissues 
227
. VEGF protein has been detected in 80% of 
prostate cancer, 18% of BPH, but not detected in normal prostate samples 
228
. Hypoxia 
inducible factor (HIF)-1α, key regulator of VEGF, has been shown to be highly expressed in 
PIN lesions and in human prostate cancer 
229
. The correlation between serum VEGF and 
micro vessel density (MVD) with the transition of a well differentiated tumour to a poorly 
differentiated tumour and prostate cancer metastasis has been confirmed 
227, 230
. Studies on rat 
model cells revealed that C-FABP may stimulate the expression of the VEGF gene and 
promote angiogenesis to facilitate tumour formation and metastasis 
189, 231
. Suppressing C-
FABP gene in highly malignant prostatic cancer cells has reduced the expression of VEGF 
and down-regulated angiogenesis in the resultant cancer cells 
168, 190
. Whereas increasing  C-
FABP expression in less malignant prostate cancer cells not only up-regulated VEGF level 
but also increased MVD 
167
. Clinical studies showed that expression levels of VEGF in urine, 
serum or plasma were correlated with poor patient outcome, higher Gleason score or 
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metastasis 
232, 233
. Furthermore anti-angiogenic treatment with VEGF inhibitors such as 
Bevacizumab, Sorafenib or Sunitinib reduced progression rate of prostate cancer and 
increased patient survival time 
234
. Oestrogen has been reported to up-regulate the expression 
of VEGF in breast cancer cells via Specificity protein (Sp1/Sp3) transcription sites in the core 
VEGF promoter 
235
. Similarly, androgen has mediated the up-regulation of VEGF expression 
in androgen dependent prostate cancer cells, through a Sp1/Sp3 binding site in the VEGF 
core promoter 
236
. 
1.2.5.3.11.2    PPARs and angiogenesis 
All PPARs are expressed in endothelial cells, where they also regulate cell proliferation, 
angiogenesis, inflammation, thrombosis and coagulation 
237
. Experimental studies showed 
that PPARα activation inhibits angiogenesis in vascular remodelling (proliferation, migration 
and tube formation) and in tumour cell growth 
238
. PPARα activation inhibited VEGF-
induced endothelial cell migration and FGF-2-induced corneal angiogenesis in vitro and in 
vivo 
239
. A significant correlation between expression of PPARα and level of secreted VEGF 
has been reported in both normal and malignant endometrial tissues 
240
. Treatment of 
implanted melanoma, glioblastoma and fibrosarcoma in mice with PPARα ligands, led to a 
reduction in tumour growth and microvessel density 
239
. PPARβ/δ activation potently induces 
angiogenesis in human and murine vascular endothelial cells in vitro and in vivo 
241
. In 
pancreatic tumours removed from patients, the expression levels of PPARβ/δ were strongly 
correlated with the advanced pathological tumour stage and increased risk of tumour 
recurrence and metastasis (via VEGF) 
242
. Up-regulation of VEGF has been shown in poorly 
differentiated bladder cancer cells in relation to PPARβ/δ ligands 243. PPARγ expression is 
associated with a vast number of cancers. It is found at higher levels in proliferating 
endothelial cells 
244
. Up-regulation of VEGF (both mRNA and protein) has been reported in 
colorectal cancer cells after induction with both PPARβ/δ and PPARγ ligands 245. VEGF 
Chapter 1: Introduction 
 
 
59 
promoter contains PPRE sequences through which PPARγ ligands are capable of inducing 
VEGF and angiogenesis in endothelial/interstitial muscle cells 
246
. Induction of VEGF was 
associated to increase activation of Akt and phosphorylation (activation) of ENOS 
(endothelial nitric oxide synthase) (NOS3) 
247
. On the other hand, it has also been shown that 
PPARγ ligands repressed VEGF gene expression via PPREs in the VEGF gene promoter 
region, in human endometrial cells 
248
. 
1.3 Aims and scope 
1- Evaluation different expression levels of PPARβ/δ and PPARγ in correlation with C-FABP 
by RT-PCR in mRNA level and by Western blotting in protein level in different benign and 
malignant prostate cell lines. 
2- Evaluation different expression levels of PPARβ/δ and PPARγ in correlation with C-FABP 
in benign and carcinoma prostate tissues using immunohistochemical staining. 
3- Assessing the correlation of different expression levels of PPARβ/δ and PPARγ in prostate 
carcinoma tissues with different expression level of C-FABP, Gleason score (degree of 
malignancy), PSA level, AR index and patient’s survival time using different statistical 
analysis methods. 
4- Suppressing the most related PPAR to C-FABP in highly malignant prostate cancer cells, 
transiently and stably, using RNAi techniques. 
5- Evaluation the silencing effects of dedicated PPAR on growth rate, invasiveness and 
anchorage-independent growth of prostate cancer cell, in vitro, using proliferation assay, 
invasion assay and soft agar assay. 
6- Evaluation the silencing effects of dedicated PPAR on the tumorigenicity of prostate 
carcinoma tissues, in vivo, using nude mice model. 
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7- Evaluation the regulatory effects of C-FABP-PPAR axis on VEGF protein expression in 
cell extracts and medium, using Western blotting and ELISA, respectively. Assessing the 
biological activity of secreted VEGF by in vitro angiogenesis assay.  
8- Evaluation the regulatory effects of C-FABP-PPAR pathway on VEGF expression through 
PPRE sequences in promoter region of VEGF, using Dual Luciferase Reporter assay. 
 
1.3.1 Research Plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluate the expression status of PPARβ/δ, PPARγ and C-FABP in  
prostate cells and tissues 
(Western blot and immunohistochemistry) 
Assess their correlation with Gleason score and patient survival (statistical analysis) 
Suppress the appropriate PPAR in highly malignant prostate cancer cells 
(Transiently and stably with RNAi techniques) 
Assess the suppression of dedicated PPAR in malignant progression of 
prostate cancer cells 
(in vitro and in vivo) 
Investigate the correlation of related PPAR and C-FABP with VEGF in  
prostate cancer cells 
(Using reporter genes and luciferase assay) 
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2 Materials and Methods 
2.1 Materials 
Reagents are listed in Appendix A, Buffers in Appendix B and Equipment in Appendix C. 
2.2 Methodology 
2.2.1 Cell culture 
2.2.1.1 Routine cell culture 
All human prostate cell lines were grown monolayer in routine medium (RM), in T75/T125 
tissue culture flasks then kept in humidified incubator (Model TC2323 CO2 incubator, 
Borolabs) at 37°C with 5% (v/v) CO2. Cells were fed with fresh medium each 3-4 days. After 
reaching 80% of confluency, cells were passaged and sub-cultured in 1/10 fold. Old medium 
was removed; cells were washed twice with PBS. Trypsin 2.5% (v/v) in Versene was used to 
detach cells, 3ml/T75 flask and 5ml/T125. Cells were incubated with T/E 2-5 minutes till 
majority of them were rounded and detached. For deactivating T/E, equal volume of RM was 
added. Cell pallets were separated by centrifuging in 25 ml universals at 800 ×g for 3 
minutes. Cell pallets were re-suspended with RM, and divided to flasks with suitable volume 
of medium. 
2.2.1.2 Cell counts 
Using Haemocytometer (Scientific Laboratory Supplies Ltd) cell numbers were counted. 
20μl of suspended cells provided in 2.2.1.1 section were placed under the cover-slip. Mean of 
cells counted in four squares were considered as the number of cell ×10
4
 in 1 ml of cell 
suspension. 
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2.2.1.3 Cryopreservation/Cell Freezing 
After reaching to 70% confluency, cells were detached (Section 2.2.1.1), re-suspended in 
PBS and counted (section 2.2.1.2). Using 3 minutes centrifuge at 1250 g, supernatant was 
separated and discarded. Pallet was re-suspended with Freezing medium (FM) containing 
7.5% DMSO to reach the concentration of 1-1.5×10
6
, then aliquot into 1 ml in Cryotubes 
(Nunc, Denmark). Cryotubes were placed in Cryobox (Nalgene, UK), filled by isopropanol 
and kept in -80
°
C freezer overnight before transferring into liquid nitrogen.  In Cryobox, 
temperature decreases gradually (-1
°
C/minute) and prevents ice crystal formation during 
freezing process in the cells.  
2.2.1.4 Cell Thawing 
Frozen cells were removed from liquid nitrogen and thawed gradually first on ice and then in 
water bath (37
°
C). Then cells transferred into 25ml universal and diluted with 10ml RM, 
before centrifuged at 800 ×g for 3 minutes to discarding supernatant which contain 
cryoprotective DMSO (because of its toxic effect on cells in >4
°
C). The pellet was re-
suspended and transferred into T75 flasks and maintained in humidified incubator with 5% 
CO2 at 37
°
C. 
2.2.2 Culturing of transfected cells  
Transfected cells were grown and maintained in routine selective medium (RSM) which 
contain 100μg/ml Zeocin (Invitrogen, CA, USA). All the cell culture techniques were same 
as non-transfected ones expect using RSM.  
2.2.3 Evaluating protein expressions in cell lines 
Western blot was used for evaluating protein expressions. Protein extracts were loaded in a 
poly acrylamide gel electrophoresis (PAGE) system where separated according to their 
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molecular weight and charge ratio. Separated proteins then transferred to polyvinylidene 
difluoride (PVDF) membranes where protein expression identified using specific antibodies. 
2.2.3.1 Protein extraction from cultured cells 
When cell reached to 80% confluency, they were trypsinized (as described in section 2.2.1.1). 
The pallet was incubated with CelLytic-M (100μl/5×106 cells) and protease inhibitor 
(1μl/5×106 cells) in a 1.5 ml micro-centrifuge tube on the roller for 15 minutes at room 
temperature. Then the mixture centrifuged at 8000 ×g for 20 minutes to separate cellular 
debris. The supernatant was kept in a fresh micro-centrifuge tube. 
2.2.3.2 Bradford assay 
Bio-Rad protein assay (Bio-Rad Laboratories GmbH, Munchen, Germany) was used to 
quantify the concentration of proteins extracted from cell lines. A concentration standard 
curve established using serial concentration of BSA (from 50μg/μl to 500μg/μl) in 50μl PBS. 
Appropriate volume of protein samples were also diluted within 50μl PBS. All controls and 
samples were incubated with 1ml of diluted (1/5) dye reagent, which filtered through 
Whatman 540 paper, for 15 minutes before measuring the absorbance at 595nm using the 
MultiSkan plate reader (BioTek Instruments, USA). Standard curve used to calculate the 
concentration of protein samples.  
2.2.3.3 Western Blotting 
2.2.3.3.1 Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins, extracted from cell lines and quantified using Bradford assay, were equalized with 
distilled water to reach the concentration of 20μg/10μl then 10μl of 2× sample loading buffer 
(SLB) was added. Prior to loading, mixture was heated at 95
°
C on hot plate (Techne, Ori-
Block, USA) for 10 minutes to linearize proteins by breaking hydrogen band of tertiary 
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structure which made the antigen recognisable with antibody then chilled on ice for 2 minutes 
and spun down before loading in SDS gel. Electrophoresis was performed in 500ml of 1× 
running buffer (Next Gel
TM 
Running Buffer, 20×, Amresco, USA) using Bio-Rad miniprotein 
system with 1mm spacers (Flowgen, Bio-Rad, Hemel, UK). Proteins were loaded in 12.5% 
polyacrylamide gel (Next Gel
TM 
12.5%, Amresco, USA) and ran at 100V for 60 minutes. 
Protein sizes were estimated using suitable protein marker (Lonza, Belgium). 
2.2.3.3.2 Transfer proteins from SDS gel to PVDF membrane 
Separated proteins were transferred from SDS gel to PVDF membrane (Immobilon-P, 
Transfer Membrane, Millipore, USA) using the Trans-Blot electrophoretic transfer system. 
Six sheets of Whatman 3mm filter paper and PVDF membrane were cut according to gel size 
and soaked in pre-chilled (4
°
C) 1× transfer buffer for 5 minutes. Then a pre-wet fiber-
pad/paper/gel/membrane sandwich was assembled in the cassette. Air bubbles removed using 
glassy roller. Transferring was undertaken in a tank containing 750ml of chilled transfer 
buffer at 80V for 60-90 minutes at 4
°
C. 
Efficacy of running and transferring was assessed at the end of each process by staining gel 
and membrane. Coomassie blue (Severn Biotech Ltd, UK) was used for staining the gel for 
one hour and washed with distilled water (slowly shaking) overnight before drying by 
vacuum gel-dryer (Flowgen, Nottingham, UK) at 70
°
C for 3 hours. Ponceau S 10% (Sigma, 
USA) was used for staining the membrane for 3 minutes and washed with TBS-T for 10 
minutes to visualized protein bands. 
2.2.3.3.3 Immunoblotting to detect protein expression 
To prevent non-specific bindings of primary antibody, membranes were blocked with 10ml 
of 5% TBS-T-milk for one hour in room temperature on gently agitated shaker. Then they 
were incubated with appropriate concentration of primary antibody (Table 2.1) in room 
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temperature for one hour, followed by washes with 1× TBS-T four times for 10 minutes to 
remove unbound primary antibody. Then membranes were incubated with appropriate 
concentration of secondary antibody (Table 2.1) in room temperature for one hour followed 
by four times washing with 1× TBS-T for 10 minutes. Finally, for visualizing probed 
antibodies, they were incubated with ECL reagents (GE Healthcare, UK) for 2 minutes in 
room temperature before developing and fixing in dark room. Expressed proteins were 
recorded on Kodak film (GE Healthcare, UK) for a serial required times (0.5-15 minutes). 
2.2.3.3.4 Correcting loading variations 
To correct possible loading variation, expression of β-actin was evaluated in each membrane. 
After detecting the target protein, membrane was washed with 1× TBS-T for overnight. Then 
it was blocked with 10ml of 5% TBS-T-Milk for 30 minutes before incubating with β-actin 
antibody for 30 minutes in room temperature. Then membrane was washed four times with 
1× TBS-T for 5 minutes followed by incubating with secondary antibody for 30 minutes in 
room temperature. It was washed four times with 1× TBS-T for 5 minutes before visualized 
by incubating with ECL reagents for 2 minutes. Membrane was developed and fixed in dark 
room and recorded on Kodak film. Expression level (EL) of each protein normalized by using 
this formula: 
Normalized EL of target protein= EL of target protein/ EL of β-actin 
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Target Protein Primary antibody Secondary antibody 
PPARβ/δ 
Rabbit polyclonal  
anti-human PPAR delta  
(Thermo PA1-823A) (1:1000) 
Swine polyclonal anti-rabbit 
Immunoglobulin/HRP 
(Dako) (1:20,000) 
PPARγ 
Rabbit polyclonal  
anti-human PPARγ  
(Santa Cruz sc-7196) (1:200) 
Swine polyclonal anti-rabbit 
Immunoglobulin/HRP 
(Dako) (1:20,000) 
C-FABP 
Rabbit polyclonal  
anti-human E-FABP  
(Hycult HP-9030) (1:500) 
Swine polyclonal anti-rabbit 
Immunoglobulin/HRP 
(Dako) (1:20,000) 
VEGF 
Mouse polyclonal  
anti-human VEGF  
(Thermo RB-9031-P1) (2µg/ml) 
Rabbit polyclonal anti-mouse 
Immunoglobulin/HRP 
(Dako) (1:20,000) 
β-actin 
Mouse monoclonal  
anti β-actin  
(Sigma) (1:50,000) 
Rabbit polyclonal anti-mouse 
Immunoglobulin/HRP 
(Dako) (1:20,000) 
 
Table  2.1: Primary and secondary antibodies used for Western blotting. 
 
2.2.4 Evaluating protein expression in tissues 
2.2.4.1 Human tissue samples 
Human prostate tissues were selected from an archival set with follow-up data held in 
Department of Molecular and Clinical Cancer Medicine (originally named Department of 
Pathology), University of Liverpool, UK. Patients who were originally diagnosed with 
prostate cancer, but died from other causes were excluded. Tissues were taken from 35 
benign prostatic hyperplasia (BPH) patients and from 97 prostate adenocarcinoma patients 
with an average age of 67.5 and 73 years, respectively. All patients studied were treated by 
trans-urethral resection of the prostate (TURP) in the Royal Liverpool University Hospital 
during 6 years between 1995 and 2001. This study was approved by the National Science 
Ethics Committee in accordance with the Medical Research Council guidelines (project 
reference number: Ke; 02/019). Specimens had been fixed in 10% (v/o) formalin and 
embedded in paraffin wax. Cut histological sections were examined independently by two 
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qualified pathologists and classified as BPH and carcinomas and further classified according 
to their combined Gleason scores (GS) 
107
. PSA levels at the initial diagnosis was obtained 
through telepath system and classified into two group low (<10ng/ml) and high (≥ 10ng/ml) 
249
. 
2.2.4.2 Preparing tissue sections 
Paraffin wax-embedded tissue blocks were pre-cooled in a container filled with ice and water. 
Using microtome (MICROM, Oxford, UK) tissues were cut at 4μm thickness and mounted 
on labelled Superior Adhesive Slides (Apex, Leica, UK), then dried overnight at 37
°
C. 
2.2.4.3 Immunohistochemistry 
Immunohistochemistry (IHC) refers to the process of detecting antigens (e.g., proteins) in 
cells of a tissue section by exploiting the principle of antibodies binding specifically 
to antigens in biological tissues 
250
. Immunohistochemical staining is widely used in the 
diagnosis of abnormal cells such as those found in cancerous tumours. In this study, it was 
used to evaluate expression of different proteins in prostate cell lines. 
For de-waxing the sections, they were washed twice in xylene (each 5 minutes) followed by 
two times rinsing in Industrial Methylated Spirits (IMS) (GENTA Environment Ltd., 
Tockwith, UK) (each 5 minutes) before transferred to fresh 3% H2O2/Methanol (15 minutes) 
to block endogenous peroxidase activity. Then sections were washed with running tap water 
for 30 seconds. Antigen retrieval achieved by incubating in 10 mM Sodium Citrate buffer 
(pH 6) on full power in the microwave for 15 minutes and allowed sections to rest in hot 
buffer for a further 15 minutes, for C-FABP, PPARγ and AR detection. For PPARβ/δ, 
antigen retrieval was performed by incubating sections in pressure cooker filled with ethylene 
diamine tetraacetic acid (EDTA) solution (pH 7) for 3 minutes. Then slides were washed 
three times with Tris Buffered Saline containing 0.025% Tween20 (TBS-T). For PPARγ and 
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PPARβ/δ, slides were racked into flat, humid chamber and incubated with appropriate 
concentration of primary antibody (Table 2.2) in 100μl of TBS-T in 4°C, overnight. For C-
FABP and AR, they were racked into sequenzer (Immunohistochemistry Staining Trays, 
Shandon, UK) and incubated with appropriate concentration of primary antibody (Table 2.2) 
in 100μl of TBS-T in room temperature, for one hour. All slides were gone through 3 step 
washes with TBS-T (each one minute) in the sequenzer. Because PPARβ/δ and PPARγ 
antibodies were derived from gout , 100μl of diluted (10μg/ml) Linker (Anti-gout IgG, 
Vector, USA) in TBS-T were applied to slides for 30 minutes and followed by 3 washes with 
TBS-T (each 1 minute). Bound antibodies were detected with 200μl of EnVisionTM 
FLEX/HRP (DakoCytomation, Ely, UK) for 1 hour then washed 3 times with TBS-T. 100μl 
of EnVision
TM
 FLEX/DAB+ Chromogen (DakoCytomation, Ely, UK) used to visualize and 
stained of each section for 10 minutes, then slides were washed with distilled water for 4 
minutes. Finally all slides counterstained with Haematoxylin solution (BWR international, 
London, UK) for 2 minutes, rinsed in 1% Acid/Alcohol, washed in water and briefly rinsed in 
Blue Scott till the blue colour appeared on slides. At the end, slides were rehydrated through 
four rinses in IMS and cleaned by three rinses in xylene, then mounted in DPX (Bios, 
Lancashire, UK).  
Target Protein Primary antibody 
PPARβ/δ 
Gout polyclonal Anti-human PPARβ  
(Santa Cruz sc1987) (1:100) 
PPARγ 
Gout polyclonal Anti-human PPARγ 
(Santa Cruz sc-1984) (1:50) 
C-FABP 
Rabbit polyclonal Anti-human E-FABP 
(Hycult HP-9030) (1:500) 
Androgen Receptor 
Mouse monoclonal Anti-human Androgen Receptor 
(Abcam ab-9474) (1:100) 
Table  2.2: Primary antibodies used for immunohistochemical staining. 
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2.2.4.4 Controls for immunohistochemistry 
To confirm the efficiency of immunohistochemical staining, specific tissues which showed 
high expression levels of dedicated antigen (according to the literatures) were used as 
positive control. Normal colorectal, colorectal adenocarcinoma and poorly differentiated 
prostate cancer tissues were used as positive control for PPARβ/δ, PPARγ and C-FABP, 
respectively. 
Also in each experiment, the same sample was used as negative control which passed through 
all staining steps except the step of primary antibody. In that step, negative control samples 
were incubated with TBS-T only.  
2.2.4.5 IHC scoring 
Intensity and percentage of staining were evaluated in both cytoplasm and nucleus by two 
independent observers. Percentage of staining were scored as 1-3; 1: ≤ 30%, 2: 31-69%, 3: 
≥70%. Intensity of obtained stains were scored as 1-3; 1: +, 2: ++, 3: +++.  In cytoplasm, 
because of homogenous staining pattern, slides were scored only through intensity. For 
nuclear staining, final scores were obtained from multiplying the percentage and intensity 
scores (1-9). This method was similar to which used for scoring immunohisochemical 
detecting of ER in breast cancer 
251
. Finally, slides classified as weakly positive, 1-3; 
moderately positive, 4-6; strongly positive, 7-9.  
2.2.5 Evaluating RNA expressions in cell lines 
2.2.5.1 Total RNA isolation 
Prostate cells were cultured in 175 cm
2
 flasks to 60-80% confluency (not more than 1×10
7
)  
before harvesting and extracting their total RNA, using RNeasy Mini Kit (QIAGEN Sample 
& Assay Technologies, CA, USA). After washing pellet with PBS, cells were disrupted using 
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600µl of buffer RTL containing 1% β-Mercaptoethanol. Cell lysates then homogenized by 
centrifugation through a QIAshedder spin column placed in a 2ml collection tube for 2 
minutes at full speed and precipitated in equal volume of 70% ethanol. Up to 700µl of 
solution were loaded in an RNeasy spin column sitting in a 2ml collection tube and 
centrifuged for 15 seconds in ≥8,000 ×g. The flow-through was discarded and column was 
washed with 700µl of Buffer RW1 which followed by centrifuged for 15 seconds in ≥8,000 
×g. To digest any DNA contamination, 10 µl of DNase I solution which diluted with 70 µl of 
buffer RDD was applied and left on benchtop for 15 minutes. The flow-through was 
discarded and column was washed with 500µl of Buffer RW1 which followed by centrifuged 
for 15 seconds in ≥8,000 ×g. To eliminate any carryover buffer, the RNeasy spin column was 
centrifuged at full speed for 1 minute. Finally, column was placed on a new collection tube 
and 30-50µl of RNase-free water were loaded directly to the membrane and centrifuged for 1 
minute at ≥8,000 ×g to elute the RNA. The total RNA yield and purity was determined using 
NanoDrop ND-1000 spectrophotometer. Quality of each RNA sample was determined by 
1.8≤ 260/280 ratio ≤ 2 252, 253.  
2.2.5.2 Reverse transcriptional polymerase chain reaction (RT-PCR) 
This technique is commonly used in molecular biology to detect RNA expression levels by 
qualitatively detection of gene expression through creation of complementary DNA (cDNA) 
transcripts from RNA, then qPCR is used to quantitatively measure the amplification of DNA 
using fluorescent probes 
254
.  RT-PCR is currently the most sensitive method of RNA 
detection available 
255
. In this study, it was applied to show the levels of PPARβ/δ and 
PPARγ gene expressions in prostate cell lines.  
2.2.5.2.1 PCR primer design 
Using PerlPrimer, primer design software (perlprimer.sourceforge.net/ (,  primers were
designed spanning exon-exon junctions of PPARβ/δ and PPARγ genes and their specificities 
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were validated by the nucleotide Blast program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LI
NK_LOC=blasthome). Primers purchased from Invitrogen by Life Technologies Ltd. 
(Paisley, UK). β-actin primers were used as a house-keeping gene (Table 2.3). 
Primers Sequences 
PPARβ/δ Sense:          5’- AGGTTACCCTTCTCAAGTATGG-3’ 
Antisense:    5’- CTTGTAGATCTCCTGGAGCAG-3’ 
PPARγ Sense:          5’- CGCCGTGGCCGCAGATTTGA -3’ 
Antisense:    5’- GCCTGTGGCATCCGCCCAAA -3’ 
β-actin Sense:          5’-  AGCCTCGCCTTTGCCGA -3’ 
Antisense:    5’-    CTGGTGCCTGGGGCG    -3’ 
Table  2.3: RT-PCR primer’s sequences. 
2.2.5.2.2 Complementary DNA (cDNA) synthesis 
In RT-PCR, the RNA template is first converted into a complementary DNA (cDNA) using 
a reverse transcriptase. The cDNA is then used as a template for exponential amplification 
using PCR. Total RNAs isolated from prostate cell lines were used to synthesize cDNA. For 
each cell line, 1µg of total RNA was mixed with 1µl of 50µM Oligo (dt)20 primer and 1µl of 
dNTP mixture (10µM each dATP, dCTP, dGTP, dTTP at neutral pH) and volume was 
adjusted to 20µl with nuclease-free water. Mixtures were incubated in 65
°
C for 5 minutes 
followed by chilling on ice for 1 minute. Then 4µl of 5× first strand buffer and 2µl of 0.1M 
DTT were added and incubated at 42
°
C for 2 minutes followed by 1µl of SuperScript II 
Reverse Transcriptase and incubating at 42
°
C for 50 minutes. Finally, reaction were 
inactivated by heating at 70
°
C for 15 minutes 
54. β-actin RNA was used as a house-keeping 
gene. 
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2.2.5.2.3 RT-PCR 
Polymerase Chain Reaction (PCR) was performed to amplify DNA template. Using the 
designed primers, PCR mixtures prepared as shown in Table 2.4: 
Forward Primer (5µM) 1µl 
Reverse Primer (5µM) 1µl 
cDNA (for each cell lines) 1µl 
Platinum
®
PCR SuperMix High Fidelity 22µl 
Table  2.4: PCR Mixture. 
Platinum 
®
PCR SuperMix High Fidelity (Invitrogen, Paisley, UK) contains anti-Taq DNA 
polymerase antibody, Mg ⁺⁺, deoxyribonucleotide triphosphates, recombinant Taq DNA 
polymerase and Pyrococcus species GB-D thermostable polymerase. 
Reactions were incubated in an automatic heat block thermal cycler (Peltier Thermal Cycler 
PTC-200) at 94
°
C for 2 minutes followed by 35 cycles of PCR amplification, each cycle 
includes of denaturing at 94
°
C for 30 seconds; annealing at 58 
°
C for 30 seconds and 
extension at 72
°
C for 1 minute. PCR was finalized by incubation at 72 
°
C for 5 minutes then 
maintained in 4
°
C 
252
. PCR amplification products were analysed and visualized by 0.8% 
agarose gel electrophoresis (section: 2.2.6.5.7.3).     
2.2.6 Molecular biology  
2.2.6.1 Small interfering RNA 
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing 
RNA, is a class of double-stranded RNA molecules, 20-25 base pairs in length. siRNAs have 
a well-defined structure: a short (usually 21-bp) double-stranded RNA (dsRNA) 
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with phosphorylated 5' ends and hydroxylated 3' ends with two overhanging nucleotides. 
siRNA plays many roles, but it is more notable in the RNA interference (RNAi) pathway, 
where it interferes with the expression of specific genes with complementary nucleotide 
sequence 
256
. Since in principle, some genes can be knocked down by a synthetic siRNA with 
a complementary sequence, siRNAs are an important tool for validating gene function and 
drug targeting in the post-genomic era. Gene knockdown by transfection of exogenous 
siRNA is often unsatisfactory because the effect is only transient, especially in rapidly 
dividing cells. This may be overcome by creating an expression vector for the siRNA. The 
siRNA sequence is modified to introduce a short loop between the two strands. The 
resulting transcript is a short hairpin RNA (shRNA), which can be processed into a functional 
siRNA by dicer in its usual fashion 
257
. 
2.2.6.2 Designing siRNA sequences 
Three target sequences were chosen using Bioinformatics & Research Computing software 
(Whitehead siRNA selection program) (Table 2.5). Specificity of these sequences to PPARγ 
was confirmed by Blast search. Sequences were ordered from Ambion (by Life technologies, 
USA). 
Position Sequences 
Sequence 1 
(278-300) 
 
Sense 5': GCCCUUCACUACUGUUGACUU 
mRNA: AA GCCCTTCACTACTGTTGACTT 
Antisense 5': GUCAACAGUAGUGAAGGGCUU 
Sequence 2 
(1209-1231) 
Sense 5': GGCUUCAUGACAAGGGAGUUU 
mRNA: AA GGCTTCATGACAAGGGAGTTT 
Antisense 5':ACUCCCUUGUCAUGAAGCCUU 
Sequence 3 
(653-675) 
Sense 5': UAAAUGUCAGUACUGUCGGUU 
mRNA: AATAAATGTCAGTACTGTCGGTT 
Antisense 5': CCGACAGUACUGACAUUUAUU 
Table  2.5: PPARγ target and siRNA sequences. 
Chapter 2: Materials and Methods 
 
 
75 
2.2.6.3 Transient transfection 
X-tremeGENE siRNA Transfection Reagent (Roche, Germany) was used for transient 
transfection. 1×10
5
/well of PC-3M cells were pulled in 6-well plates 24 hours prior to 
transfection to reach the confluency of 30-60%. 1, 5 or 10 μl of X-tremeGENE siRNA 
Transfection Reagent (for each well) was diluted in 99, 95 and 90 μl of Opti-MEM I medium 
(Gibco, Invitrogen, Paisley, UK) to a final volume of 100 μl. Also1, 2 or 4μg/well of siRNAs 
was diluted in Opti-MEM I medium to a final volume of 100μl. After 15 minutes incubation 
in room temperature, diluted X-tremeGENE siRNA Transfection Reagent and siRNA were 
mixed by gently flicking the tubes and incubating in room temperature for another 15 
minutes.  Silencer
®
 Negative Control #1 siRNA (Ambion, Inc., USA) was also diluted to use 
as scrambled RNA (control). Complex was overlaid drop-wise onto wells then distributed by 
gently rocking back and front. Dishes were incubated in normal cell culture conditions for 24, 
48 and 72 hours. Proteins from cells were extracted (2.2.3.1) in different time points and 
expression of PPARγ was assessed in extracts (2.2.3.3). The most efficient siRNA was used 
to design shRNA for stable transfection in the most appropriate incubation time. 
2.2.6.4 Designing short hairpin RNA (shRNA) sequences 
The sequence which produced most suppression level for PPARγ (sequence 3) was chosen to 
design shRNA using siRNA Wizard™ Software (InvivoGen, USA) (Table 2.6). Specificity 
of these sequences to PPARγ was confirmed by Blast searching. Sequences were ordered 
from Ambion (by Life technologies, USA). Acc651 (GGTACC) and HindIII (AAGCTT) 
sequences were considered as restriction enzyme sites. 
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shRNA Sequences (oligos) 
 
 
PPARγ 
 
Sense: 
5' GTACCTCATAAATGTCAGTACTGTCGGTCAAGAGCCG
ACAGTACTGACATTTATTTTTTGGAAA 3' 
Antisense 
5' AGCTTTTCCAAAAAATAAATGTCAGTACTGTCGGCTC
TTGACCGACAGTACTGACATTTATGAG 3' 
 
 
Scramble 
Sense 
5' GTACCTCGGTAGAAATCGACGTATCTTTCAAGAGAAG
ATACGTCGATTTCTACCTTTTTGGAAA 3' 
Antisense 
5' AGCTTTTCCAAAAAGGTAGAAATCGACGTATCTTCTC
TTGAAAGATACGTCGATTTCTACCGAG 3' 
 
Table  2.6: PPARγ and negative control shRNA sequences. 
 
2.2.6.5 Cloning silencing sequences into vector 
2.2.6.5.1 Vector selection 
psiRNA-h7SKGFPzeo plasmid (InvivoGen, USA) was chosen to perform the vector base 
approach of shRNA. psiRNA is specifically designed for cloning.
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                                          Figure  2.1: psiRNA-h7SK-GFPzeo vector map 258. 
 
2.2.6.5.2 Annealing sense and anti-sense oligos 
Oligonucleotides (forward and reverse) were dissolved first at a concentration of 100μM then 
more diluted to 25μM. After that annealing reaction was prepared by mixing the following 
components (Table 2.7). The reaction was incubated for 2 minutes at 80
°
C then stopped the 
heating and maintained in water bath till the temperature reached to 35
°
C. Annealed inserts 
were stored at -20
°
C. 
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Forward oligonucleotide (25μM) 2μl 
Reverse oligonucleotide (25μM) 2μl 
NaCl (0.5M) 6μl 
H2O to a final volume of 30μl 
 
Table  2.7:  Annealing reaction.      
                         
2.2.6.5.3 Competent cell preparation 
E.coli GT116 strain, a sbcCD deletion mutant, which is more compatible with hairpin 
harbouring plasmids than standard laboratory strains, used for transformation. E.coli GT116 
was provided as lyophilized cells, so first put them on ice for 5 minutes, then added 1ml of 
cold re-constitutive solution and kept on ice for 5 minutes. Solution was gently homogenised 
and cells were allowed completely rehydrate on ice for 25-30 minutes. Because re-
constitutive cells can only be used once, a stock solution of E.coli GT116 strain was provided 
by inoculating 25 ml of LB medium (without antibiotic) with 25-100μl of re-constitutive 
cells. Overnight culture was aliquot in 20% glycerol, flash freezing in liquid Nitrogen and 
stored in -80
°
C. 
For preparing competent cells, 1ml of overnight grown bacteria was put in a flask containing 
100ml sterile SOB medium with 1ml of 2M magnesium salt, then incubated in 37
°
C for 90 
minutes with shaking at 225 rpm . OD550 density was measured with spectrophotometer 
(Jenway, Genova, UK) in certain intervals (10-30 minutes) till OD reached 0.4. After that 
cultured medium was divided into 8 universals (12.5ml/tube) and cooled on ice for 10 
minutes before being centrifuged at 4
°
C in 2000 ×g for 10 minutes. Then supernatants were 
discarded and pellets were re-suspended in 66ml (8.25ml/tube) RF1 buffer (RF1 calcium 
chloride/glycerol buffer) and kept on ice for 10 minutes before being centrifuged at 4
°
C in 
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2000 ×g for 10 minutes. Supernatants were discarded and pellets were re-suspended in 16ml 
(2ml/tube) RF2 buffer (RF2 calcium chloride/glycerol buffer) and pooled. Finally it has been 
dispensed into 1ml cryovials, flash freezing in liquid nitrogen and stored at -80
°
C. 
2.2.6.5.4 Double digestion of plasmid DNA 
After thawing psiRNA plasmid in ice, digestion reaction was prepared by mixing the 
following components (Table 2.8): 
psiRNA-h7SK-GFPzeo plasmid (1μg) ~2μl 
Enzyme buffer (2) 2μl 
Hind III, restriction enzyme 1μl 
Acc651, restriction enzyme 1μl 
H2O to a final volume of 20μl 
Table  2.8: Double digestion reaction. 
The reaction was incubate at 37
°
C water bath for one hour then put at 68
°
C for 10 minutes to 
inactivate enzymes. Enzyme digestion was confirmed by running the DNA samples on 
agarose gel (0.8%). 
 To purify digested plasmid, Wizard
®
 SV Gel and PCR Clean-Up System (Promega, WI, 
USA) was used. After running the gel, band belong to digested plasmid was cut with sterile 
blade and put in a sterile microcetrifuge tube then Membrane Binding Solution was added to 
this (10µl/10µg of gel). Reaction was mixed by vortex and incubated at 50-65
°
C for 10 
minutes before loaded in Wizard
® 
SV Mini columns followed by 1 minute centrifuge in 
10,000 ×g. After two step washing with 700 and 500µl of Membrane Wash Solution which 
removed by 5 minutes centrifuging at 10,000 ×g, 30-50µl of nuclease-free water was applied 
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directly to the centre of column then centrifuged for 1 minute at 14,000 rpm. Eluted DNA 
(plasmid) was used for ligation or stored in -20
°
C 
259
.   
 
2.2.6.5.5 Ligation of shRNA insert into psiRNA 
psiRNA-h7SK-GFPzeo plasmid was linearized and ligation ready. Silencing sequences 
(PPARγ and negative control) were annealed. Then ligation reaction was prepared by mixing 
the following components (Table 2.9), the reaction was incubated at 16
°
C overnight (or at 
27
°
C for 2 hours). 
Digested psiRNA 1μl (100ng) 
Annealed shRNA insert 1μl 
T4 DNA Ligase 1μl (1unit) 
10X ligation buffer 2μl 
H2O to a final volume of 20μl 
Table  2.9: Ligation reaction. 
2.2.6.5.6 Transformation 
10μl of ligation product (no more than 50ng of supercoiled plasmid DNA) was introduced 
into pre-chilled Falcon 2059 tubes contained 200μl of E.coli GT116 competent cells, mixed 
by tapping gently and incubated on ice for 30 minutes. Alongside these transformation 
reactions, another tube was prepared containing only competent cell as control. All reactions 
were incubated in 42
°
C water-bath for exactly 90 seconds then placed on ice for 2 minutes. 
Then 800μl of freshly made SOC which pre-heated at 42°C were added to transformation 
product and incubated at 37
°
C for one hour with shaking at 225 rpm. Finally the transformed 
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mixtures were plated on LB-Zeocin agar plates each containing 100μg/ml Zeocin and 
incubated at 37
°
C overnight. Following incubation, colonies were picked and each grown in 
10ml LB containing 100μg/ml Zeocin at 37°C with shaking, overnight. Plasmids were 
extracted using QIAGEN Plasmid mini-preparation kit (QIAGEN, USA). If more amount of 
plasmid needed, it grown in 10ml LB + Zeocin for 8 hours then 200μl of cultured product 
was diluted in 100ml LB + Zeocin and grown at 37
°
C with shaking overnight. In such cases 
plasmids were extracted using QIAGEN Plasmid midi-preparation kit (QIAGEN, USA).  
2.2.6.5.6.1 Transformation efficiency 
Transformation efficiency is the efficiency by which cells can take up extracellular DNA and 
express genes encoded by it. This is based on the competence of the cells. Many factors affect 
transformation efficiency of cells such as: plasmid size, forms of DNA, genotype of cell, 
growth of cell, method of transformation and damage to DNA 
260-262
. It can be calculated by 
dividing the number of successful transformants or colony forming unit (cfu) by the amount 
of DNA (per μg) used during a transformation procedure.  
2.2.6.5.7 Plasmid DNA preparation 
QIAGEN plasmid preparation kits were used to extract and purified plasmid DNA 
263, 264
. 
Preparation of up to 20μg plasmid DNA was performed using QIAGEN Plasmid mini-
preparation kit (QIAGEN Sample & Assay Technologies, CA, USA) while for 20-100μg 
plasmid, QIAGEN Plasmid midi-preparation kit (QIAGEN Sample & Assay Technologies, 
CA, USA) was used. 
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2.2.6.5.7.1  Miniprep DNA extraction 
Five millilitre of bacterial cell were harvested by centrifugation at > 6800 ×g for 3 minutes at 
room temperature. Pellets were collected and re-suspended with buffer P1 (250μl) in 1.5ml 
micro-centrifuge tubes. Then buffer P2 (250μl) was added and mixed thoroughly by inverting 
4-6 times. After that, buffer N3 (350μl) was added and immediately mixed thoroughly by 
inverting tube 4-6 times. The mixture was centrifuged at 17,900 ×g for 10 minutes and the 
supernatant which containing plasmid DNA was applied to a QIAprep spin column. Column 
was centrifuged for 30-60 seconds before washed by buffer PB (500µl) followed by 
centrifuging 30-60 seconds. Next wash was done by applying buffer PE (750µl) and 
centrifuging for 30-60 seconds. Flow-through was discarded and the column was centrifuged 
for an additional 1 minute to remove residual wash buffer. Finally, the QIAprep spin column 
was placed into a clean micro-centrifuge tube and plasmid DNA was eluted by loading 30-50 
µl buffer EB (10mM Tris-Cl, pH 8.5) which was let stand for 1 minute and centrifuged for 1 
minute. 
2.2.6.5.7.2  Midiprep DNA extraction 
100-200ml of bacterial cell was harvested by centrifugation at > 6800 ×g 15 minutes at 4
°
C. 
Pellets were collected and re-suspended with buffer P1 (4ml) in PP bottles. Buffer P2 (4ml) 
was then added and mixed thoroughly by inverting sealed tube 4-6 times and incubated at 
room temperature (15-25
°
C) for 5 minutes. Pre-chilled buffer P3 (4ml) was added and 
immediately mixed thoroughly by inverting tube 4-6 times and incubated on ice for 5 
minutes. The mixture centrifuged at ≥20,000 ×g for 30 minutes then the supernatant which 
containing plasmid DNA was transferred into a clean PP bottle and centrifuged again at 
≥20,000 ×g for 30 minutes. Then supernatant was applied in a QIAGEN-tip 100 that 
equilibrated by applying buffer QBT (4ml) and allowed to enter the resin by gravity flow. At 
Chapter 2: Materials and Methods 
 
 
83 
this point, QIAGEN-tip 100 was washed with Buffer QC (10ml) twice before eluting DNA 
with buffer QF (5ml). The eluted DNA was collected in 15ml glass tube then DNA was 
precipitated by adding room-temperature isopropanol (3.5ml) which immediately centrifuged 
at ≥20,000 ×g for 30 minutes at 4°C. Supernatant was carefully decanted and DNA pellet was 
washed with 70% ethanol (2ml) and again centrifuged at 20,000 ×g for 10 minutes. DNA 
pellet was air-dried for 5-10 minutes then DNA was resolved in appropriate volume of TE 
Buffer (pH 8.0). DNA concentration was evaluated by NanoDrop spectrophotometer 
(Labtech International, Ringmer, UK). Extracted plasmid DNA was stored at -20
°
C. 
2.2.6.5.7.3  Agarose gel analysis 
To confirm the presence of shRNA insert, first the plasmid DNA was double digested 
(section 2.2.6.5.4). Then a 0.8% agarose gel was prepared by dissolving 0.8g of agarose in 
100ml of 0.5×TBE buffer using microwave. When the temperature reached to 50
°
C, Safe 
View (Nucleic Acid Stain) (NBS Biological Ltd., Cambridgeshire, UK) (5µl/100ml) was 
added for visualization and poured in cassette to set. Using undigested plasmid as control, 
samples were loaded in the gel. The gel was run at 80v in 0.5 × TBE buffer for one hour then 
visualized under UV light and subjected to densitometry for quantification using DNA 
molecular weight marker. 
2.2.6.5.7.4   Sequencing analysis 
Internal psiRNA-h7SK-GFPzeo plasmid primers [OL559 primer 
(forward):5’CGATAAGTAACTTGACCTAAGTG3’; OL408 primer 
(reverse):5’GCGTTACTATGGGAACATAC3’] were used to conduct sequencing the 
cloning site of plasmid. Plasmid DNAs were sent to Beckman Coulter Genomics, UK for 
sequencing. Sequence alignment was determined using BioEdit for searching Genbank 
(BLAST).  
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2.2.6.6 Stable transfection 
X-tremeGENE HP DNA Transfection Reagent (Roche, Germany) was used for stable 
transfection. 1×10
5
/well of PC-3M cells were put in 6-well plates 24 hours prior to 
transfection to reach the confluency of 30-60%. 1μl of X-tremeGENE HP DNA Transfection 
Reagent (for each well) was diluted in 99μl of Opti-MEM I medium (Gibco, Invitrogen, 
Paisley, UK) to a final volume of 100μl. Also 4μg/well of psiRNA with inserted shRNA was 
diluted in Opti-MEM I medium to a final volume of 100μl. After 15 minutes incubation in 
room temperature, diluted X-tremeGENE HP DNA Transfection Reagent and plasmid were 
mixed by gently flicking the tubes and incubate in room temperature for another 15 minutes.  
Complex was overlaid drop-wise onto wells then distributed by gently rocking back and 
forth. Dishes were incubated in normal cell culture conditions until cells were passaged (1-2 
days). At that time, medium was replaced with those containing Zeocin
TM
 (100μg/ml) 
(Invitrogen, by Life technology, USA) which has been changed every three day. Zeocin
TM
 is 
a copper-chelated glycopeptide isolated from Streptomyces verticillus. When the antibiotic 
enters the cell, the copper cation is reduced from Cu
2+ 
to Cu
1+ 
and removed by sulfhydryl 
compounds in the cell. Upon removal of the copper, Zeocin
TM
 is activated and will bind DNA 
and cleave it which causing cell death 
265
. Unsuccessfully transfected cells were killed by 
Zeocin
TM
 while successfully transfected cells were survived. After about one week, 
transfected cells were distributed into 9cm cell culture plates (petri dish) and cultured with 
selective medium containing Zeocin
TM
 for two weeks. 
2.2.6.6.1 Ring cloning of transfected cells 
When colonies reached to approximate diameter of 2-3 mm, single colonies were selected by 
ring cloning to generate single transfected cloned cell lines. Rings were created by cutting 
tops of 1ml pipette tips which then  sterilized by autoclaving together with forceps and silicon 
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grease. Using the forceps, cloning rings were dipped in silicon grease and put over the 
colony. Small amount of silicon grease stacked the ring to plate and provided a watertight 
seal around the colony. Then 80μl of 2.5% Trypsin (v/v) in Versene (T/E) was added to each 
single colony and incubated for 2-3 minutes till cells became round and detached. T/E was 
deactivated by adding 160μl selective medium then cells from a clone transferred to 96-well 
plate. The medium was changed next day and colonies were grown in normal cell culture 
conditions. 
2.2.7 In vitro assays 
2.2.7.1 Proliferation assay 
Proliferation is an important biological process for maintaining cell growth. Cell growth is 
defined as the increase in cell number and offset by the net cell loss by apoptosis and 
necrosis. The increased proliferation ability of cells is a characteristic hallmark in cancer 
malignancy. High proliferative activity can be occurred either from a high growth fraction or 
a short generation time. Especially in cancer cells, proliferation activity predicts the potential 
of tumorigenicity and metastasis. Thus it was necessary to determine the proliferation activity 
of knockdown cancer cell lines.     
2.2.7.1.1 Growth curve preparation 
Cells were grown in 175cm
2
 flask up to 60-80% confluency then harvested and re-suspended 
in 10ml of complete culture medium. Using haemocytometer, a cell suspension containing 
5×10
5
/ml was prepared. A standard growth curve was prepared in a serial dilution as: 
6.25×10
3
/ml, 1.25×10
4
/ml, 2.5×10
4
/ml, 5×10
4
/ml, 1×10
5
/ml, 2.5×10
5
/ml, 5×10
5
/ml from 
which 200μl was placed  in 96-well plate in triplicate. Each cell line needs its own standard 
curve. To measure proliferation activity of each cell line, same cell suspension containing 
6.25×10
4
/ml was prepared and 200μl (1.25×104 cells) was incubated in 96-well plate in 
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triplicate. As proliferation activity was assessed in 5 serial days, five similar set of cells were 
prepared. All plates were incubated at 37
°
C and 5% CO2. 
2.2.7.1.2 Cell number determination by MTT assay 
MTT (3-(4, 5-dimethylthiazl-2-yl)-2, 5-diphenylterazolium bromide) is a yellow colour 
chemical reagent which can enter into the mitochondria of cells where then is converted by 
oxidative enzymes into a soluble blue dye as formazan that forms blue crystals in cell 
cytoplasm. Formazan crystals are dissolved by adding DMSO and prepare a blue solution 
which is directly proportional to the number of present cells. Optical density (OD) of dye will 
be measured at 570nm.  
A MTT stock solution was prepared by concentration of 5mg/ml (in PBS) and stored in 4
°
C. 
Fifty μl of MTT was applied in each well of cells and incubated for 4 hours at 37°C. About 
200μl of medium was removed from each well and 200μl of DMSO was loaded and 
incubated for 10min. The optical density of each well was measured at 570nm using the 
MultiSkan plate reader (BioTek Instruments, USA). Standard curve were established for each 
cell line by plotting OD against cell number. Then sample cell numbers were determined by 
extrapolating from standard curve. 
2.2.7.2 Invasion assay 
Invasiveness is one of the most important features of cancer cells, distinguishing benign and 
malignant lesions. Invasiveness and motility rate are indicators of tumour malignancy. A 
complex multi-stage process involves in prostate cancer cell metastasis. Invasion assay is an 
established method to measure invasive potential in cancer cells. The principal is those cells 
migrate along a chemoattractant gradient from an upper compartment through a porous 
membrane into the lower compartment. The BD BioCoat
TM
 Growth Factor Reduced (GFR) 
Matrigel
TM
 Invasion Chamber (BD Biosciences, USA) has been used for assessment of 
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metastatic potential of tumour cells 
266
 and different invasion aspects of cancer cells. BD 
Matrigel Matrix, a solubilized tissue basement membrane preparation, contains laminin, 
collagen type IV, heparin sulphate proteoglycan, entactin and growth factor 
267
. PC3-M cells 
and transfected cells in an active growth phase with confluency less than 80% were 
maintained in serum free RPMI 1640 medium for 24 hours prior to setting up the invasion 
assay.  After 24 hours starvation, cells were harvested and counted using haemocytometer to 
prepare a mixture containing 5×10
4 
cells/ml in serum free medium. 
At the meantime, chambers were brought out of -20
°
C freezer and allowed to come to room 
temperature. Then 0.5ml of warm medium (37
°
C) was applied to the interior of inserts and 
allowed to rehydrate for 2 hours in a humidified tissue culture incubator at 37
°
C, 5% CO2 
atmosphere. After rehydration, medium was carefully removed without disturbing the GFR 
Matrigel
TM
 Matrix layer on the membrane. Finally, 2.5×10
4 
cells in 0.5ml medium were 
loaded into every upper compartment of chambers while routine medium (with 10% (v/v) 
FCS) was placed 1ml per well in lower compartments. Negative control was set up for each 
cell line by using serum free medium in lower compartment. All cell lines were set as 
triplicate and assay was run in a humidified tissue culture incubator at 37
°
C, 5% CO2 
atmosphere for 24 hours. Then, cells which remain in upper side of filter were removed 
gently using cotton swabs and washed with PBS. The cells migrated to the lower part of filter 
were fixed and stained using 2% crystal violet for 10 minutes. After several washes with 
water, chambers were left at 37
°
C to dry. The number of stained cell in lower part were 
counted using light microscope (Leitz, labovert, Luton, UK) at 125× magnification. 
Photographs were taken using Olympus digital camera (Olympus C-4040) at 100× 
magnification.                                                                                                                                                                                                   
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Figure  2.2: Invasion assay; performed in chambers with 8µm pore size which coated with 
Matrigel matrix. 
 
 
2.2.7.3 Soft agar assay 
Neoplastic transformation occurs via a series of genetic and epigenetic alterations which yield 
a cell population that is capable of proliferating independently of both external and internal 
signals that normally restrain growth. Basement membrane supports normal epithelial cells in 
vivo by providing a variety of physical and hormonal signals important for their homeostasis 
and phenotype differentiation. In suspension culture, many of these cells undergo apoptosis 
268
. Alternatively, cancer cells are able to evade attachment regulated apoptosis (anoikis), 
leading to uncontrolled proliferation. Therefore, anchorage-independent growth is one of the 
hallmarks of cell transformation, which is considered the most accurate and stringent in vitro 
assay for detecting malignant transformation of cells, with normal cells typically not capable 
Cell suspension is placed in upper chamber 
Invasive cells pass through the protein matrix layer 
 and cling to the bottom of the insert membrane. 
Non-invasive cells stay in the upper chamber 
After removal of non-invasive cells, invasive cells 
are stained and quantified 
Serum Free Medium 
Staining Solution 
Protein Matrix Layer 
Chemoattractant/Medium 
24-48h 
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of growth in semisolid matrices. The soft agar colony formation assay is a common method 
to monitor anchorage-independent growth, which measures proliferation in a semisolid 
culture media after 3-4 weeks by counting colonies 
269
. So the more malignant a tumour cell, 
the greater the ability to produce colonies of cells in soft agar assay. In this study, parental 
and shRNA transfected PC3M cells were cultured in soft agar to evaluate their ability in 
colony formation. 
The assay was carried out in 6-well plates which pre-coated 2ml of 2% (w/v) low-melting 
point agarose gel in routine and selective culture medium with 10% (v/v) FCS that solidified 
in refrigerator at 4
°
C for 20 minutes. In the meantime, parental and transfected cell lines were 
harvested and adjusted with routine and selective medium to 5000 cells/ml which then mix 
with 1ml of pre-warm 1% (w/v) low-melting point agarose gel and were placed on top of the 
present basement gel layer. Complex were again put in 4
°
C for 20 minutes for solidification 
before incubation at 37
°
C in humid incubator with 5% CO2 atmosphere for 4-6 weeks. During 
this period, cells were feed with 200µl/well once a week. At the end of assay, colonies were 
stained by adding 0.5ml of 2% MTT (3-(4, 5-dimethylthiazl-2-yl)-2, 5-diphenylterazolium 
bromide) then incubated at 37
°
C, 5% CO2 for 4 hours. Colonies larger than 150µm were 
counted using Gel Count (Oxford Optronix, UK). 
2.2.7.4 Angiogenesis assays 
Angiogenesis is a process of generating new capillary blood vessels. It is a fundamental 
component for a number of normal (reproduction and wound healing) and pathological 
processes (diabetic retinopathy, rheumatoid arthritis, tumour growth and metastasis) 
270
. 
VEGF (Vascular endothelial growth factor) is also called VEGF-A, following the 
identification of several VEGF-related factors (VEGF-B, VEGF-C, VEGF-D, VEGF-E). 
VEGF significantly influence vascular permeability and is a strong angiogenesis protein in 
several bioassays and also plays a role in neovascularization under physiological conditions 
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271
. In this study, expression levels of VEGF were assessed, in proteins extracted from cell 
lines by Western blotting (as section 2.2.3.3) and in conditional medium (secreted VEGF) by 
ELISA. Activity of VEGF was also tested by evaluation of tube formation in in vitro 
angiogenesis assay. 
2.2.7.4.1 Enzyme-linked immunosorbent assay for evaluating VEGF 
The RayBio®Human VEGF ELISA (Enzyme-Linked Immunosorbent Assay) kit was used 
for quantitative measurement of human VEGF in the conditional media of 22RV1cells. This 
assay employs a specific human VEGF antibody coated in a 96-well plate. After loading 
standards and samples into wells, present VEGF was bound to wells by immobilized 
antibody. Biotinylated secondary antibody was added to each well after wash. Then after 
washing away unbounded biotinylated antibody, HRP-conjugated streptavidin was pipetted 
into each well to detect the secondary antibody. After another set of washing, the amount of 
bound VEGF was developed by adding the TMB substrate solution. Finally, the Stop 
Solution changed the colour from blue to yellow and the intensity of the colour was measured 
at 450nm 
272
. 
2.2.7.4.1.1 Standard curve preparation 
Four hundred microliter of diluent buffer were loaded in each tube then the recombinant 
human VEGF was diluted in 50mM sodium carbonate (PH: 7.6) to a concentration of 
50ng/ml which then used to prepare serial dilutions as showed in Figure 2.3. Diluting buffer 
served as the zero standard (0pg/ml). 
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Figure  2.3: Serial dilutions for VEGF ELISA standard curve. 
2.2.7.4.1.2 Human VEGF ELISA 
1×10
6
 cells were seed in 75cm
2
 culture flasks and cultured in growth factor deprived medium 
(phenol red-free RPMI 1640 containing 10% charcoal stripped FCS) for 48 hours. The 
conditional medium of each different treatments were collected then 100 l of each standard 
(Fig. 2.3) and samples were loaded into VEGF microplate wells. The plate covered by lead 
and incubated at room temperature for 2.5 hours (or overnight at 4
°
C) with gentle shaking. 
Supernatant was discarded and wells were washed four times with 300 l of wash solution 
provided by VEGF ELISA Kit. After that, 100µl of biotinylated secondary antibody was 
loaded into each well and incubated at room temperature for 1 hour which followed by four 
step wash as mentioned above. 100µl of HRP-Streptovidin solution was added to the wells 
and incubated for 45 minutes at room temperature. Finally for visualizing the VEGF level, 
after four washes, 100µl of TMB substrate reagent was loaded to each well and incubated for 
30 minutes which followed by adding 50µl of 2M sulphuric acid to stop the reaction. The 
plate was immediately read at 450nm in the optical density plate reader and the expression 
level of VEGF secreted in conditional medium for each culture condition was quantified 
using standard curve. Results were the mean ± SD of three separate experiments. 
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2.2.7.4.2 In vitro angiogenesis assay 
Millipore
® 
In Vitro Angiogenesis Assay Kit was used for evaluation the tube formation of 
endothelial cells induced by secreted VEGF in conditional medium. When cultured on 
ECMatrix
TM
, a solid gel of basement proteins prepared from the Engelbreth Holm-Swarm 
(EHS) mouse tumour pre-angiogenic factors, can provide the condition in which these 
endothelial cells rapidly align and form hollow tube-like structures 
273
.  
2.2.7.4.2.1 Preparation of ECMatrix coated plate  
ECMatrix and 10× diluent buffers were thawed overnight on ice in a 4
°
C refrigerator before 
mixing together (100µl of 10× diluent buffer with 900µl of ECMatrix) in a sterile micro-
centrifuge tube. Undiluted ECMatrix is highly viscous, so it is necessary to cut off pipette tips 
with a sterile knife to ease pipetting and to prevent air bubble. All devices such as pipette 
tips, plates and tubes were precooled and experiment was carried out in cold room. 50µl of 
diluted ECMatrix was loaded in each well of 96-well plate then incubated at least for one 
hour at 37
°
C to solidify. 
2.2.7.4.2.2 Angiogenesis assay 
Human umbilical vein  endothelial cells (HUVEC) were cultured to 60-80% confluency in 
75cm
2
 flask in EndoGRO basal medium added with Endo GRO LS supplement kit before 
harvesting and preparing a solution contain 10
4
cells/100µl which was seeded on top of 
ECMatrix layer in each well. Then 100µl of conditional medium of each different treatment 
were loaded and plates were incubated at 37
°
C, 5%CO2 for 6 hours. Recombinant human 
VEGF (10ng/ml) was used as positive control and each sample loaded as triplicate. Finally, 
cell-tubes were visualized by adding 50µl of 2% MTT  for 10 minutes at room temperature 
and quantified under  an inverted light microscope at 40 × magnification 
274
. 
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2.2.7.4.2.3 Quantitation of tube formation 
Activated endothelial cells form cellular network (mesh like structure) from capillary tubes, 
which is a dynamic process, starting with cell migration and alignment, followed by 
development of capillary tubes, sprouting of new capillaries and terminate by formation of 
cellular networks. Although in vitro angiogenesis Assay is a qualitative assay, it is possible to 
quantitate by assigning a numerical value to each pattern. By this way, a numerical value is 
associated with progression of angiogenesis (Table 2.10). Five random field per well were 
examined and the values were averaged. Results of assays were statistically assessed using 
Student’s t-test and the p-value less than 0.05 was considered as statistical significance. 
Pattern Value 
Individual cells, well separated 0 
Cells begin to migrate and align themselves 1 
Capillary tubes visible. No sprouting 2 
Sprouting of new capillary tubes visible 3 
Closed polygons begin to form 4 
Complex mesh structures develop 5 
 
Table  2.10: Numerical values for degree of angiogenesis progression. 
 
 
 
2.2.7.5 Dual-Luciferase
®
Reporter (DLR
TM
) Assay 
Genetic reporter systems are widely used to study eukaryotic gene expression and cellular 
physiology, receptor activity, transcription factors, intracellular signalling, mRNA processing 
and protein folding 
41
. Dual reporters, the simultaneous expression and measurement of two 
individual reporter enzymes within a single system, are commonly used to improve 
experimental accuracy. Typically, the "experimental" reporter correlates with the effect of 
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specific experimental conditions, while the activity of co-transfected "control" serves as 
baseline response. Normalizing the activity of experimental reporter to the activity of internal 
control minimize experimental variability caused by difference of cell viability or 
transfection efficiency 
275
. In the DLR
TM 
Assay (Promega, WI, USA), the activities of firefly 
(Photinus pyralis) and Renilla (Renilla reniformis) luciferases are measured sequentially 
from a single sample. The firefly luciferase reporter is measured first by adding Luciferase 
assay reagent II (LAR II) to generate a stabilized luminescent signal, followed by adding 
Stop & Glo
®
 reagent assay to produce a  stabilized signal from the Renilla luciferase. Finally, 
by dividing the firefly luciferase activity to Renilla luciferase activity, luciferase expression 
of designated vector can be determined. 
2.2.7.5.1 Luciferase Reporter Vector (pGL3-Promoter Vector) 
The pGL3 Luciferase Reporter Vectors (Promega, WI, USA) are designed for quantitative 
analysis of factor which potentially regulates gene expression in mammalian. The pGL3 
Vectors backbone contains a modified coding region for firefly (Photinus pyralis) luciferase, 
used to monitor transcriptional activity in transfected eukaryotic cells. The assay of this 
genetic reporter is rapid, sensitive and quantitative. pGL3 vectors contain numerous features 
that aid the characterization and mutagenesis of the putative regulatory sequences. This study 
based on promoter VEGF gene, so pGL3-promoter vector has been chosen. The pGL3-
promoter vector contains SV40 promoter upstream of the luciferase gene.  Inserts containing 
putative enhancer elements can be inserted in either orientation and upstream or downstream 
to the promoter-luc transcriptional unit (Fig. 2.4) 
276
. 
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Figure  2.4: pGL3-Promoter Vector circle map. 
2.2.7.5.2 Reporter constructs 
Three promoter reporter constructs based on human VEGF promoter 
277
 were designed from 
whole VEGF promoter sequence (gi|224589818:43727945-43737944 Homo sapiens 
chromosome 6, GRCh37.p10 Primary Assembly) and constructed by Gen Script 
(Transforming Biology Research, NJ, USA). Main truncated promoter-reporter construct 
(Wild type) contained 5’flanking sequences extending -805 nucleotides from the 
transcriptional start site and including two peroxisome proliferative responsive elements 
(PPRE) (-796 to -790bp and -443 to -437bp) 
248
. PPRE sequence (AGGCCA) 
278
 was 
mutated in Mutant1 constructs (ATGCAT) and in Mutant2 it made shorten to -393bp. Kpnl 
(GGTACC) and Xhol (CTCGAG) sequences were added to each end of constructs as enzyme 
sites to be compatible for inserting in pGL3-promoter vector (complete constructs sequences 
shown in Appendix D). 
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2.2.7.5.3 Cell culture and transfection 
22RV1, PC3-M, PC3-M-PPARγ-si-H and PC3-M-3 prostate cancer cell lines were cultured 
in normal cell culture condition up to 60-80% confluency before harvesting and seeding into 
24-well plates. 5×10
4
cells/well in 1ml medium was cultured overnight, then culture medium 
replaced with 900µl fresh medium, overlaid with 100µl of a transfection solution containing 
1µg of each luciferase plasmids, 100ng of Renilla luciferase,1µl of X-treme GENE HP DNA 
Transfection Reagent (Roche, Germany) in Opti-MEM I medium (Gibco, Invitrogen, Paisley, 
UK). Transfection solution was incubated at least 15 minutes prior to overlaying in room 
temperature. In each set of experiment, cells were transfected with pGL3-promoter vector 
only, pGL3-promoter vector containing Wild type, Mutant1 or Mutant2, separately. After 
overnight transfection, reaction was stopped by refreshing medium, then after 6 hours 
recovery, cell were exposed to 0.5µM of Rosiglitazone (Sigma-Aldrich, UK) a synthetic 
PPARγ agonist, 20µM of GW9662 (Sigma-Aldrich, UK) a  synthetic PPARγ antagonist, 
2µM of wild type C-FABP recombinant protein, 2µM of single mutant C-FABP recombinant 
protein, 2µM of double mutant C-FABP recombinant protein or 0.1µM of Mithramycin A 
(Sigma-Aldrich, UK) as Sp1 inhibitor individually or as combination, overnight.  
2.2.7.5.4 DLRTM Assay Protocol 
After 16-24 hours treatment, culture medium was removed and cells were washed twice with 
PBS (phosphate buffer saline) before lysis with 100µl of 1× Passive Lysis Buffer. Cells were 
incubated with 1×PLB for 15 minutes in room temperature then cell lysates were collected in 
micro-centrifuge tubes and centrifuged in13, 000 rpm at 4°C for 30 seconds to separate the 
pellet. In the meantime, Luciferase Assay Reagent II (LARII) was prepared and loaded 100µl 
into the appropriate number of luminometer tubes to complete the desired number of DLR
TM
 
assays. Then 20µl of cell lysate was mixed to LARII by pipetting 2 or 3 times before first 
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measurement with Sirius Luminometer (Berthold detection system, Germany) which 
recorded firefly luciferase activity. Finally 100µl of Stop & Glo
®
 assay reagent was added 
and vortex briefly to mix before second measurement with luminometer which represented 
Renilla luciferase activity. Pure luciferase expression of designated vector was calculated by 
dividing the firefly luciferase activity to Renilla luciferase activity and different expressions 
with different treatments were statistically assessed using Student`s t-test. P-value less than 
0.05 were regarded as statistically significant. 
2.2.8 In vivo tumorigenicity assay 
2.2.8.1 Mice and cell lines 
All the experiments were conducted in accordance to UKCCCR guideline under Home Office 
Licence: PPL 40/3578 to Prof. Y. Ke and the personal licence: PIL 40/10535 to Farzad S. 
Forootan. To investigate the tumorigenicity of suppressed PPARγ PC3-M cell lines, 30 male 
Balb/C immune-incompetent nude mice (6-8 week old) were purchased from Charles River 
Laboratories. They were weighted in their arrival and ranged between 18-21g. After one 
week settling down, they were divided to three groups of 10 and the following three cell lines 
were tested in them at same time: 
Group 1: Control; PC3-M cells  
Group 2: PC3-M-PPARγ-si-M (moderately suppressed PPARγ-PC3-M cells) 
Group 3: PC3-M-PPARγ-si-H (highly suppressed PPARγ-PC3-M cells) 
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2.2.8.2 Mice inoculation 
Cell lines for in vivo tumorigenicity assay, were cultured up to 80% confluency. On the day 
of inoculation, cells were harvested and re-suspended in PBS at the concentration of 
5×10
6
/ml. Cell suspensions were kept on ice before injecting 200µl (1×10
6
 cells) 
subcutaneously in right or left flank region of each mice. Weight of mice and tumour size 
were measured twice a week using a calliper. Tumour volume were calculated by the 
following formula: Length×Width×Heigth×0.5236 
279
 and primary tumours were weighted 
after autopsy. 
2.2.8.3 Processing of primary tumour tissues 
 Primary tumours were removed by dissection and fixed in 10% formalin at least for 24 
hours. The fixed tissue samples were trimmed and put in an embedding cassette and 
processed in Tissue-Tek VIP5 processor. Then processed tissues were embedded in paraffin 
wax at 60°C and cooled on ice. After solidification, blocks were cut using microtome 
(MICROM, Oxford, UK) and 4µm sections were mounted on labelled Superior Adhesive 
Slides (Apex, Leica, UK) prior to processing for immunohistochemistry. 
2.2.8.4 Immunohistochemistry 
To visualizing reduced expression of PPARγ in suppressed tissue, prepared sections were 
underwent immunohistochemical staining (section 2.2.4.3) and scored by evaluating intensity 
and percentage of staining in both cytoplasm and nucleus (section 2.2.4.4). 
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2.2.9 Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS), 
version 20 (SPSS Inc., Chicago, IL., USA). In all statistical analyses, results were regarded as 
significant when p is smaller than 0.05. 
2.2.9.1 Two-sided Fisher’s exact test & Chi-square (χ2) 
2-sided Fisher exact test and χ2 analysis are used to determine whether there is a significant 
difference between the expected frequencies and the observed frequencies in one or more 
categories. Correlation between PPARβ/δ and PPARγ, C-FABP and AR expression and the 
nature of prostate tissue (benign or malignant) were assessed by 2-sided Fisher exact test and 
χ2 analysis. Two-sided Fisher’s exact test was used when samples evaluated only for two 
parameters while χ2 was used for assessing more than two parameters. A value of p ≤ 0.05 
was used to define the statistical significance. 
2.2.9.2 Survival analysis   
2.2.9.2.1 Kaplan-Meier curve 
Correlation between survival and expression of individual factors was analysed by Kaplan-
Meier survival test. In this study correlation between expression of PPARβ/δ, PPARγ, C-
FABP (both in nucleus and cytoplasm), Androgen receptor, PSA level and Gleason score and 
patients’ survival time were assessed by Kaplan-Meier curves. 
2.2.9.2.2 Cox regression test 
Cox regression test was used to analysis the effect of multiple factors on patient survival. 
Multiple effects of combined C-FABP with PPARγ or PPARβ/δ to patients’ survival period 
were evaluated using Cox regression test. 
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2.2.9.2.3 Log Rank test 
Log Rank test was used to assess the difference of survival time between different groups in 
Kaplan-Meier and Cox regression tests.  It is a nonparametric test and appropriate to use 
when the data are right skewed and censored (technically, the censoring must be non-
informative). A value of p ≤ 0.05 was used to define the statistical significance. 
2.2.9.3 Mann-Whitney U test 
Man-Whitney U test is a nonparametric test of the null hypothesis that two populations are 
the same against an alternative hypothesis, especially that a particular population tends to 
have larger values than the other. Box plot is a convenient way of graphically depicting 
groups of numerical data through their quartiles. Box plot and Man-Whitney U test were used 
to assess the correlation between expression levels of PPARγ or PPARβ/δ and PSA level or 
AR index. A value of p ≤ 0.05 was used to define the statistical significance. 
2.2.9.4 Student’s t-test 
Student’s t-test was used to evaluate the significant difference in average between two groups 
and is most commonly applied when the test statistic would follow a normal distribution. In 
this study, Student’s t-test was used to compare any observed difference between 
experimental and control groups in proliferation assay, invasion assay, soft agar assay, in 
vitro angiogenesis assay , tumour volume in in vivo assay and difference in luciferase levels 
in DLR assay. A value of p ≤ 0.05 was used to define the statistical significance. 
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3 Results 
3.1 Expression of PPARβ/δ, PPARγ and C-FABP at protein level in prostate cell lines 
3.1.1 Expression of PPARβ/δ protein 
The results of Western blot analysis of C-FABP and its possible receptors PPARβ/δ, PPARγ 
are shown in Figure 3.1. A single PPARβ/δ band of 52kDa was detected in benign PNT2 
cells, weakly malignant LNCaP cells, and highly malignant PC3 and DU145 cells, but was 
barely detectable in the highly malignant PC3M cells (Fig. 3.1, A). When the densitometric 
level of PPARβ/δ in PNT2 was set at 1 (Fig. 3.1, D), the relative level in weakly malignant 
LNCaP cells was 0.66 ± 0.04; levels in highly malignant DU145, PC3-M and PC3 cells were 
1.57 ± 0.15, 0.31 ± 0.03 and 0.61 ± 0.1, respectively. The changes in levels of PPARβ/δ did 
not appear to be related to changes in malignant characteristics. 
3.1.2 Expression of PPARγ protein  
 A single PPARγ band of 57kDa was detected in all 5 cell lines by Western blotting (Fig. 3.1, 
B). When the densitometric level of PPARγ in PNT2 was set at 1 (Fig. 3.1, E), the level in 
weakly malignant LNCaP cells was 0.74 ± 0.09; levels in highly malignant DU145, PC3-M 
and PC3 cells were 1.14 ± 0.16, 2.73 ± 0.28 and 3.66 ± 0.23, respectively. Thus the level of 
PPARγ increased with increasing malignancy in these prostatic cells. 
3.1.3 Expression of C-FABP protein 
Western blots showed that C-FABP expression was not detected in benign PNT2 and weakly 
malignant LNCaP cells, but a strong 15kDa C-FABP band was detected in highly malignant 
cell lines DU145, PC3M, and PC3 (Fig. 3.1, C). When the densitometric level of C-FABP in 
PC3 was set at 1 (Fig. 3.1, F), levels expressed in other malignant PC3-M and DU145 cells 
Chapter 3: Results 
 
 
103 
were reduced to 0.9 ± 0.07 and 0.59 ± 0.07, respectively. In contrast levels in the benign 
PNT2 and weakly malignant LNCaP cells were not detectable.  
 
                                                                                                    
 
  
                                                                                                                                                                                                    
                                                                                                                                             
     
Figure  3.1: Measurement of levels of C-FABP and its possible nuclear receptors (PPARβ/δ 
and PPARγ) in prostate cell lines. 
More accurate quantitative analysis on levels of PPARβ/δ (A), PPARγ (B) and C-FABP (C) 
were conducted by scanning the peak areas of the bands on the blots. To standardize the 
immune reactions, the same blot was incubated with an anti-β-actin antibody. Relative levels 
of each protein (D: PPARβ/δ, E: PPARγ and F: C-FABP) were measured by densitometric 
scanning of the intensities of the relevant protein bands and normalized to that of β-actin on 
the same blot. In D and E, the level of immunoreactive-proteins in PNT2 was set at 1; Levels 
expressed in other cell lines were obtained by comparison with that in PNT2. In F, the level 
of immunoreactive-proteins in PC3 was set at 1; Levels expressed in other cell lines were 
obtained by comparison with that in PC3. Results were obtained from 3 separate experiments 
(mean ± SD). 
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3.2 Expressions of PPARβ/δ and PPARγ at mRNA levels in prostate cell lines 
RT-PCR used to evaluate mRNA expressions of PPARβ/δ and PPARγ in the total RNAs 
isolated from six prostate cell lines. RT-PCR products were analysed by agarose gel 
electrophoresis (Fig. 3.2).  RT-PCR showed a single PPARβ/δ band (481 bp) in benign PNT2 
cells, moderately malignant 22RV1 cells, highly malignant PC3, PC3-M and DU145 cells, 
but was barely detectable in the weakly malignant LNCaP cells (Fig. 3.2, A). A single PPARγ 
band (463 bp) was detected prominently in PC3 and PC3-M cell lines, weakly in 22RV1 cells 
but was not found in DU145, LNCaP and PNT2 cell lines (Fig. 3.2, B). Expression levels of 
β-actin mRNA were used as a house-keeping gene (Fig. 3.2, C) to standardise the 
measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.2: Detection of PPARβ/δ, PPARγ and β-actin mRNA in prostate cell lines. 
RT-PCR results, analysed on a 0.8% agarose gel in 0.5×TBE buffer alongside 100 base pair 
ladder DNA marker revealed: A: Expressions of PPARβ/δ mRNA (481 bp), B: Expressions of 
PPARγ mRNA (463 bp), C: Expressions of β-actin mRNA (174 bp). 
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3.3 Expression of PPARβ/δ, PPARγ and C-FABP in prostate tissues 
Immunehistochemical staining of 132 prostate tissue sections, including 35 BPH and 97 
carcinoma samples were performed to detect PPARβ/δ, PPARγ and C-FABP proteins (in 
each experiment, some cases were excluded from the study because of technical reasons). 
Staining for PPARβ/δ in BPH and carcinomas was detected in both cytoplasm and nucleus 
(Fig. 3.3, A-D) (Table 3.1-1). Among 32 stained BPH cases, 28 (88%) were stained weakly 
and 4 (12%) moderately positive with PPARβ/δ antibody in both cytoplasm and nucleus (Fig. 
3.3, A). Among 94 stained adenocarcinoma cases, both cytoplasmic and nuclear staining was 
observed. Cytoplasmic staining was weak in 32 (34%), moderate in 50 (53%) and strong in 
12 (13%) cases and in the nucleus, staining was weak in 13 (14%), moderate in 65 (69%) and 
strong in 16 (17%) cases (Fig. 3.3, B-D). The levels of both cytoplasmic (χ2 test, p < 0.001) 
and nuclear (χ2 test, p < 0.001) staining for PPARβ/δ were significantly higher in carcinomas 
than those in BPH (Table 3.1-1).  
Staining for PPARγ was detected in both cytoplasm and nucleus of cells in BPH and 
carcinoma tissues (Fig. 3.3, E-H) (Table 3.1-2). In 32 analysed BPH samples, cytoplasm was 
stained weakly in 31 (97%) and moderately in 1 (3%) cases; while nuclear staining was weak 
in 30 (94%) and moderate in 2 (6%) samples (Fig. 3.3, E). Among a total of 90 stained 
carcinomas, cytoplasm was stained weakly in 35 (39%), moderately in 45 (50%) and strongly 
in 10 (11%) cases; while nuclear staining was weak in 12 (13%), moderate in 57 (63%) and 
strong in 21 (24%) samples (Fig. 3.3, F-H). Staining for PPARγ in both cytoplasm (χ2 test, p 
< 0.001) and nucleus (χ2 test, p < 0.001) of carcinomas was significantly higher than those in 
BPH (Table 3.1-2).  
Immunohistochemical staining for C-FABP was observed in both cytoplasm and nucleus of 
BPH and carcinoma cells (Fig. 3.3, I-L) (Table 3.1-3). Among 35 BPH cases, 33 (94%) were 
unstained and 2 (6%) stained weakly in the cytoplasm. In the nucleus, 25 (71%) were 
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unstained, 7 (20%) stained weakly, 5 (14%) stained moderately and 3 (8%) stained strongly 
(Fig. 3.3, I). Among 97 analysed adenocarcinomas, cytoplasmic and nuclear staining was 
observed in 94 (96%) and 88 (91%) of cases, respectively (Fig. 3.3, J-L). Cytoplasmic 
staining was weak in 23 (24%), moderate in 54 (56%) and strong in 17 (18%) cases. In the 
nucleus, 20 (21%) cases stained weakly, 32 (33%) moderately and 36 (37%) strongly. 
Intensities of both cytoplasmic (χ2 test, p < 0.001) and nuclear (χ2 test, p < 0.001) staining for 
C-FABP were significantly higher in carcinomas than those in BPH (Table 3.1-3). 
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 A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.3: Immunohistochemical staining of BPH and prostatic carcinoma tissues with 
antibodies against PPARβ/δ, PPARγ, and C-FABP.  
Carcinoma tissues were divided into weakly (GS ≤ 5), moderately (GS 6-7) and highly (GS 
8-10) malignant groups according to their combined Gleason scores (GS). Cytoplasmic and 
nuclear staining is shown in the inserts (arrows). Original magnifications of images of 
representative slides were 100×; original magnifications of the inserts were 250×. 
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                                                                   3.1-3: C-FABP stain 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table  3.1: Cytoplasmic and nuclear expression of different PPARs and C-FABP in benign 
and malignant human prostate tissues. 
   Cytoplasmic 
Stain intensities 
No. Of 
cases Tissue + ++ +++ ≤3 4-6 ≥7 
 
BPH 
Carcinomas 
(total) 
Scores* ≤5 
Scores* 6-7 
Scores* 8-10 
28 
 
32 
6 
12 
14 
4 
 
50 
6 
18 
26 
0 
 
12 
2 
5 
5 
32
• 
 
94
 •
 
14 
35 
45 
28 
 
13 
4 
5 
6 
4 
 
65 
9 
25 
31 
0 
 
16 
3 
5 
8 
3.1-1: PPARβ/δ stain 
BPH 
Carcinomas 
(total) 
Scores* ≤5 
Scores* 6-7 
Scores* 8-10 
31 
 
35 
5 
13 
17 
1 
 
45 
7 
18 
20 
0 
 
1
0 
1 
3 
6 
32
 • 
 
90
 •
 
13 
34 
43 
30 
 
12 
4 
4 
4 
2 
 
57 
8 
21 
28 
0 
 
21 
1 
9 
11 
3.1-2: PPARγ stain 
Nuclear stain intensity &  
Percentage score  
+++ + ++ +++ + ++ 
 
BPH 
Carcinomas 
(total) 
Scores* ≤5 
Scores* 6-7 
Scores* 8-10 
 
* Combined Gleason Scores 
●
 Total BPH cases were 35 and total carcinoma cases were 97, but in each experiment,                          
some cases were excluded from the study because of technical reasons. 
 
2 
 
23 
8 
12 
3 
0 
 
54 
5 
17 
32 
0 
 
17 
1 
8 
8 
35 
 
97 
16 
37 
44 
7 
 
20 
6 
7 
7 
5 
 
32 
4 
12 
16 
3 
 
36 
4 
14 
18 
0 0 
33 
 
3 
2 
0 
1 
25 
 
9 
2 
4 
3 
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3.4 Correlations between PPARβ/δ, PPARγ and C-FABP  
When the relationship among the staining levels for PPARβ/δ, PPARγ and C-FABP in 
carcinomas was assessed, the increased level of PPARβ/δ in both cytoplasm and nucleus 
were not significantly correlated with either staining for PPARγ or C-FABP (Fisher’s Exact 
test, p > 0.05). While increased nuclear staining for C-FABP was significantly correlated 
with increased nuclear staining for PPARγ (Fisher’s Exact test, p < 0.05), increased 
cytoplamic staining for C-FABP was not significantly correlated with cytoplasmic staining 
for PPARγ (χ2 test, p > 0.05).  Interestingly, the increased cytoplasmic staining for C-FABP 
was significantly correlated with nuclear staining for PPARγ (Fisher’s exact test, p < 0.05), 
whereas the increased cytoplasmic staining for PPARγ was not significantly correlated with 
nuclear staining for C-FABP (χ2 test, p > 0.05). To correlate the staining for C-FABP and 
PPARs with GS, carcinomas were divided into low (≤5), moderate (6-7) and high (8-10) GS 
groups. 
3.5 Correlation with Gleason score 
Although expression levels of PPARβ/δ, PPARγ and C-FABP are higher in carcinoma tissues 
compare to benign, only increased nuclear PPARγ and cytoplasmic C-FABP staining 
significantly correlate with increased GS in patients. 
3.5.1 Correlation of PPARβ/δ and Gleason score 
Although cytoplasmic staining for PPARβ/δ was significantly correlated with its nuclear 
levels (χ2 test, p < 0.001), neither nuclear (χ2 test, p > 0.05) nor cytoplasmic (χ2 test, p > 0.05) 
staining for PPARβ/δ was significantly correlated with increased GS in these cases. 
3.5.2 Correlation of PPARγ and Gleason score 
The increased cytoplasmic level of PPARγ was positively correlated with that in the nucleus 
(χ2 test, p < 0.001). When correlation between staining for PPARγ and GS was assessed, 
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increased nuclear staining for PPARγ was significantly correlated with the higher GS of the 
carcinomas (Fisher’s Exact test, p ≤ 0.05), but the correlation between its cytoplasm staining 
and the increased GS was not significant (Fisher’s Exact test, p > 0.05).  
3.5.3 Correlation of C-FABP and Gleason score 
The increased cytoplasmic level of C-FABP was positively correlated with that in the nucleus 
(χ2 test, p < 0.05). When correlation between staining for C-FABP and GS was assessed, 
increased cytoplasmic staining for C-FABP was significantly correlated with the increased 
GS of the carcinomas (χ2 test, p < 0.05), but the correlation between increased nuclear 
staining and  high GS was not significant (χ2 test, p >  0.05). 
3.6 Correlations with patient survival  
The level of PPARβ/δ, PPARγ or C-FABP and the duration of patients’ overall survival time 
(the length of survival time from initial diagnosis) was plotted using Kaplan-Meier survival 
curves and the significance of the differences was assessed by Log Rank test (Fig. 3.4,5).  
3.6.1 PPARβ/δ expression and patient survival 
The median survival time for patients with strongly, moderately and weakly positive 
cytoplasmic staining for PPARβ/δ, was 47, 37 and 42 months, respectively (Fig. 3.4, A). For 
patients with a strongly positive nuclear staining for PPARβ/δ, the median survival time was 
31 months (Fig. 3.4, B). This was shorter than 39 and 57 months for moderately and weakly 
stained cases, respectively. Correlation between the level of nuclear (Log Rank test, p ≥ 
0.204) and cytoplasmic (Log Rank test, p ≥ 0.532) staining of PPARβ/δ and patient survival 
time was not statistically significant. 
 
 
Chapter 3: Results 
 
 
111 
3.6.2 PPARγ expression and patient survival  
When the correlation between nuclear staining for PPARγ (Fig. 3.4, D) and patient survival 
was assessed, the median survival time for the patients with weak nuclear staining was 48 
months, this was reduced to 36 months (Log Rank test, p ≥ 0.422) and significantly reduced 
to 12 months (Log Rank test, p ≤ 0.035) for patients with moderate and strong staining, 
respectively. Overall, nuclear staining for PPARγ was significantly associated with patient 
survival (Log Rank test, p ≤ 0.044). For cytoplasmic staining for PPARγ, although the 
median survival time for the cases with low staining (48 months) was not significantly (Log 
Rank test p ≥ 0.995) different from those cases with moderate staining (48 months), it was 
significantly (Log Rank test, p ≤ 0.010) reduced to 12 months for cases with strong staining. 
Similar to nuclear staining for PPARγ, overall reduced survival time was significantly 
associated with the increased cytoplasmic staining for PPARγ (Log Rank test, p ≤ 0.049) 
(Fig. 3.4, C).  
3.6.3 C-FABP expression and patient survival  
For the patients with both strong and moderate staining for cytoplasmic C-FABP, the median 
survival time was 24 months, this was significantly shorter than that of 80 months for patients 
with weak staining and those unstained (Log Rank test, p ≤ 0.002) (Fig. 3.5, A). The median 
survival time for patients with strongly, moderately and weakly positive nuclear staining for 
C-FABP, was 39, 34 and 48 months, respectively (Fig. 3.5, B). While increased cytoplasmic 
staining for C-FABP was significantly associated with a reduced patient survival time (Log 
Rank test, p ≤ 0.027) (Fig. 3.5, A), no significant correlation between nuclear C-FABP levels 
and patient survival time was observed (Log Rank test, p ≥ 0.364) (Fig. 3.5, B). 
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Figure  3.4: Kaplan-Meier survival curves of prostate cancer patients.  
The cumulative survival of patients was plotted against time in months for different levels of 
4 parameters. A, Different levels of cytoplasmic staining for PPARβ/δ: Weakly positive 
group (n=32); moderately positive group (n=51); and highly positive group (n=17). B, 
Different levels of nuclear staining for PPARβ/δ: Weakly positive group (n=13); moderately 
positive group (n=65); and highly positive group (n=16).  C, Different levels of cytoplasmic 
staining for PPARγ: Weakly positive group (n=36); moderately positive group (n=43); and 
highly positive group (n=11).  D, Different levels of nuclear staining for PPARγ: Weakly 
positive group (n=12); moderately positive group (n=57); and highly positive group (n=21). 
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Figure  3.5: Kaplan-Meier survival curves of prostate cancer patients.  
The cumulative survival of patients was plotted against time in months for different levels of 
2 parameters. A, Different levels of cytoplasmic staining for C-FABP: Weakly positive group 
(n=26); moderately positive group (n=54); and highly positive group (n=17).  B, Different 
levels of nuclear staining for C-FABP: Weakly positive group (n=38); moderately positive 
group (n=38); and highly positive group (n=22). 
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3.6.4 Gleason scores and patient survival  
To assess the relationship between the GS and patient survival, 97 carcinoma cases were 
divided into three groups: weakly malignant with GS ≤ 5, moderately malignant with GS 6-7 
and highly malignant with GS 8-10. The median survival time of patient with highly, 
moderately and weakly malignant carcinomas was 12, 60 and 80 months, respectively. The 
increased GS was significantly (Log Rank test p ≤ 0.0001) associated with reduced survival 
time (Fig. 3.6, A).  
3.6.5 Androgen receptor and patient survival   
The correlation between patient survival time and staining for AR showed that the median 
survival time for patients with weak, moderate and strong staining was 60, 24 and 24 months, 
respectively. Overall survival time was not significantly reduced by the increased staining for 
AR (Log Rank test, p ≥ 0.052) (Fig. 3.6, B). 
3.6.6 Prostatic specific antigen and patient survival   
  The correlation between patient survival and blood PSA showed that the median survival 
time for patients with low (<10 ng/ml) and high (≥10 ng/ml) levels of PSA was 48 and 18 
months, respectively (Fig. 3.6, C) but the difference was not statistically significant (Log 
Rank test, p ≥ 0.246). 
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Cumulative survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.6: Kaplan-Meier survival curves of patients with prostatic cancer. 
The cumulative survival of patients was plotted against time in months for different levels of 
3 parameters. A, Different Gleason scores: Group 1, GS 2-5 (n=17); Group 2, GS 6-7 (n=38); 
Group 3, GS 8-10 (n=45). B, Different AR indices: Low group, or AR index1-3 (n=41); 
moderate group, or AR index 4-6 (n=50) and high group, or AR index 6-9 (n=11). C, 
Different levels of PSA: Group 1, PSA < 10 ng/ml (n=56) and Group 2, PSA ≥ 10 ng/ml 
(n=42). 
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3.6.7 Inter-relationship of C-FABP and PPARγ in predicting patient survival 
To assess the possible effect of staining for C-FABP and PPARγ of both cytoplasm and 
nucleus in association with patients’ survival, 90 carcinoma cases were divided into 4 groups: 
low C-FABP, low PPARγ; low C-FABP, high PPARγ; high C-FABP, low PPARγ and high 
C-FABP, high PPARγ. For cytoplasmic C-FABP and nuclear PPARγ, Kaplan-Meier plot 
(Fig. 3.7, A) showed that the median survival time for patients with high C-FABP, high 
PPARγ or high C-FABP, low PPARγ levels (33 & 30 months, respectively) were 
significantly shorter than whose had low C-FABP, low PPARγ or low C-FABP, high PPARγ 
levels (60 & 72 months, respectively) (Log Rank test, p ≤ 0.004). Similar results were 
obtained when dividing up the carcinomas into cytoplasmic staining for C-FABP and 
cytoplasmic staining for PPARγ. Kaplan-Meier plot (Fig. 3.7, B) show that the median 
survival time for the patients with high C-FABP, high PPARγ or high C-FABP, low PPARγ 
levels (31 & 39 months, respectively) were significantly shorter than those had low C-FABP, 
low PPARγ or low C-FABP, high PPARγ levels (64 & 60 months, respectively) (Log Rank 
test, p ≤ 0.008). When subjected to Cox’s multivariate regression analysis, staining for 
cytoplasmic C-FABP still showed a significant association with patients’ survival (p ≤ 
0.048), but increased staining for PPARγ in the nucleus was not significantly independently 
associated with clinical survival (p ≥ 0.143) (Table 3.2) . Similar results were obtained when 
analysing cytoplasmic staining for C-FABP and cytoplasmic staining for PPARγ in relation 
to patients’ survival (p ≥ 0.362).  Overall these results show that the significant association of 
staining for PPARγ with patient survival was confounded by that of staining for C-FABP 
when tested together. These results suggest that nuclear PPARγ staining is dependent on 
cytoplasmic C-FABP staining when they used as prognostic marker in prostate cancer 
patients. When nuclear staining of C-FABP and nuclear staining of PPARγ was analysed 
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(results are not shown), high level of C-FABP and high level of PPARγ was not significantly 
associated with shorter patients’ survival (Log Rank test, p ≥ 0.195). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.7: Kaplan-Meier survival curves of patients with prostatic cancer. 
The cumulative survival of patients was plotted against time in months for different levels of 
2 parameters. A, Different levels of joint nuclear staining for PPARγ and cytoplasmic 
staining for C-FABP: low C-FABP, low PPARγ group (n=6); low C-FABP, high PPARγ 
group (n=18); high C-FABP, low PPARγ group (n=8); high C-FABP, high PPARγ group 
(n=58). B, Different levels of joint cytoplasmic staining for PPARγ and cytoplasmic staining 
for C-FABP: low C-FABP, low PPARγ group (n=9); low C-FABP, high PPARγ group 
(n=14); high C-FABP, low PPARγ group (n=27); high C-FABP, high PPARγ group (n=40). 
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 Univariate analysis 
(Log Rank test, p value) 
 
Multivariate analysis 
(Cox Regression test, p value) 
 
C-FABP(cytoplasm) ≤ 0.027 ≤ 0.048 
PPARγ (nucleus) 
 
≤ 0.044 ≥ 0.143 
PPARγ (cytoplasm) ≥ 0.059 ≥ 0.362 
PPARβ∕δ (nucleus) 
 
≥ 0.204 --------- 
 
 
Table  3.2: Multiple Cox regression test between levels of C-FABP and PPARs with patients’ 
survival. To test whether each protein can be used independently or even dependent to the 
other as prognostic biomarker in predicting patient’s survival time, data subjected to multiple 
Cox regression test. p value ≤ 0.05 consider as significant. 
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3.7 Correlations between PPARβ/δ, PPARγ and PSA level and AR index 
3.7.1 Correlation of PPARβ/δ and PSA level 
The correlation between levels of PSA and cytoplasmic expression of PPARβ/δ is shown in 
Fig. 3.8, A. In the patients with weak, moderate and strong cytoplasmic PPARβ/δ staining, 
the median PSA was 8.3ng/ml, 6.7ng/ml and 11.6ng/ml, respectively. Box plot analysis 
showed no significant difference between levels of PSA in the patients with different levels 
of cytoplasmic PPARβ/δ (Mann-Whitney U test, p ≥ 0.807). 
The correlation between levels of PSA and nuclear expression of PPARβ/δ is shown in Fig. 
3.8, B. In the patients with weak, moderate and strong nuclear PPARβ/δ staining, the median 
PSA was 2.5ng/ml, 11.5ng/ml and 7.5ng/ml, respectively. Box plot analysis showed no 
significant difference between levels of PSA in the patients with different levels of nuclear 
PPARβ/δ (Mann-Whitney U test, p ≥ 0.188).      
3.7.2 Correlation of PPARγ and PSA level 
The correlation between levels of PSA and cytoplasmic expression of PPARγ is shown in 
Fig. 3.8, C. In the patients with weak, moderate and strong cytoplasmic PPARγ staining, the 
median PSA was 8.6ng/ml, 7.6ng/ml and 10.4ng/ml, respectively. Box plot analysis showed 
no significant difference between levels of PSA in the patients with different levels of 
cytoplasmic PPARγ (Mann-Whitney U test, p ≥ 0.731). 
The correlation between levels of PSA and nuclear expression of PPARγ is shown in Fig. 3.8, 
D. In the patients with weak, moderate and strong nuclear PPARγ staining, the median PSA 
was 3.5ng/ml, 9ng/ml and 11ng/ml, respectively. Box plot analysis showed no significant 
difference between levels of PSA in the patients with different levels of nuclear PPARγ 
(Mann-Whitney U test, p ≥ 0.15).   
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Figure  3.8: Box plot analysis of correlation between different levels of PSA with cytoplasmic 
and nuclear PPARβ/δ and PPARγ staining. 
A: Correlation between different levels of PSA in three groups of prostate cancer patients 
with different cytoplasmic staining of PPARβ/δ; weakly positive (n=43), moderately positive 
(n=45) and strongly positive (n=12). B: Correlation between different levels of PSA in three 
groups of prostate cancer patients with different nuclear staining of PPARβ/δ; weakly positive 
(n=11), moderately positive (n=63) and strongly positive (n=27). C: Correlation between 
different levels of PSA in three groups of prostate cancer patients with different cytoplasmic 
staining of PPARγ; weakly positive (n=37), moderately positive (n=46) and strongly positive 
(n=11). D: Correlation between different levels of PSA in three groups of prostate cancer 
patients with different nuclear staining of PPARγ; weakly positive (n=15), moderately 
positive (n=58) and strongly positive (n=21).     
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3.7.3 Correlation of PPARβ/δ and AR index 
The correlation between AR index (section 2.2.4.5) and cytoplasmic expression of PPARβ/δ 
is shown in Fig. 3.9, A. In the patients with weak, moderate and strong cytoplasmic PPARβ/δ 
staining, the median AR index was 4, 4.1 and 4, respectively. Box plot analysis showed no 
significant difference between AR indexes in the patients with different levels of cytoplasmic 
PPARβ/δ (Mann-Whitney U test, p ≥ 0.525).  
The correlation between AR index and nuclear expression of PPARβ/δ is shown in Fig. 3.9, 
B. In the patients with weak, moderate and strong nuclear PPARβ/δ staining, the median AR 
index was 4, 3.9 and 3.8, respectively. Box plot analysis showed no significant difference 
between AR indexes in the patients with different levels of nuclear PPARβ/δ (Mann-Whitney 
U test, p ≥ 0.59).  
3.7.4 Correlation of PPARγ and AR index 
The correlation between AR index and cytoplasmic expression of PPARγ is shown in Fig. 
3.10, A. In the patients with weak, moderate and strong cytoplasmic PPARγ staining, the 
median AR index was 3.9, 4 and 4.1, respectively. Box plot analysis showed no significant 
difference between AR indexes in the patients with different levels of cytoplasmic PPARγ 
(Mann-Whitney U test, p ≥ 0.195). 
The correlation between AR index and nuclear expression of PPARγ is shown in Fig. 3.10, 
B. In the patients with weak, moderate and strong nuclear PPARγ staining, the median AR 
index was 2, 4.2 and 4, respectively. Although median AR index were increased in those with 
moderately or strongly nuclear PPARγ staining compare to weakly staining group, Box plot 
analysis showed no statistical difference in AR indexes between two groups of weakly and 
moderately nuclear PPARγ staining (Mann-Whitney U test, p ≥ 0.23) or weakly and strongly 
nuclear PPARγ staining (Mann-Whitney U test, p ≥ 0.08).    
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Figure  3.9: Box plot analysis of correlation between different AR indexes with cytoplasmic 
and nuclear PPARβ/δ staining. 
A: Correlation between different AR indexes in three groups of prostate cancer patients with 
different cytoplasmic staining of PPARβ/δ; weakly positive (n=43), moderately positive 
(n=45) and strongly positive (n=12).   
B: Correlation between different AR indexes in three groups of prostate cancer patients with 
different nuclear staining of PPARβ/δ; weakly positive (n=15), moderately positive (n=55) 
and strongly positive (n=26).   
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Figure  3.10: Box plot analysis of correlation between different AR indexes with cytoplasmic 
and nuclear PPARγ staining. 
A: Correlation between different AR indexes in three groups of prostate cancer patients with 
different cytoplasmic staining of PPARγ; weakly positive (n=11), moderately positive (n=63) 
and strongly positive (n=27).   
B: Correlation between different AR indexes in three groups of prostate cancer patients with 
different nuclear staining of PPARγ; weakly positive (n=15), moderately positive (n=55) and 
strongly positive (n=26).  
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3.8 Suppression of PPARγ expressions by siRNA  
Highly malignant prostate cancer cells, PC3-M, express high level of PPARγ (Fig. 3.1, B). 
Using RNAi technique, PPARγ expression was suppressed in PC3-M cells transiently. After 
identifying the most efficient siRNA sequence by transient transfection, stable transfection 
was performed to investigate whether suppression of tumorigenicity of prostate cancer cells 
can be achieved by reducing PPARγ expression. 
3.8.1 Selection of most efficient siRNA for PPARγ suppression 
Three 21-nt sequences within the PPARγ cDNA for RNAi were designed to form double-
strand siRNA constructs. PC3-M cells were transiently transfected with different 
concentrations of each siRNA in combination with different concentrations of transfection 
reagent for 24, 48 or 72 hours (section 2.2.6.3). Using Western blot, expression levels of 
PPARγ were evaluated in protein extracts of the cancer cells with different combination of 
siRNA and transfection reagent. The highest suppression efficiency for PPARγ was achieved 
by siRNA-3 (2μg/ml) in combination with 2.5µl/ml of X-tremeGENE siRNA Transfection 
Reagent in 24 hours incubation , which reduced PPARγ expression up to 88% from the level 
detected in parental cells (Fig. 3.11, 3.12). Thus siRNA-3 was selected as the most efficient 
sequence to design shRNA for stable transfection.   
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Figure  3.11: Expression levels of PPARγ in PC3-M cells after transient transfection with 
different siRNAs. 
A: Detecting of PPARγ protein expression by Western blotting. The anti-β-actin antibody 
was used to correct possible loading errors in the same blot.  
B: The relative expression levels of PPARγ. The expression level of PPARγ in parental PC3-
M cells was set as 1.0. The levels of PPARγ in other cells were calculated by relating to the 
level of PPARγ expressed in parental PC3-M. Results were obtained from three different 
measurements (mean ± SD).        
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Figure  3.12: Different morphological patterns in PC3-M cells, after 24 hours transient 
transfection with different siRNAs. 
A: Parental PC3-M cells; B: PC3-M cells treated only with X-tremeGENE siRNA 
Transfection Reagent; C: PC3-M cells transfected by scramble siRNA (negative control); D: 
PC3-M cells transfected by siRNA-1; E: PC3-M cells transfected by siRNA-2; F: PC3-M 
cells transfected by siRNA-3. Original magnifications of images were ×100. 
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3.9 Establishment of stably PPARγ-suppressed PC3-M cell lines  
Using siRNA-3 sequence as template, shRNA was designed and used in stable transfection 
(section 2.2.6.4). psiRNA-h7SKGFPzeo plasmid was double digested with Hind III and 
Acc651 restriction enzymes. Digestion was confirmed by electrophoresis in low-melting 
temperature agarose gel (1%) (Fig. 3.13). Appropriate band of digested plasmid was cut, 
purified (section 2.2.6.5.4), then ligated with annealed oligonucleotides (forward and reverse) 
of shRNA (sections 2.2.6.5.2 and 2.2.6.5.5). Ligation products were transformed into E.coli 
GT116 competent cells (section 2.2.6.5.6) and plated onto the LB-zeocin agar plates each 
containing 100μg/ml zeocin and incubated at 37°C, overnight. Transformation efficiency for 
PPARγ-suppressed plasmid and the control scrambled RNA-plasmid were 1500 and 3800 cfu, 
respectively.  
 
 
 
                                    
 
 
 
 
 
 
Figure  3.13: Digestion of psiRNA-h7SKGFPzeo plasmid. 
Electrophoresis was performed in Low-melting temprature agarose gel (1%) to confirm the 
successful cleavage of the plasmid DNA. Undigested psiRNA-h7SKGFPzeo plasmid was 
loaded in well 1 and digested one in well 2. The extra small band (arrow) was the 369 bp 
fragment of plasmid which was replaced by shRNA in ligation process. 
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Five single clones of transformed bacteria with PPARγ-suppressed plasmid and two clones 
from scramble shRNAs were picked up and grown in LB medium containing 100μg/ml 
Zeocin.  Plasmid DNAs were extracted and purified from the bacterial cells using QIAGEN 
Plasmid mini-preparation kit (section 2.2.6.5.7.1). Plasmids were double digested with Hind 
III and Acc651 restriction enzymes and the presence of inserted oligonucleotides were 
confirmed by electrophoresis in agarose gel (Fig. 3.14).  Finally, plasmid DNAs from three 
different clones (1-3) were sent for sequencing analysis (section 2.2.6.5.7.4) using internal 
plasmid primers [OL559 primer (forward); OL408 primer (reverse)]. Plasmids from clone 1 
in which habituation of correct DNA insert was confirmed by sequencing analysis, was 
chosen for DNA amplification and the subsequent stable transfection (Table 3.3). 
              
Figure  3.14: Confirmation of the correct DNA insertion. 
Mini-preparation of DNA was made from 5 colonies harbouring PPARγ-suppressed DNA 
constructs and 2 colonies harbouring scramble-shRNA plasmids. DNA from each clone was 
double digested using Hind III and Acc651 restriction enzymes and an undigested plasmid 
DNA sample was loaded in parallel with the digested sample as control. As shown in the 
figure, the first 5 pairs of samples (1-5) were DNAs isolated from clones harbouring PPARγ-
suppressed constructs and the last 2 pairs of samples (6-7) were DNAs isolated from colonies 
harbouring scramble-shRNA plasmids.  
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Forward 
5’              NNAATGAATCCTTGGTTAATAGCTTGTGCGCCGCCTGGGTACCTCATAAATGT 
CAGTACTGTCGGTCAAGAGCCGACAGTACTGACATTTATTTTTTGGAAAAGCTTCTAGA
CTTAATTAACCTGCAGGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC
CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTA
CATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCC
CGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA
CGTATTAGTCATCGCTATTACCATGATGATGCGGTTTTGGCAGTACATCAATGGGCGTG
GATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGT
TTGTTTTGACTAGTAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTG
ACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAG
TGAACCGTCAGATCAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTA
CCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCT
CCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGT
CCGGCGCTCCCTTGGAGCCTACCTAGACTCANCCGGCTCTCCACGCTTTGCCTGAANCCT
GCTTGCTCACTCTACGTCTTTNGTTCGTTTTCTGTNCTGCNCCGTTACAGATCCCAGCCA
CCATNGNGTTCTAAGGANAANAAACTCTTACTGGNGNTGTCCCATTTCTGGTGAACTGG
ATNGTGATGTGAATGGCNNCAATTNNCTGTNNCTGGGAAAGTGAAGAANNGCACTTNT
GGAACTGANNCTGAATTCATTGACANNAGAAACTGCNNNGCTTGCCANNNTGGGACAC
CTGACTAAGGT      3’ 
Reverse 
5’          NNNNGNNAGGGCGGGNNNGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGT 
AAGTTATGTAACGCCTGCAGGTTAATTAAGTCTAGAAGCTTTTCCAAAAAATAAATGTC
AGTACTGTCGGCTCTTGACCGACAGTACTGACATTTATGAGGTACCCAGGCGGCGCACA
AGCTATATAAACCTGAAGGAAATCTCAACTTTACACTTAGGTCAAGTTACTTATCGTAC
TAGAGCTTCAGCAGGAAATTTAACTAAAATCTAATTTAACCAGCATAGCAAATATCATT
TATTCCCAAAATGCTAAAGTTTGAGATAAACGGACTTGATTTCCGGCTGTTTTGACACTA
TCCAGAATGCCTTGCAGATGGGTGGGGCATGCTAAATACTGCAGCACTAGTATCGATTA
AGAACATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTA
GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA
ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCT
TTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGT
AGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTG
CTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGA
CTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGC
ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGC
TATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG
CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTT
TATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCA
GGGGGGCGGAACCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTT
TTGCTGGCCTTTTGCTCCNATGCATAAAAAAACCNGCCGAACCGGGTTTTTAATTAAAN
NNNNGCANANCAAAACTTTAACCTCCAAATCAAGCCTNNNNNTGAATCCTTTNNNNNN
AGNNNNAAA     3’ 
 
Table  3.3: A part of psiRNA-h7SKGFPzeo plasmid sequence map.  
To check and confirm the correct insertion of shRNA, plasmid was sequenced using internal 
plasmid primers by Beckman Coulter Genomics, UK. Sequence alignment was performed 
using BioEdit for searching Genbank and the alignment results proved that the insertion was 
accurate. 
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3.9.1 Stable transfection 
PC3-M cells were transfected using plasmids extracted from clone 1 (2μg/ml) with X-
tremeGENE HP DNA Transfection Reagent (2.5µl/ml). After 36 hours, culture medium was 
replaced with fresh medium containing Zeocin
TM
 (100μg/ml). A week later, transfected cells 
were transferred into 9cm cell culture plates (petri dish) and continued to grow until single 
clones appeared and visualized with naked eye (2-3 weeks). Then, using ring cloning method 
(section 2.2.6.6.1), ten single clones of PPARγ-suppressed transfectants and five of scramble-
transfectants were picked up and transferred onto a 96-well plate. The medium was changed 
next day and colonies were grown in normal cell culture conditions. 
Using Western blotting, expression levels of PPARγ were evaluated in different transfectants. 
A single PPARγ band of 57kDa was detected in parental and transfectant cells (Figure 3.15, 
A). When the densitometric level of PPARγ in PC3-M cells (parental) was set at 1 (Figure 
3.15, B), the level in scramble (control) cells was 0.98 ± 0.11; levels in clone 1, clone 2, 
clone 3 and clone 4 cells were 0.86 ± 0.09, 0.64 ± 0.08, 0.48 ± 0.11 and 0.18 ± 0.06, 
respectively. Levels of PPARγ suppressed by 52% and 82% in clone 3 and clone 4 cells, 
respectively; whereas there was no significant change in its level in scramble cells. Thus 
clone 3 and clone 4 cell lines were selected as moderately and highly PPARγ-suppressed 
transfectants (derived from PC3-M cells), respectively. For future investigation, highly 
PPARγ-suppressed transfectants is named as PC3-M-PPARγ-si-H and moderately PPARγ-
suppressed transfectants is named as PC3-M-PPARγ-si-M. Also scramble cells were used as 
control. 
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Figure  3.15: Effect of shRNA on levels of PPARγ expression in PC3-M-derived 
transfectants. 
A: Detecting of PPARγ protein expression by Western blotting. The anti-β-actin antibody 
was used to correct possible loading errors in the same blot.  
B: Relative levels of PPARγ in different transfectants. The expression level of PPARγ in 
parental PC3-M cells was set as 1.0. The levels of PPARγ in control and other 4 transfectant 
clones were calculated by relating to that in parental PC3-M cells. Results were obtained 
from three different measurements (mean ± SD).  
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3.10 Effect of PPARγ suppression on tumour cells in vitro 
3.10.1 Effect of PPARγ suppression on cellular proliferation 
To find whether suppression of PPARγ would affect on the growth rate of PC3-M cells, 
proliferation assay was performed on control and transfectants cell lines over 5 days (120 
hours). Standard curve of each tested cell line is shown in Fig. 3.16 (section 2.2.7.1.1). 
  
 
 
Figure  3.16: Standard curves of parental PC3-M and different transfected cell lines. 
Using linear regression analysis, Standard curves were established for each cell line by 
plotting absorbance (OD at 570 nm) (Y axis) against the cell numbers (X axis). The curve 
equation and regression of each standard curve is presented in diagram. 
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The density of culture cells were determined by extrapolating from the standard curve and 
cell counts were obtained by MTT assays (section 2.2.7.1.2). Overall, growth rate of parental 
cells and control (scramble) exhibited very similar growth pattern. In the first 48 hours, no 
significant difference was detected between different cell lines. But from the 3
rd
 day onward, 
growth rates were significantly reduced in both PC3-M-PPARγ-si-H cells and PC3-M-
PPARγ-si-M cells compare to controls. At the end of the 5th day, cell numbers in PC3-M and 
scramble groups raised to 262,000 ± 14,000 and 283,000 ± 9810, respectively; whereas in 
PC3-M-PPARγ-si-H cells and PC3-M-PPARγ-si-M cells, numbers reached to 134,000 ± 
19,040 and 224,000 ± 15,200, respectively (Table 3.4). Cell proliferation rate of PC3-M-
PPARγ-si-H cells (Student’s test, p ≤ 0.0009) and PC3-M-PPARγ-si-M cells (Student’s test, 
p ≤ 0.004) were significantly reduced by 53% and 21%, respectively, compare to control cells 
(Fig. 3.17). 
 
 
Table  3.4: Cell counts of parental and transfected PC3-M cells at the 5th day of proliferation 
assay. Using Student’s t-test,  p values were obtained by comparing data from test groups to 
parental group. 
 
 
 
Cell line Mean number of cells ± SD p Value 
PC3-M 262,000 ± 14,000 
____ 
Scramble (control) 283,000 ± 9810 ≥ 0.44 
PC3-M-PPARγ-si-M  224,000 ± 15,200 ≤ 0.004 
PC3-M-PPARγ-si-H  134,000 ± 19,040 ≤ 0.0009 
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Figure  3.17: The impact of PPARγ silencing on the proliferation rate of transfectant cells. 
The growth rates of parental, scramble (control), PC3-M-PPARγ-si-M and PC3-M-PPARγ-
si-H cells during 5 days experimental period. Cell count of each sample was calculated by 
comparing serially diluted standard from standard curve. Results were obtained from three 
separate measurements (mean ± SE).  
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3.10.2 Effect of PPARγ suppression on invasiveness of prostate cancer cell  
The effect of PPARγ suppression on invasiveness of parental and transfectant cells was 
assessed using BD Matrigel coated invasion chambers (section 2.2.7.2).  Transfected cells in 
an active growth phase with confluency less than 80% were maintained in serum-free RPMI 
1640 medium for 24 hours prior to setting up the invasion assay.  After 24 hours starvation, 
cells were harvested and counted to prepare a mixture containing 5×10
4 
cells in serum-free 
medium. Chambers were rehydrated for 2 hours before 2.5×10
4 
cells in 0.5ml medium were 
loaded into every upper compartment of chambers. Routine medium (with 10% (v/v) FCS) 
was placed 1ml / well in lower compartments. All cell lines were set as triplicate and assay 
was run in a humidified tissue culture incubator for 24 hours. Finally, remaining cells in 
upper part were removed by gently using cotton swabs and washed with PBS. Migrated cells 
were fixed and stained using 2% crystal violet for 10 minutes and counted in nine random 
fields using light microscope at 125 × magnifications. Mean number of invaded cells in 
scramble (control), PC3-M-PPARγ-si-M and PC3-M-PPARγ-si-H group was 54 ± 4, 11 ± 2 
and 6 ± 1, respectively. Invasiveness of PC3-M-PPARγ-si-H cell (Student’s t-test, p ≤ 
0.0002) and PC3-M-PPARγ-si-M cell (Student’s t-test, p ≤ 0.0003) was reduced by 88.9% 
and 79.7%, respectively, in comparison with the control cell (Fig. 3.18) (Table 3.5). 
Table  3.5: Number of invaded cells per field in invasion assay. 
Differences of invasiveness between different groups were assessed by Student’s t-test. p 
values were obtained by comparing data in test groups to control group. 
 
Cell line Mean number of migrated cells ± SD p Value 
Scramble (control) 54 ± 4 ------- 
PC3-M-PPARγ-si-M 11 ± 2 ≤ 0.0003 
PC3-M-PPARγ-si-H 6 ± 1 ≤ 0.0002 
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A 
 
 
 
 
 
 
 
 
B 
   
Figure  3.18: The impact of PPARγ silencing on invasiveness of transfectants. 
A: Representative fields of invasion assay; cells were fixed and stained by crystal violet 
(2%). Original magnifications of images were ×100. 
B: Number of invaded cells per field in invasion assay; cells were incubated in BD Matrigel 
coated invasion chambers with serum-free medium for 24 hours. Normal culture medium 
used as chemo-attractant. Results were obtained from three separate measurements (mean ± 
SE).  
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3.10.3 Effect of PPARγ suppression on anchorage-independent growth of 
prostate cancer cells 
To investigate the effect of PPARγ suppression on tumorigenicity of transfectant cells, their 
anchorage-independent growth rates in the soft agar colony-formation were assessed. 
Scramble cells were used as control. Assay was set as triplicate and cells were grown for 4 
weeks. Colonies were stained by adding 0.5ml of 2% MTT for 4 hours. Colonies larger than 
150µm were counted using Gel Count. The number of colonies produced in soft agar after 4 
weeks by scramble (control), PC3-M-PPARγ-si-M and PC3-M-PPARγ-si-H were 756 ± 64, 
80 ± 14 and 45 ± 9, respectively. Colony formation potency of PC3-M-PPARγ-si-H cells 
(Student’s t-test, p ≤ 0.0015) and PC3-M-PPARγ-si-M cells (Student’s t-test, p ≤ 0.0012) 
were reduced by 94.1% and 89.5%, respectively, in comparison to control cells (Fig. 3.19) 
(Table 3.6). 
 
Table  3.6: Colony counts of transfected cells at 4th week of soft agar assay.  
Differences of number of colonies between different groups were assessed by Student’s t-test. 
p values were obtained by comparing sample groups to control group data. 
 
 
 
Cell line Mean number of colonies ± SD p Value 
Scramble (control) 756 ± 64 ------- 
PC3-M-PPARγ-si-M 80 ± 14 ≤ 0.0012 
PC3-M-PPARγ-si-H 45 ± 9 ≤ 0.0015 
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 A
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Figure  3.19: The impact of PPARγ silencing on the anchorage-independent growth of 
tranfectant cells. 
A: Representative plates of soft agar colony formation with different transfectants. 
B: Colony counts of different transfectants; Results were obtained from three separate 
measurements (mean ± SE).  
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3.11 Effect of PPARγ suppression on tumorigenicity of prostate cancer cells in vivo 
To evaluate the effect of PPARγ suppression on the tumorigenicity of PC3-M cells in vivo, 
parental and transfected cells were harvested and re-suspended in PBS (1×10
6
 cells/200 µl). 
Thirty male Balb/C immune-incompetent nude mice were divided into three equal groups and 
cells were injected subcutaneously into their flanks (section 2.2.8.2). Weight of mice and 
tumour sizes were measured twice a week using a calliper. The median latent period for 
group inoculated with PC3-M-PPARγ-si-H cells was 21 days which was significantly longer 
than those inoculated with parental cells [6 days (ranged 5-14)] and with PC3-M-PPARγ-si-
M cells [11 days (ranged 7-19)]. After three weeks, only 1 out of 10 (10%) of mice which 
inoculated with PC3-M-PPARγ-si-H cells produced tumour whereas all mice (100%) 
inoculated with parental cells and 7 out of 10 (70%) inoculated with PC3-M-PPARγ-si-M 
cells produced tumour (Table 3.7). At the end point of this experiment, average volume of 
tumours produced by control cells (250.6 mm
3
 ± 60) was significantly larger than those 
produced by  PC3-M-PPARγ-si-M cells (19.5 mm3 ± 14.6) (Student’s t-test, p ≤ 0.008) and 
PC3-M-PPARγ-si-H cells (2 mm3) (Student’s t-test, p ≤ 0.0009) (Fig. 3.20). At autopsy (three 
weeks after inoculation), average weight of the tumours produced by parental cells was 275 
mg ± 105 which was significantly higher than those produced by  PC3-M-PPARγ-si-M cells 
(26.5 mg ± 12.6) (Student’s t-test, p ≤ 0.002) and PC3-M-PPARγ-si-H cells (4 mg) (Student’s 
t-test, p ≤ 0.0003). Representative nude mice from each group, corresponding tumour mass, 
H&E and immunohistochemical staining of tumour tissues were shown in Figure 3.21. 
Primary tumours were fixed in 10% formalin for 24 hours before processed and paraffin 
embedded. Expression levels of PPARγ protein were evaluated in all primary tumours by 
immunohistochemical staining then intensity and percentage of nuclear staining were scored 
(section 2.2.4.3 and 2.2.4.4) (Table 3.8). When tumour sections were stained with anti-
PPARγ antibody, the intensity of nuclear staining in both test groups were much weaker than 
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that of control group which indicate that reduced PPARγ was responsible for reduction of 
tumour mass. In control group, 5 (50%) sections stained moderately positive in the nucleus 
and 5 (50%) sections stained strongly positive in the nucleus (Figure 3.21). Among a total of 
7 stained sections from PC3-M-PPARγ-si-M group, 2 (29%) stained weakly positive in the 
nucleus and 5 (71%) stained moderately positive in the nucleus. Nuclear expression of 
PPARγ in the only tumour that produced by PC3-M-PPARγ-si-H cells was weakly positive. 
No significant difference in cytoplasmic expression of PPARγ in different primary tumours 
was detected. Intensity of staining for PPARγ in tumours produced by PC3-M-PPARγ-si-H 
cells (χ2 test, p ≤ 0.002) or PC3-M-PPARγ-si-M cells (χ2 test, p ≤ 0.02) was significantly 
weaker compare to those produced by parental cells.  
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Cell lines 
No. of 
inoculated 
mice 
Incidence of tumours 
I Median of 
latent period 
(range) 
II 
Tumour weight 
(mg) 
III 
No. % 
PC3-M-PPARγ-si-H 10 1 10 21 4 
PC3-M-PPARγ-si-M 10 7 70 11 (7-19) 26.5 ± 12.6 
PC3-M (control) 10 10 100 6 (5-14) 275 ± 105 
 
Table  3.7: Incidence, latent period and weight of tumours developed by parental and 
transfectant cells in nude mice. 
I: Tumour incidence calculated by the percentage of number of the mice with tumour/total 
number of inoculated animals. 
II: Latent period is the number of days from the inoculation time to the time of first 
appearance of tumour. 
III: Tumour weight was measured at autopsy in 21
st
 day after inoculation of parental and 
transfectant cells. 
 
 
 
Origin of tissue 
(mice groups) 
No. of 
cases 
Nuclear stain intensity & percentage score  
 
≤ 3 4-6 ≥ 9 
Control 10 0 5 5 
PC3-M-PPARγ-si-M 7 2 5 0 
PC3-M-PPARγ-si-M 1 1 0 0 
 
Table  3.8: Nuclear expression of PPARγ in different primary tumours resected from nude 
mice. 
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Figure  3.20: Average tumour volume of each test group. 
Parental and transfectant cells were inoculated subcutaneously into the flank of nude mice of 
each test group (10 animals in each group). Weight of mice and tumour size were measured 
twice a week using a calliper. Tumour volume was calculated by the following formula: 
Length×Width×Heigth×0.5236. 
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Figure  3.21: Representative mice and corresponding tumour mass of each test group. 
The tumour produced by parental cells and PC3-M-PPARγ-si-M cells were pointed by an 
arrow but the one developed by PC3-M-PPARγ-si-H cells was barely visible. Presence of 
tumour cells in all tumour masses has been confirmed by H&E staining. 
Immunohistochemical staining with PPARγ antibody (1/50) showed significant difference 
between the expressions of PPARγ in test groups compare to the control. Original 
magnifications of images of representative slides were 250×. 
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3.12 Interaction of C-FABP and PPARγ and its effects on regulation of  
                 VEGF expression 
To investigate the possible interaction between C-FABP and PPARγ and its effect on 
regulation of VEGF in prostate cancer cells, moderately malignant 22RV1 cell line was 
subjected to different treatments, so the effect of the interaction of C-FABP and PPARγ could 
be assessed. Prior to the treatment, the level of C-FABP and PPARγ in 22RV1 and PC3-M 
cells were detected with Western blot. Both C-FABP and PPARγ levels appeared to be much 
lower in 22RV1 cells than in PC3-M cells (Fig. 3.22, A). Further quantitative analysis 
showed that the level of C-FABP in PC3-M was 5.4-fold higher than that in 22RV1. The 
level of PPARγ in PC3-M cells was also higher (3.2-fold) than that in 22RV1 cells (Fig. 3.22, 
B). 
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Figure  3.22: Levels of C-FABP and PPARγ in PC3-M and 22RV1 cells. 
A: Western blot analysis of C-FABP and PPARγ expressed in 22RV1 and PC3-M cells. The 
anti-β-actin antibody was used to correct possible loading errors in the same blot.  
B: Relative expression of C-FABP and PPARγ. The levels of both proteins in 22RV1 cells 
were set as 1.0. Levels in PC3-M cells were calculated by relating to those in 22RV1. Results 
were obtained from three different measurements (mean ± SE). 
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3.12.1 C-FABP and PPARγ up-regulated VEGF expression 
In order to study the possible role of C-FABP on up-regulation of VEGF (through PPARγ), 
the 60% confluent 22RV1 cells were treated with Rosiglitazone (PPARγ synthetic agonist) 
(0.5 µM) 
248
 or C-FABP recombinant protein (2 µM) 
167, 280
, overnight. The level of VEGF 
was assessed before and after treatments. Using Western blotting, different levels of VEGF 
expressed in protein extracted from 22RV1 cells before and after treatments were analysed. 
Two VEGF bands of 19 & 22kDa were detected in untreated and treated cells (Fig. 3.23, A). 
When the densitometric level of VEGF in untreated 22RV1 cells was set at 1, levels in those 
treated with Rosiglitazone and recombinant C-FABP were 1.41 ± 0.12 and 1.36 ± 0.08, 
respectively (Fig. 3.23, B). Levels of VEGF in the protein extracted from cells showed 41% 
and 36% increment after exposing to Rosiglitazone and recombinant C-FABP, respectively.  
When the levels of secreted VEGF in conditional media of 22RV1 cells before and after 
treatments were analysed by ELISA, VEGF was detected in all culture media from treated 
and untreated cells (Fig. 3.24, B). While the amount of VEGF produced by 22RV1 cells 
without any treatment, was detected about 120 ± 8.3 pg/ml, in those which treated with 
Rosiglitazone (0.5 µM) and recombinant C-FABP (2 µM) were increased to 915 ± 37.8 pg/ml 
(7.6 times) and 756 ± 25.6 pg/ml (6.3 times), respectively. Statistical analysis showed a 
significant difference between the levels of secreted VEGF in those treated with 
Rosiglitazone (Student’s t-test, p ≤ 0.0003) or recombinant C-FABP (Student’s t-test, p ≤ 
0.0005) and VEGF level of untreated cells. The relative level of VEGF was greater in 
conditional media compare to cell lysates (especially for those treated with Rosiglitazone or 
recombinant C-FABP) and both sets of experiment followed a similar pattern. 
Biological activity of secreted VEGF from 22RV1 cells which exposed to different 
treatments were evaluated by endothelial tube formation assay (in vitro angiogenesis assay). 
The tube formation ability of HUVEC cells were strongly promoted and well-assembled 
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organizations formed in those treated with Rosiglitazone (Fig. 3.25, D) or recombinant C-
FABP (Fig. 3.25, F), similar to positive control (cells were treated with recombinant human 
VEGF, 10ng/ml) (Fig. 3.25, A). Conditional medium from the untreated 22RV1 cells caused 
partially visible sprouting of new capillary tubes (Fig. 3.25, C). The average numerical 
values associated with tube formation showed a significant increase in cells treated with 
Rosiglitazone (2-fold) and recombinant C-FABP (1.8-fold) compare to untreated cells (Fig. 
3.26). Comparing to untreated cells, the network formation value in cells treated with 
Rosiglitazone (Student’s t-test, p ≤ 0.003) or recombinant C-FABP (Student’s t-test, p ≤ 
0.006) was significantly higher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
 
 
148 
 
 
 
 
                                                            
Figure  3.23: Levels of VEGF protein in 22RV1 cells exposed to different treatments.  
A: VEGF levels in 22RV1 cells treated overnight in different conditions were analysed by 
Western blotting (according to the instruction of  manufacture, antibody reacts with two 
splice variant of VEGF antigen by molecular weight of 19 & 22 kDa); 1: 22RV1 cells 
without any treatment, 2: 22RV1 cells treated with Rosiglitazone (PPARγ agonist) (0.5 µM), 
3: 22RV1 cells treated with GW9662 (PPARγ antagonist)  (20 µM), 4: 22RV1 cells treated 
with C-FABP recombinant protein (2 µM), 5: 22RV1 cells treated with a mixture of C-FABP 
recombinant protein (2 µM) & GW9662 (20 µM), 6: 22RV1 cells treated with single mutant 
C-FABP protein (2 µM), 7: 22RV1 cells treated with double mutant C-FABP protein (2 µM). 
The anti-β-actin antibody was used to correct possible loading errors in the same blot.  
B: Relative levels of VEGF. The level of VEGF in untreated 22RV1 cells was set as 1.0; 
levels in other cells were calculated by relating to level that in untreated 22RV1 cells. Results 
were obtained from three different measurements (mean ± SE).  
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Figure  3.24: Levels of secreted VEGF in conditional media of 22RV1 cells exposed to 
different treatments.  
A: Standard VEGF curve generated by ELISA. The quantity of VEGF was determined by 
comparing to serially-diluted concentrations of the standard curve.  
B: VEGF levels in conditional media of 22RV1 cells treated overnight with different 
conditions were analysed by ELISA; 1: 22RV1 cells without any treatment, 2: 22RV1 cells 
treated with Rosiglitazone (PPARγ agonist) (0.5 µM), 3: 22RV1 cells treated with GW9662 
(PPARγ antagonist)  (20 µM), 4: 22RV1 cells treated with C-FABP recombinant protein (2 
µM), 5: 22RV1 cells treated with a mixture of C-FABP recombinant protein (2 µM) & 
GW9662 (20 µM), 6: 22RV1 cells treated with single mutant C-FABP protein (2 µM), 7: 
22RV1 cells treated with double mutant C-FABP protein (2 µM). Results were obtained from 
three different measurements (mean ± SE).  
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Figure  3.25: HUVEC cells network formation on ECMatrix, exposed to conditional media of 
22RV1 cells with different treatments. 
After 6 hours incubation of endothelial cells with conditional media from 22RV1 cell culture 
media exposed to different treatments, network structures were visualized by MTT (2%). 
Original magnifications of images of representative slides were 250×. A: Positive control 
(recombinant human VEGF, 10ng/ml); B: Negative control (normal culture medium); C: The 
medium of 22RV1 cells without any treatment; D: The medium of 22RV1 cells treated with 
Rosiglitazone (PPARγ agonist)  (0.5 µM); E: The medium of 22RV1 cells treated with 
GW9662 (PPARγ antagonist)  (20 µM); F: The medium of 22RV1 cells treated with C-FABP 
recombinant protein (2 µM); G: The medium of 22RV1 cells treated with a mixture of C-
FABP recombinant protein (2 µM) & GW9662 (20 µM); H: The medium of 22RV1 cells 
treated with single mutant C-FABP protein (2 µM); I: The medium of 22RV1 cells treated 
with double mutant C-FABP protein (2 µM). 
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Figure  3.26: Relative values of HUVEC cells network formation under 22RV1 cells’ 
conditional media exposed to different treatments. 
The effects of conditional media (from 22RV1 cells subjected to different treatments) on 
HUVEC cells network formation were assessed and quantified according the cell network 
pattern. Three individual assays were performed for each treatment and the values of five 
random fields in each assay were averaged (mean ± SD). C: The medium of 22RV1 cells 
without any treatment (2.33 ± 0.66); D: The medium of 22RV1 cells treated with 
Rosiglitazone (0.5 µM) (4.66 ± 0.67); E: The medium of 22RV1 cells treated with GW9662 
(20 µM) (0.67 ± 0.66); F: The medium of 22RV1 cells treated with C-FABP recombinant 
protein (2 µM) (4.33 ± 0.67); G: The medium of 22RV1 cells treated with a mixture of C-
FABP recombinant protein (2 µM) & GW9662 (20 µM) (1.33 ± 0.67); H: The medium of 
22RV1 cells treated with single mutant C-FABP recombinant protein (2 µM) (1.67 ± 0.66); I: 
The medium of 22RV1 cells treated with double mutant C-FABP recombinant protein (2 µM) 
(0.67 ± 0.66).  
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3.12.2 Suppression of C-FABP or PPARγ down-regulated VEGF expression 
In order to study the possible role of C-FABP suppression on down-regulation of VEGF 
(through PPARγ), the 60% confluent 22RV1 cells were treated with GW9662 (PPARγ 
synthetic antagonist) (20 µM) 
167
 , single mutant C-FABP recombinant protein (2 µM) or 
double mutant C-FABP recombinant protein (2 µM) 
167, 280
, overnight. Western blot was used 
to assess the level of VEGF in cellular extracts of 22RV1 cells before and after treatments. 
Two VEGF bands of 19 & 22 kDa were detected in untreated and treated cells (Fig. 3.23, A). 
When the level of VEGF in untreated 22RV1 cells was set at 1, level in those treated with 
GW9662, single mutant and double mutant recombinant C-FABP were 0.47 ± 0.08, 0.56 ± 
0.08 and 0.49 ± 0.12, respectively (Fig. 3.23, B). Levels of VEGF in the cell extracts was 
reduced by 53%, 44% and 51% after treatment with GW9662, single mutant or double 
mutant recombinant C-FABP, respectively.  
When the levels of secreted VEGF in conditional medium of 22RV1 cells before and after 
treatments were analysed by ELISA, VEGF was detected in all culture media from treated 
and untreated cells (Fig. 3.24, B). While the amount of VEGF produced by 22RV1 without 
any treatment was about 120 ± 8.3 pg/ml, the amount of VEGF in those treated with GW9662 
(20 µM), single and double mutant recombinant C-FABP (2 µM) were 96 ± 12.1 pg/ml, 102 
± 18.4 pg/ml  and 74 ± 6.2 pg/ml, respectively.  Thus treating with GW9662, single and 
double mutant recombinant C-FABP produced 20%, 15% and 39% reductions in secreted 
VEGF level. The amount of VEGF in media of cells treated with GW9662 (Student’s t-test, p 
≤ 0.02) and double mutant recombinant C-FABP (Student’s t-test, p ≤ 0.0009) was 
significantly reduced in comparison with that of the untreated cells. The level of VEGF in 
medium of cells treated with single mutant recombinant C-FABP was not statistically 
different (Student’s t-test, p ≥ 0.1) from that in control. 
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Biological activity of secreted VEGF from 22RV1 cells was evaluated by endothelial tube 
formation assay (in vitro angiogenesis assay). HUVEC cells remained randomly separated 
without any sign of formation of complex mesh likes structures after treatment with GW9662 
(Fig. 3.25, E) or double mutant recombinant C-FABP (Fig. 3.25, I), similar to that of the 
negative control (cells were treated with normal culture medium) (Fig. 3.25, B). Conditional 
medium of cells treated with single mutant recombinant C-FABP only induced some visible 
capillary tubes without any sprouting (Fig. 3.25, H). Conditional medium from the untreated 
22RV1 cells caused partially visible sprouting of new capillary tubes (Fig. 3.25, C). The 
average numerical values associated with tube formation showed a prominent reduction in 
cells treated with GW9662 or double mutant recombinant C-FABP in comparison to 
untreated 22RV1 cells (72%) (Fig. 3.26). Comparing with the untreated cells, the network 
formation value in cells treated with GW9662 (Student’s t-test, p ≤ 0.01) and double mutant 
recombinant C-FABP (Student’s t-test, p ≤ 0.01)  were significantly lower; whereas the 
difference between the value of the cells treated with single mutant recombinant C-FABP and 
that of control was not statistically different (Student’s t-test, p ≥ 0.11). 
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3.12.3 Suppression of PPARγ neutralized up-regulatory effect of C-FABP on                                                                                                                                                                                              
VEGF expression 
To study the possible effect of PPARγ inhibition in  counteracting up-regulatory effect of C-
FABP on VEGF,  60% confluent 22RV1 cells were treated with GW9662 (PPARγ synthetic 
antagonist) (20 µM) , C-FABP recombinant protein (2 µM) or a combination of C-FABP 
recombinant protein with GW9662, overnight. Western blot detected two VEGF bands of 19 
& 22 kDa in cellular extracts of untreated and treated 22RV1 cells (Fig. 3.23, A). When the 
level of VEGF in untreated 22RV1 cells was set at 1, levels in those treated with GW9662, 
recombinant C-FABP and mixture of recombinant C-FABP with GW9662 were 0.47 ± 0.08, 
1.36 ± 0.08 and 0.69 ± 0.04, respectively (Fig. 3.23, B). Although level of VEGF showed 
36% increment after treating with recombinant C-FABP, 31% decrement was detected after 
treating with a mixture of recombinant C-FABP with GW9662.  
When the level of secreted VEGF was analysed by ELISA, VEGF was detected in all culture 
media from treated and untreated 22RV1 cells (Fig. 3.24, B). While the amount of VEGF 
produced by untreated 22RV1 cells was 120 ± 8.3 pg/ml, the amount of VEGF in cells treated 
with GW9662 (20 µM), recombinant C-FABP (2 µM) and mixture of recombinant C-FABP 
with GW9662 were 96 ± 12.1 pg/ml, 756 ± 25.6 pg/ml  and 105 ± 9.6 pg/ml, respectively. 
Although treatment with recombinant C-FABP produced 6.3-fold increase in secreted VEGF 
level, combination of recombinant C-FABP with GW9662 produced 12.5% reduction in 
secreted VEGF level. The amount of VEGF in media of cells treated with GW9662 
(Student’s t-test, p ≤ 0.02) and recombinant C-FABP (Student’s t-test, p ≤ 0.0005) was 
significantly different from that of the untreated cells. The level of VEGF in medium of cells 
treated with mixture of recombinant C-FABP and GW9662 was not statistically different 
(Student’s t-test,  p ≥ 0.05) from that in control. 
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Biological activity of secreted VEGF from 22RV1 cells was evaluated by endothelial tube 
formation assay (in vitro angiogenesis assay). The tube formation ability of HUVEC cells 
was strongly enhanced and well-assembled organizations formed in those treated with C-
FABP recombinant protein (Fig. 3.25, F). Conditional medium from treated cells with 
combination of recombinant C-FABP with GW9662 only induced some visible capillary 
tubes without any sprouting (Fig. 3.25, G). Conditional medium from the untreated 22RV1 
cells caused partially visible sprouting of new capillary tubes (Fig. 3.25, C). The average 
numerical values associated with tube formation showed a significant increase in the cells 
treated with recombinant C-FABP (1.8-fold); whereas in those treated with combination of 
recombinant C-FABP and GW9662 showed about 42% reduction from control level 
(Fig.3.26). Comparing with untreated cells, the network formation value in cells treated with 
recombinant C-FABP (Student’s t-test, p ≤ 0.006)  was significantly higher; whereas the  
difference between the value of the cells treated with mixture of C-FABP recombinant 
protein and GW9662 and that of control was not statistically different (Student’s t-test, p ≥ 
0.05) . 
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3.12.4 Effects of C-FABP and PPARγ on VEGF activity through PPREs 
To investigate whether the activated PPARγ (by fatty acids transported via C-FABP) up-
regulated VEGF through binding to the PPREs in promoter region of the VEGF gene, a 
luciferase reporter gene system was employed to test the relationship between the presence or 
absence of PPRE and the level of VEGF expression. pGL3-promoter luciferase vector was 
used to make three DNA constructs: In construct A (Wild type), 805bp segment of VEGF 
promoter region containing two PPREs was cloned upstream of the luciferase reporter gene. 
In construct B (Mutant1) a segment of DNA from the same region with mutated sequences to 
replace two PPREs was inserted into upstream of the reporter gene. In construct C (Mutant2), 
a 393bp section of DNA from VEGF promoter region in which both PPREs were deleted was 
cloned upstream of reporter gene. Thus three constructs harbouring a section of VEGF 
promoter in the upstream of luciferase gene, were made; one contains two PPREs, the other 
one contains two mutated PPRE sequences and the last one contains no PPRE. In addition, 
pGL3-promoter vector alone was used as control. Four different prostate cancer cell lines 
including: 22RV1 cells, PC3-M cells, PC3-M-3 cells (C-FABP knockdown PC3-M cells) 
168
 
and PC3-M-PPARγ-si-H cells (PPARγ-suppressed PC3-M cells) were used to perform 
transient transfection with three luciferase gene constructs, respectively. Different levels of 
luciferase activity were measured in co-transfected prostate cancer cell lines before exposing 
to any treatment (Fig. 3.27). When the level of luciferase activity in 22RV1 cells transfected 
with control plasmid was set as 1, levels in those transfected with Wild type, Mutant1 and 
Mutant2 plasmids were 2.62 ± 0.26, 2.41 ± 0.25 and 1.29 ± 0.17, respectively. When the 
level of luciferase activity in PC3-M cells transfected with control plasmid was set as 1, 
levels in those transfected with Wild type, Mutant1 and Mutant2 plasmids were 3.3 ± 0.12, 2 
± 0.14 and 1 ± 0.21, respectively. When the level of luciferase activity in PC3-M-PPARγ-si-
H cells transfected with control plasmid was set as 1, levels in those transfected with Wild 
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type, Mutant1 and Mutant2 plasmids were 2.16 ± 0.22, 1.75 ± 0.24 and 0.99 ± 0.23, 
respectively. When the level of luciferase activity in PC3-M-3 cells transfected with control 
plasmid was set as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 
plasmids were 2.5 ± 0.32, 1.71 ± 0.31 and 0.99 ± 0.2, respectively. 
Luciferase activity in 22RV1, PC3-M, PC3-M-PPARγ-si-H and PC3-M-3 cells which 
transfected with Wild type showed 262%, 330%, 216% and 250% increase, respectively; 
whereas levels in the same set of cell lines transfected with Mutant2 plasmid only increased 
by 29%, 21%, 24% and 31%, respectively. After being transfected with Muatnt1 plasmid, 
levels of luciferase activity raised 241%, 200%, 175% and 171% in 22RV1, PC3-M, PC3-M-
PPARγ-si-H and PC3-M-3 cells, respectively. 
Then transfected cell lines were treated with Rosiglitazone (PPARγ agonist) (0.5µM), 
GW9662 (PPARγ antagonist) (20µM), C-FABP recombinant protein (2µM), single mutant 
C-FABP recombinant protein (2µM), double mutant C-FABP recombinant protein (2µM) 
and Mithramycin A (Sp1 inhibitor) (0.1µM) to investigate their effects on the luciferase 
activity. 
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Figure  3.27: Luciferase activity in different prostate cancer cell lines transfected with 
different luciferase reporter gene constructs. 
VEGF-promoter luciferase and Renilla luciferase plasmids were co-transfected into 22RV1, 
PC3-M, PC3-M-PPARγ-si-H and PC3-M-3 cell lines. Luciferase activity of transfected cells 
with control (pGL3-promoter) was set as 1. Levels in other cells were calculated by relating 
to that of the control. Results were obtained from three different measurements (mean ± SD). 
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3.12.4.1  PPARγ regulated VEGF-promoter activity  
Different levels of luciferase activity were measured in co-transfected prostate cancer cell 
lines before and after subjecting them to different treatments. 
When the level of luciferase activity in 22RV1 cells transfected with control plasmid was set 
as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 plasmids were 2.62 ± 
0.26, 2.41 ± 0.25 and 1.29 ± 0.17, respectively; after treating with Rosiglitazone (PPARγ 
agonist) (0.5µM) luciferase activity in the same set of transfectants detected as 4.25 ± 0.35, 
2.33 ± 0.50 and 1.42 ± 0.26, respectively (Fig. 3.28, A). Comparing with the control, the 
luciferase level in cells transfected with Wild type and treated with Rosiglitazone (Student’s 
t-test,  p ≤ 0.0003)  was significantly higher; whereas the  difference between the levels in the 
cells transfected with Mutant1 (Student’s t-test, p ≥ 0.44) and Mutant2 (Student’s t-test,  p ≥ 
0.25) and that of control was not statistically significant. 
When the level of luciferase activity in PC3-M cells transfected with control plasmid was set 
as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 plasmids were 3.3 ± 
0.12, 2 ± 0.14 and 1 ± 0.21, respectively; after treating with GW9662 (PPARγ antagonist) 
(20µM) luciferase activity in the same transfectants was reduced to 2.23 ± 0.12, 1.70 ± 0.22 
and 1.15 ± 0.32, respectively. When the level of luciferase activity in PC3-M-PPARγ-si-H 
cells transfected with control plasmid was set as 1, levels in those transfected with Wild type, 
Mutant1 and Mutant2 plasmids were 2.16 ± 0.22, 1.75 ± 0.24 and 0.99 ± 0.23, respectively 
(Fig. 3.28, B). Comparing with untreated control cells, the luciferase level in PC3-M cells 
transfected with Wild type and treated with GW9662 (Student’s t-test, p ≤ 0.002)  was 
significantly lower; whereas the  difference between levels of the cells transfected with 
Mutant1 (Student’s t-test, p ≥ 0.08) or Mutant2 (Student’s t-test, p ≥ 0.27) and that of the 
control was not statistically significant. No significant difference was detected between levels 
of luciferase in transfected PC3-M cells treated with GW9662 and that in PC3-M-PPARγ-si-
H cells. 
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Figure  3.28: Effects of PPARγ on VEGF-promoter activity in prostate cancer cells. 
VEGF-promoter luciferase and Renilla luciferase plasmids were co-transfected into 22RV1, 
PC3-M and PC3-M-PPARγ-si-H cells. Luciferase activity of transfected cells with vector 
only (pGL3-promoter) was set as 1. Levels in other cells were calculated by relating to the 
control. Results were obtained from three different measurements (mean ± SD). A: 
Luciferase activity level in transfected 22RV1 cells before and after Rosiglitazone (0.5µM) 
treatment; B: Luciferase activity levels in transfected PC3-M cells before and after GW9662 
(20µM) treatment. Luciferase activity levels in transfected PC3-M-PPARγ-si-H cells without 
any treatment. 
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3.12.4.2   C-FABP regulated VEGF-promoter activity 
Different luciferase activity levels were measured in co-transfected prostate cancer cell lines 
before and after different treatments. 
When the level of luciferase activity in 22RV1 cells transfected with control plasmid was set 
as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 plasmids were 2.62 ± 
0.26, 2.41 ± 0.25 and 1.29 ± 0.17, respectively; after treating with recombinant C-FABP, 
luciferase activity levels in the same transfectants were increased to 4.23 ± 0.41, 2.04 ± 0.32 
and 1.26 ± 0.40, respectively. After treating with recombinant double mutant C-FABP, 
luciferase level in 22RV1 cells transfected with Wild type, Mutant1 and Mutant2 were 2.29 ± 
0.35, 2.14 ± 0.32 and 1.1 ± 0.41, respectively (Fig. 3.29, A). Comparing with untreated cells, 
the luciferase level in 22RV1 cells transfected with Wild type and treated with recombinant 
C-FABP (Student’s t-test, p ≤ 0.004)  was significantly higher; whereas the  difference 
between the value of the cells transfected with Mutant1 (Student’s t-test, p ≥ 0.44) or Mutant2 
(Student’s t-test, p ≥ 0.09) and that of the control was not statistically significant. No 
significant difference was detected between luciferase level in transfected 22RV1 cells treated 
with recombinant double mutant C-FABP and that in the control (Student’s t-test, p ≥ 0.33).  
When the level of luciferase activity in PC3-M cells transfected with control plasmid was set 
as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 plasmids were 3.3 ± 
0.12, 2 ± 0.14 and 1 ± 0.21, respectively; level of luciferase activity in the same transfectants 
in PC3-M-3 cells were 2.15 ± 0.12, 1.71 ± 0.22 and 0.99 ± 0.32, respectively (Fig. 3.29, B). 
Comparing with PC3-M cells, the luciferase level in PC3-M-3 cells transfected with Wild 
type (Student’s t-test,  p ≤ 0.001) was significantly lower; whereas the difference between the 
level of the cells transfected with Mutant1 (Student’s t-test,  p ≥ 0.07) or Mutant2 (Student’s 
t-test, p ≥ 0.48) and that of control was not statistically significant.  
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Figure  3.29: Effects of C-FABP on VEGF-promoter activity in prostate cancer cells. 
VEGF-promoter luciferase and Renilla luciferase plasmids were co-transfected into 22RV1, 
PC3-M and PC3-M-3 cells. Luciferase activity level of the transfected cells with control 
(pGL3-promoter) was set as 1. Levels in other cells were calculated by relating to the control. 
Results were obtained from three different measurements (mean ± SE). A: Luciferase activity 
in transfected 22RV1 cells before and after treatment with recombinant C-FABP (2µM) or 
recombinant double mutant C-FABP (2µM); B: Luciferase activity in transfected PC3-M and 
PC3-M-3 cells without any treatment. 
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3.12.4.3   Combined effects of C-FABP and PPARγ on VEGF-promoter activity 
Different luciferase activity levels were measured in co-transfected prostate cancer cell lines 
before and after different treatments.  
Levels of luciferase activity in all untreated and treated 22RV1 cells transfected with Wild 
type plasmid were increased in comparison to control group (Fig. 3.30, A). When the 
luciferase activity of transfected cells with control plasmid was set as 1, levels of those 
treated with Rosiglitazone (0.5µM), recombinant C-FABP (2µM) and combination of 
Rosiglitazone and recombinant C-FABP were 4.25 ± 0.12, 4.13 ± 0.22 and 4.36 ± 0.32, 
respectively. Level in untreated 22RV1 cells was 2.62 ± 0.26. The luciferase levels in cells 
transfected with Wild type and treated with either Rosiglitazone (Student’s t-test, p ≤ 0.0003), 
recombinant C-FABP (Student’s t-test, p ≤ 0.004) or combination of Rosiglitazone and 
recombinant C-FABP (Student’s t-test,  p ≤ 0.001) were significantly higher in comparison to 
untreated control cells; whereas they were not significantly different when compared to each 
other (Student’s t-test, p ≥ 0.17). 
Levels of luciferase activity in PC3-M and PC3-M-3 cells transfected with Wild type plasmid 
were enhanced compare to control group (Fig. 3.30, B). When the level of luciferase activity 
of PC3-M cells transfected with control plasmid was set as 1, levels in cells transfected with 
Wild type was 3.3 ± 0.18. Levels in PC3-M cells treated with GW9662 (20µM), untreated 
PC3-M-3 cells and PC3-M-3 cells treated with GW9662 (20µM) were 2.05 ± 0.24, 2.23 ± 
0.21, 1.95 ± 0.19, respectively.  
Comparing to untreated PC3-M cells, the luciferase levels in PC3-M cells treated with 
GW9662 (Student’s t-test, p ≤ 0.001), untreated PC3-M3 cells (Student’s t-test, p ≤ 0.001) 
and PC3-M-3 cells treated with GW9662 (Student’s t-test, p ≤ 0.0004) were significantly 
lower; whereas these levels were not significantly different when compared to each other 
(Student’s t-test, p ≥ 0.25). 
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Figure  3.30: Combined effects of C-FABP and PPARγ on VEGF-promoter activity in prostate 
cancer cells. VEGF-promoter luciferase and Renilla luciferase plasmids were co-transfected 
into 22RV1, PC3-M and PC3-M-3 cells. Luciferase activity level of transfected cells with 
control plasmid (pGL3-promoter) was set as 1. Levels in other cells were calculated by 
relating to control. Results were obtained from three different measurements (mean ± SE). A: 
Luciferase activity in 22RV1 transfectant cells (transfected with Wild type or Control) before 
and after treating with Rosiglitazone (0.5µM) and C-FABP recombinant protein (2µM) either 
individually or combined; (1) 22RV1 transfectants, (2) 22RV1 transfectants + Rosiglitazone, 
(3) 22RV1 transfectants +  C-FABP recombinant protein, (4) 22RV1 transfectants + 
Rosiglitazone & C-FABP recombinant protein; B: Luciferase activity in PC3-M and PC3-M-
3 transfectant cells before and after GW9662 (20µM) treatment; (1) PC3-M transfectants, (2) 
PC3M transfectants + GW9662, (3) PC3-M-3 transfectants, (4) PC3-M-3 transfectants + 
GW9662. 
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3.12.5   Effects of Sp1 (Androgen binding site) on VEGF-promoter activity 
Different levels of luciferase activity were measured in co-transfected prostate cancer cell 
lines before and after subjecting them to different treatments. 
When the level of luciferase activity in androgen-dependent 22RV1 cells transfected with 
control plasmid was set as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 
plasmids were 2.62 ± 0.26, 2.41 ± 0.25 and 1.29 ± 0.17, respectively. After treating with 
Mithramycin A (Sp1 inhibitor) (0.1µM) luciferase activity in the same set of transfectants 
was reduced to 1.73 ± 0.11, 1.19 ± 0.24 and 0.97 ± 0.31, respectively (Fig. 3.31, A). 
Comparing with the untreated control, after treating with Mithramycin A the luciferase level 
in cells transfected with Wild type (Student’s t-test,  p ≤ 0.007) and Mutant1 (Student’s t-test 
p ≤ 0.001) were significantly lower; whereas the  difference between the level in cells 
transfected with Mutant2 (Student’s t-test, p ≥ 0.101) and that in control cells was not 
statistically significant. 
When the level of luciferase activity in androgen-independent PC3-M cells transfected with 
control plasmid was set as 1, levels in those transfected with Wild type, Mutant1 and Mutant2 
plasmids were 3.3 ± 0.12, 2 ± 0.14 and 1 ± 0.21, respectively. After treating with 
Mithramycin A level of luciferase activity in the same transfectants were 3.2 ± 0.23, 1.7 ± 
0.11, 0.95 ± 0.25, respectively (Fig. 3.31, B). After treating with Mithramycin A the 
difference between the luciferase levels in PC3-M cells transfected with Wild type (Student’s 
t-test, p ≥ 0.27), Mutant1 (Student’s t-test, p ≥ 0.06) or Mutant2 (Student’s t-test p ≥ 0.40) and 
that of control was not statistically significant.  
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Figure  3.31: Effects of Sp1 binding site on VEGF-promoter activity in prostate cancer cells. 
VEGF-promoter luciferase and Renilla luciferase plasmids were co-transfected into 22RV1 
and PC3-M cells. Luciferase activity level of transfected cells with control plasmid (pGL3-
promoter) was set as 1. Levels in other cells were calculated by relating to the control. 
Results were obtained from three different measurements (mean ± SE). A: Luciferase activity 
in 22RV1 transfectants before and after Mithramycin A (Sp1 inhibitor) (0.1µM) treatment; B: 
Luciferase activity in PC3-M transfectants before and after Mithramycin A treatment. 
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3.12.5.1   Combined effects of Sp1 and PPARγ on VEGF-promoter activity 
Different levels of luciferase activity were measured in co-transfected prostate cancer cells 
before and after subjecting them to different treatments. 
When the level of luciferase activity in 22RV1 cells transfected with control plasmid (pGL3-
promoter) was set as 1, levels in those transfected with Wild type plasmid and treated with 
Mithramycin A (Sp1 inhibitor) (0.1µM), GW9662 (PPARγ antagonist) (20µM) and 
combination of Mithramycin A with GW9662 were 1.73 ± 0.11, 2.09 ± 0.12 and 1.68 ± 0.35, 
respectively. The level in untreated 22RV1 cells was 2.62 ± 0.26 (Fig. 3.32). Comparing with 
the untreated control, the luciferase level in cells transfected with Wild type and treated with 
Mithramycin A (Student’s t-test, p ≤ 0.007), GW9662 (Student’s t-test, p ≤ 0.026) and 
combination of Mithramycin A with GW9662 (Student’s t-test, p ≤ 0.011) was significantly 
lower; whereas the difference between the level in the cells treated with combination of 
Mithramycin A with GW9662 to the level of those treated with Mithramycin A (Student’s t-
test, p ≥ 0.416) or GW9662 (Student’s t-test, p ≥ 0.085) was not statistically significant. 
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Figure  3.32: Combined effects of Sp1 binding site and PPARγ on VEGF-promoter activity in 
prostate cancer cells. VEGF-promoter luciferase and Renilla luciferase plasmids were co-
transfected into 22RV1 cells. Luciferase activity of transfected cells with control plasmid 
(pGL3-promoter) was set as 1. Levels in other cells were calculated by relating to the control. 
Results were obtained from three different measurements (mean ± SE). Luciferase activity in 
transfected 22RV1 cells before and after treating with Mithramycin A (0.1µM) and GW9662 
(20µM), either individually or combined; (1) 22RV1 transfectants, (2) 22RV1 transfectants + 
Mithramycin A, (3) 22RV1 transfectants + GW9662, (4) 22RV1 transfectants + Mithramycin 
A & GW9662. 
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4 Discussion 
C-FABP is a 15 kDa cytosolic protein that belongs to the fatty acid binding protein family 
281
 
and binds to long chain fatty acids with high affinity. In addition to skin, C-FABP is detected 
in endothelial cells of placenta, heart, skeletal muscle, small intestine, renal medulla and in 
Clara and goblet cells of lung 
282
. Apart from prostate cancer 
188
, C-FABP has been 
implicated in malignancies of bladder and pancreas 
283-285
 and its expression is associated 
with poor survival in breast cancer 
286
 and glioblastoma 
287
. Recently, the molecular 
mechanisms involved in cancer-promoting activity of C-FABP in prostate cancer were 
investigated. Based on the currently available evidences, it was hypothesized that there may 
be a fatty acid-initiated signalling pathway that leads to the malignant progression of prostate 
cancer cells. This pathway may work through following  route: Increased level of C-FABP 
transports a large amount of intracellular fatty acids into the cancer cells and the excessive 
amount of fatty acids may generate enhanced signals through their nuclear PPAR receptors to 
trigger a chain of molecular events that ultimately leads to the increased activities of down-
stream cancer-promoting genes which facilitate angiogenesis and inhibit apoptosis and 
thereby enhance the malignant progression 
288, 289
. Although this hypothesis was partly 
justified by the results of some recent studies 
167
, more evidence is needed to fully 
demonstrate the existence of the hypothesized signalling pathway in prostate cancer cells. 
This current work investigated the detailed molecular mechanisms involved in each step of 
connections of the hypothesized pathway and discovered a C-FABP (fatty acids)-PPARγ-
VEGF axis that promotes the malignant progression of the cancer cells. Thus the results in 
this study provided more evidence to justify the original hypothesis.  
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4.1 C-FABP and PPARγ were overexpressed in prostate cancer cells and tissues 
There are three nuclear PPARs (PPARα, PPARβ/δ and PPARγ) that could act as fatty acid 
receptors 
290. Previous studies were shown weak expression of PPARα in prostate cell lines 
and tissues. Moreover no significant difference has been detected in expression levels of 
PPARα between benign and malignant prostate cell lines or tissues 200, 291. Thus, PPARα is 
unlikely to be involved in activities exerted by C-FABP in prostate cancer. 
Although results from this study revealed that PPARβ/δ is expressed in cultured prostate 
cells, its level was not demonstrably different between benign and malignant cell lines (Fig. 
3.1, A). However, expression of PPARβ/δ in tissue samples appeared to be different from that 
in the cell lines. While staining for PPARβ/δ was detected in BPH and carcinoma cases, 
levels detected in malignant tissues were significantly higher than those in BPH (Table 3.1-
1). These results suggested that expression of PPARβ/δ in cultured cell lines measured by 
Western blot may not reflect the levels in human tissues measured by immunohistochemical 
staining. However, increased nuclear staining for PPARβ/δ was not significantly correlated 
with increased cytoplasmic staining for C-FABP, indicating that elevated PPARβ/δ may not 
be directly related to C-FABP and hence to fatty acid stimulation in prostate cancer cells. 
In contrast to the other PPARs, patterns of expression level for PPARγ in cell lines measured 
by Western blot and in tissues measured by immunohistochemistry were very similar to those 
of C-FABP (Fig. 3.1, B-C). The levels of C-FABP and PPARγ in malignant cells were 
significantly higher than those in benign PNT2 cells and elevated levels of PPARγ and C-
FABP were associated with increasing malignancy of the prostatic cancer cells (Fig. 3.1, E-
F). Similarly in immunohistochemical analysis, the staining levels for PPARγ and C-FABP 
were significantly higher in carcinomas than in BPH and the enhanced staining levels in the 
carcinomas were significantly associated with GS (Table 3.1-2&3). Furthermore, increased 
cytoplasmic staining for C-FABP was significantly correlated with increased nuclear staining 
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for PPARγ in the carcinomas. These findings are in line with our separate work, in which we 
found that C-FABP acted with PPARγ in a coordinated manner to promote malignant 
progression in prostatic cancer cells 
292
 and hence, PPARγ is more likely to be the receptor 
for the fatty acids transported by C-FABP than PPARβ/δ.   
4.2 Increased expression levels of C-FABP and PPARγ were associated with poor   
patient survival 
In prostate cancer management, a major problem is the lack of reliable biomarkers to predict 
the aggressiveness or potential therapeutic response of an individual prostate cancer. Results 
in this work suggested that AR (Fig. 3.6, B) and PSA (Fig. 3.6, C) are not significant 
prognostic markers in this tested patient group although the number of patients is relatively 
small. It is also suggested that  PSA, the most commonly employed biomarker cannot be used 
to predict patient outcomes, as previously suggested to be unreliable 
293
. Current results 
showed that increased levels of nuclear PPARγ and cytoplasmic C-FABP (Table 3.1-2&3) 
were significantly correlated with GS and significantly associated with reduced survival time 
(Fig. 3.4, D) (Fig. 3.5, A). These findings suggested that increased levels of nuclear PPARγ 
and cytoplasmic C-FABP may be alternative biomarkers for reduced cellular differentiation 
(GS), as well as reliable prognostic factors to predict patient survival. Multivariate survival 
analysis revealed that prognostic value of nuclear PPARγ expression in prostate cancer 
patients is dependent on prognostic value of cytoplasmic C-FABP (Table 3.2).  Assessment 
of the conjoined expression levels of C-FABP and PPARγ showed that in 75% of cases, 
expression pattern of PPARγ (either in the nucleus or in cytoplasm) was detected the same as 
cytoplasmic expression of C-FABP (either high or low) (Fig. 3.7, A & B). So conjoined 
cytoplasmic C-FABP and nuclear PPARγ expression may, together, have better prognostic 
value than each of the individual parameters. In contrast, no correlation was found between 
cytoplasmic or nuclear levels of PPARβ/δ and patient survival (Fig. 3.4, A&B). Increased 
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levels of PPARβ/δ were not significantly associated with increased Gleason scores. 
Therefore, PPARβ∕δ was not considered to be a suitable biomarker to assess the degree of 
malignancy in prostate cancer or a marker that would predict patients’ outcome. 
Results in this work also showed that the level of staining for PPARγ in the cytoplasm was 
also increased. Although this increase was not correlated with an increased GS, it was 
significantly associated with a shorter patients’ survival time. While the increase of C-FABP 
in the cytoplasm is significantly associated with GS or patients’ survival, the increased 
nuclear C-FABP is not significantly associated with either factor (Fig. 3.5, B). This result 
suggested that transporting fatty acids to PPARγ through C-FABP may be a short delivery 
process, after which C-FABP may return to the cytoplasm, rather than staying on the nuclear 
membrane. 
As a steroid hormone receptor, activated PPARγ should be theoretically localized in the 
nuclear membrane. However, many previous studies revealed that the cellular distribution of 
PPARγ was predominantly cytoplasmic in a number of cancer types 294-297. The reason for the 
cytoplasmic staining for PPARγ is not known and current opinions on this are inconsistent 298, 
299
. In line with previous study 
300, results in this work showed that the level of PPARγ 
expressed in the cytoplasm of prostatic carcinoma cells is significantly higher than that in 
BPH. More study is needed to understand the biological significance of the increase in 
cytoplasmic PPARγ and its interaction with C-FABP in prostate cancer cells. 
4.3 Suppression of PPARγ reduced the tumorigenicity of prostate cancer cells 
Troglitazone (classic PPARγ agonist) was shown to exhibit some levels of anticancer effect 
through PPARγ-independent pathways 82, 301. On the other hand although most TZDs are 
potent PPARγ agonists, they also have some degrees of affinity to PPARα or PPARβ/δ 302, 
303
. Moreover, it was shown that TZDs had inhibitory effects on cholesterol biosynthesis, 
independently from PPARγ-related pathways 304. Thus when assessing the possible key role 
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of PPARγ in the fatty acid-initiated signalling pathway, particularly its function on 
tumorigenicity, it is more appropriate to use RNAi gene knock down technique than using 
PPARγ antagonists suppression method due to their possible non-specific effects. Since the 
discovery of RNAi technique 
305
 , it has been used  to evaluate the biological activity of many 
genes in plants, fungi and animals 
306
. Previous studies revealed that RNAi could successfully 
silence the expression of genes in cancer cells and reduced subsequent protein expressions 
307, 
308
. In this work, RNAi was used to suppress the expression of PPARγ in highly malignant 
prostate cancer cells, PC3-M and the stablely PPARγ-suppressed PC3-M derived sub-lines 
were established (Fig. 3.15). Effects of PPARγ-suppression on proliferation rate, invasiveness 
and anchorage-independent growth of prostate cancer cells were evaluated by proliferation 
assay (Fig. 3.17) (Table 3.4), invasion assay (Fig. 3.18) (Table 3.5) and soft agar assay (Fig. 
3.19) (Table 3.6), respectively. Nude mice model was used to investigate the effect of 
PPARγ-suppression in tumorigenicity of prostate cancer cells, in vivo (Fig. 3.20-21) (Table 
3.7-8). Anchorage-independent growth, invasiveness and growth rate are three important 
criteria in tumorigenesis and capability of metastasis in cancer cells 
309
. Results of this work 
showed that suppression of PPARγ in highly malignant prostate cancer cells produced a 
significant reduction in growth rate (up to 55%), invasiveness (up to 90%) and anchorage-
independent growth (up to 95%). Furthermore, by inoculating the PPARγ-suppressed PC3-M 
cells into nude mice, it was shown that suppression of PPARγ in PC3-M cells could 
significantly reduce the sizes of tumours formed in nude mice by 99% in highly suppressed 
group and by 92% in moderately suppressed group. Tumour incidence was decrease by 30% 
in moderately suppressed group and by 90% in highly suppressed group. Latent period of 
those inoculated with highly suppressed group was significantly longer than in control (3.5-
fold). These results suggested that PPARγ played a determined role in tumour growth in nude 
mice. Similarly previous studies showed that suppression of C-FABP expression in PC3-M 
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cells significantly reduced invasiveness in vitro 
190
 and inhibited the tumorigenicity in vivo 
191
. Combining the results from this study and those of the previous studies suggested that C-
FABP and PPARγ may be functioning in a co-ordinated manner to promote the malignant 
progression of human prostate cancer cells. Thus the results obtained from this study support 
our original hypothesis 
191, 292, 310
. Understanding the detailed molecular mechanisms on how 
C-FABP and PPARγ co-ordinately functioning in prostate cancer cells may provide a novel 
opportunity for developing new therapeutic approaches to regulate the malignant phenotype 
and to switch prostatic cancer cells from an aggressive to indolent behaviour, as previously 
proposed 
311, 312
. 
4.4 C-FABP promoted biological activity of VEGF through PPARγ in  
         prostate cancer cells  
There are some evidences indicated that increased level of PPARγ in several cancers 
including breast, prostate, pancreas and colon carcinoma could stimulate angiogenesis 
through up-regulation of VEGF or other pro-angiogenic factors 
245, 247, 313, 314
. Moreover it has 
been shown that overexpression of the C-FABP gene in prostate cancer cells induced 
metastasis through up-regulation of the VEGF
189
; while suppression of C-FABP inhibited the 
tumorigenicity by decreasing VEGF expression in prostate cancer tissues
191
. Moderately 
malignant prostate cancer cells, 22RV1, which expresses low levels of C-FABP and PPARγ 
(Fig. 3.22) was used to study the effect of both C-FABP and PPARγ on the expression level 
of VEGF. 22RV1 cells were exposed to different treatments and then the expression level of 
VEGF was evaluated both in cell extracts (Fig. 3.23) and in the conditional media (for 
secreted VEGF) (Fig. 3.24). To find out whether the VEGF produced by the cancer cells is 
biologically active, the angiogenesis activity of secreted VEGF in conditional media was 
assessed by a HUVEC assay (Fig. 3.25-26). 
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As showed in Fig. 3.23, levels of VEGF in cell extracts were increased by 41% and 36% after 
the cells were treated with PPARγ agonist (Rosiglitazone) and wild type recombinant C-
FABP, respectively. After the same treatments, levels of secreted VEGF in conditional media 
were increased by 7.6-times and 6.3-times, respectively (Fig. 3.24). Treatments of prostate 
cancer cells with Rosiglitazone and C-FABP recombinant protein increased the angiogenesis 
activity of secreted VEGF in the conditional media by 2-fold and 1.8-fold, respectively (Fig. 
3.25-26). These increments can be blocked by the anti-VEGF antibody 
167
, indicating that the 
increased angiogenesis was the result of the increased VEGF production.  
On the other hand, after treating 22RV1 cells with PPARγ antagonist (GW9662) and 
recombinant double mutant C-FABP which is incapable of binding to fatty acids, levels of 
VEGF in cell extracts were reduced by 55% and 50%, respectively (Fig. 3.23). Similarly, in 
conditional media, they were reduced by 20% and 40%, respectively (Fig. 3.24). The 
angiogenesis activity of secreted VEGF was reduced by 70% after 22RV1 cells were treated 
by either GW9662 or double mutant recombinant C-FABP (Fig. 3.25-26). 
Further analysis showed that there was no significant difference between level of VEFG or 
angiogenesis index obtained by stimulation with PPARγ agonist and those with recombinant 
C-FABP. Similarly, differences between reduced level of VEGF obtained by treating the cells 
with GW9662 and that by double mutant recombinant C-FABP was not statistically 
significant.  
Like other FABPs, the biological function of C-FABP is to bind and to transport intracellular 
fatty acids into cells. When its fatty acid-binding motif was changed by mutating 2 of the 3 
key amino acids (double mutant C-FABP), it lost the ability of binding or transporting fatty 
acids 
167
. The result showed that stimulating 22RV1 cells with the wild type recombinant C-
FABP increased VEGF and angiogenesis activity, but when the cells were stimulated with the 
double mutated recombinant C-FABP which was deprived of fatty acid-binding ability, 
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reduced the level of VEGF and angiogenesis. These results indicated that the VEGF up-
regulation was produced by the increased cellular intake of large amount of fatty acids 
transported by the wild type recombinant C-FABP. When the ability of binding and 
transporting fatty acids was deprived, the double mutated recombinant C-FABP did not only 
incapable of inducing VEGF, it also blocked, at least partially, the biological activity of the 
wild type C-FABP and prevented its promotion on VEGF expression. Although it is not clear 
how C-FABP delivers fatty acids to their receptor and thus to activate the receptor, it is likely 
that the presence of an excessive amount of double mutated C-FABP may competitively 
inter-react with the fatty acid receptor to suppress the wild type C-FABP to deliver the fatty 
acids to their nuclear receptors and hence to prevent the down-stream activity. This result 
suggested that the double mutated recombinant C-FABP can act as an inhibitor to suppress 
the tumorigenicity-promoting activity of the wild type C-FABP. 
The results of this study also showed that like C-FABP, PPARγ agonist can promote the up 
regulation of VEGF and increase the angiogenesis, whereas the PPARγ antagonist can reduce 
the VEGF level of the cancer cells and suppress angiogenesis. This result suggested that the 
suppression of tumorigenicity of prostate cancer cells by knocking down PPARγ gene with 
RNAi was achieved through, at least partially, inhibiting the biological activity of VEGF. 
Thus up-regulating VEGF expression must be an immediate consequence of the PPARγ when 
it is activated by its legends, such as fatty acids which are transported by FABPs, particularly 
C-FABP in prostate cancer cells. The result also showed that the wild type C-FABP plus 
PPARγ antagonists could not induce the up-regulation of the VEGF expression, or in another 
word, the biological activity of C-FABP was blocked by the PPARγ antagonists. This result 
suggested that C-FABP promoted VEGF expression and angiogenesis by PPARγ (through 
the stimulation of the fatty acids transported by C-FABP). When PPARγ was blocked with its 
antagonists, it did not respond to stimulation signal produced by fatty acids, even when high 
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level of fatty acids was available. These results suggested that there is a C-FABP- PPARγ-
VEGF axis in prostate cancer which can facilitate the malignant progression of the cancer 
cells. Identification of this axis provided a novel target to suppress the malignant progression 
of prostate cancer cells. 
4.5 C-FABP-PPARγ up-regulated VEGF expression in prostate cancer cells via acting 
with the PPREs in the promoter region of VEGF gene 
The results in this study combined with the results in some of our previous studies suggested 
that large amount of fatty acids transported by the elevated level of C-FABP may stimulate 
and activate their nuclear receptor PPARγ which triggers a chain of molecular events that 
lead to the up-regulation of some down-stream cancer-promoting genes, and a major such 
gene is VEGF 
167, 168, 189, 190, 231
. Although it was demonstrated that androgen can mediate the 
up-regulation of VEGF expression in androgen-dependent cells through the Sp1/Sp3 binding 
site in VEGF core promoter 
236
, it was not previously known how PPARγ exactly up-
regulated VEGF in prostate cancer cells. Some studies showed that regulatory effect of 
PPARγ ligands on VEGF gene expression in human endometrial cells was modulated through 
PPREs in the promoter region of VEGF gene 
248
. Could PPARγ up-regulate VEGF 
expression and promote angiogenesis in prostate cancer cells through acting with the PPREs 
in the promoter region of VEGF gene, as it does in endometrial cells?  
To answer this question, a luciferase reporter gene system was employed to test the 
relationship between the presence or absence of PPRE and the level of VEGF expression 
when prostate cancer cells were treated with PPARγ agonists or antagonists. Although the 
promoter region of VEGF gene is relatively long and contains many sequences of PPREs, the 
efficiency in promoting the reporter gene expression generated by the full length (2274bp) 
and the efficiency produced by a truncated (790bp) segment of VEGF promoter region were 
very similar 
248
. Thus in this study, a truncated DNA segment containing 2 PPREs, rather 
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than the full-length of the promoter region, was used to assess whether PPARγ up-regulates 
VEGF gene through PPREs in promoter region. The pGL3-promoter-luciferase plasmid was 
used to make 3 reporter-gene constructs by ligating (to the up-stream of the 5’- end) 3 
different DNA fragments from the VEGF promoter region: Construct A (Wild type) 
containing a 805bp segment of VEGF promoter region which includes 2 PPREs; Construct B 
(Mutant1) containing a 805bp segment of DNA from the same region with both PPREs 
mutated;  and construct C (Mutant2) containing a 393bp sequence of DNA from VEGF 
promoter region in which both PPREs were deleted. Following cell lines were chosen to 
perform transient transfection experiments: 22RV1 cells, a moderately malignant cell line 
which expresses relatively low levels of C-FABP and PPARγ 110;  PC3-M cells, which 
expresses very high levels of C-FABP and PPARγ 5, 115; PC3-M-3 cells, a PC3-M-derived 
cell line established by knocking down C-FABP gene 
168
;  and PC3-M-PPARγ-si-H, a PC3-
M- derived cell line established by suppressing PPARγ expression (section 3.8.1).   
When Wild type and the control plasmids were co-transfected into the 22RV1 cells, which 
expressed low levels of PPARγ and C-FABP, and treated with PPARγ agonist 
(Rosiglitazone), the relative level of luciferase activity was significantly increased from 2.62 
to 4.25; whereas in cells transfected with other constructs which did not contain PPREs, the 
luciferase activity was not remarkably changed (Fig. 3.28, A). Similarly, when the co-
transfected highly malignant PC3-M cells, which expressed high levels of both PPARγ and 
C-FABP, were treated with a PPARγ antagonist (GW9662), the luciferase level was 
remarkably reduced to the level similar to that in Mutant1 transfectants or that in PPARγ-
suppressed cells (PC3-M-PPARγ-si-H).These results suggested that increased VEGF 
expression in prostate cancer cells was due to the interaction between PPARγ with the PPREs 
in VEGF promoter region to activate and up-regulate VEGF expression. 
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When the co-transfected 22RV1 cells (with control vector and Wild type, Mutant1 and 
Mutant2 plasmids, respectively) were treated with wild type recombinant C-FABP, the level 
of luciferase activity of the Wild type transfectants was increased by 62% (Fig. 3.29, A). No 
increment was observed in either Mutant1 or Mutant2 transfectants (Fig. 3. 29, A). This 
result suggested that C-FABP can promote VEGF expression only at the presence of PPREs. 
When the same transfectants were treated with the mutant C-FABP which is incapable of 
binding fatty acids, no increment was observed in any of the 3 transfectants. This result 
indicated that it was the fatty acids transported by C-FABP that activated PPARγ and up-
regulated VEGF through PPREs. This was further confirmed by the result that when C-FABP 
was knocking down (PC3-M-3 cells), the luciferase activity was reduced by 35% compared 
to the co-transfected PC3-M cells, as the suppressed C-FABP expression (Fig. 3.29, B). 
After treating 22RV1 co-transfectants (transfected with Wild type) with PPARγ agonist 
(Rosiglitazone) and recombinant C-FABP, levels of luciferase activity of VEGF promoter 
were increased by 60% and 55%, respectively (Fig. 3.30, A); while subjecting them to a 
combination of both treatments could only raise the level of luciferase activity to 65% (Fig. 
3.30, A). There was no significant difference between the level of luciferase activity obtained 
by combined PPARγ agonist and recombinant C-FABP treatment and that obtained by each 
of individual treatment. This result suggested that in 22RV1 cells expressing low levels of 
PPARγ and C-FABP, both PPARγ agonist and recombinant C-FABP can effectively increase 
VEGF expression. Alternatively, levels of luciferase activities in PC3-M co-transfectants 
(transfected with Wild type) treated with PPARγ antagonist (GW9662), the untreated PC3-
M-PPARγ-si-H co-transfectants (transfected with Wild type) and PC3-M-3 co-transfectants 
(transfected with Wild type) were reduced by 32.5%, 35% and 34%, respectively (Fig. 3.28, 
B) (Fig. 3.29, B). This result suggested that in PC3-M transfectant cells, which expressed 
high levels of both PPARγ and C-FABP, suppressing the biological activity of PPARγ by 
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either its antagonist or knocking down its mRNA by RNAi (as seen in PC3-M-PPARγ-si-H 
cells) can reduce the level of VEGF expression.   Furthermore, suppression of C-FABP 
expression in PC3-M cells can also reduce the level of VEGF (as seen in PC3-M-3). The 
difference between the level of luciferase activity in the untreated C-FABP-knockdown PC3-
M-3 cells and that in the cells treated with PPARγ antagonist was not significantly different. 
This result indicated that when VEGF was already reduced by suppressing C-FABP, little 
further reduction can be achieved by further treatment with PPARγ antagonist. Combined 
these results together, it is clear that both C-FABP and PPARγ may be involved in an 
identical signalling pathway which regulated VEGF promoter activity in prostate cancer cells. 
Based on these results, the detailed route of the proposed fatty acid-C-FABP-PPARγ-VEGF 
axis that leading to a facilitated malignant progression of the prostate cancer cells can be 
shown by following illustration (Fig. 4.1):  
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Figure  4.1: Schematic illustration of “C-FABP (fatty acids)-PPARγ-VEGF” axis.  
The excessive amount of intracellular fatty acids was transported by over-expressed C-FABP 
into the cancer cells to activate their nuclear receptors PPARγ which then up-regulated VEGF 
gene through acting with PPREs in the promoter region of VEGF. Secreted VEGF promoted 
angiogenesis by facilitating vasculature network formation (paracrine pathway). It also 
directly promoted tumorigenicity by stimulating VEGFR-2 (autocrine pathway).  
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4.6 Androgen regulated VEGF activity in androgen-dependant prostate cancer cells 
            through Sp1 (Androgen binding site) in promoter region of VEGF  
When 22RV1 cells were co-transfected with different constructs, Wild type, Mutant1 and 
Mutant2 produced increases in relative luciferase activities (Fig. 3.27) by 260%, 240%, and 
30%, respectively. The increment produced by Wild type was similar to that by Mutant1. 
Mutant1 or Mutant2 did not contain PPREs and luciferase activities did not change when the 
Mutant1 or Mutant2 transfectants were stimulated with PPARγ agonist (Rosiglitazone). Thus 
these increment caused by Mutant1 was not produced by the PPREs in the promoter region. 
This result suggested that there are some other elements, rather than PPREs, in the promoter 
region of the VEGF gene which can up-regulate VEGF expression in the 22RV1 prostate 
cancer cells. When PC3-M cells were transfected with different DNA constructs, both Wild 
type and Mutant1 produced increase in luciferase activity. While 3.3-fold increment was seen 
when Wild type was transfected, Mutant1 produced a 2-fold increase when compared with 
control. Mutant1 also produced some increments in PC3-M-PPARγ-si-H and PC3-M-3 
transfectants.  This result further confirmed that except PPREs, there are some other elements 
in the promoter region of VEGF gene that can modulate the VEGF expression in the highly 
malignant PC3-M cells (Fig. 3.27).  
The occurrence and development of prostate cancer has been related to the level of 
circulating male hormone. Thus androgen receptor played a key role in the carcinogenesis of 
prostate cells 
315-317
. Prostate cancer cells are generally sensible to the initial androgen 
blockade treatment, but in the majority of cases, cancer relapses in about 2 years after the 
initial androgen blockade therapy with a more aggressive form (named castration resistant 
prostate cancer) (CRPC). The growth and expansion of castration resistant prostate cancer 
does not completely depend on androgen supply anymore, but in large number of 
circumstances, continuation of androgen blockade therapy can still suppress the malignant 
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progression 
318, 319
. The molecular pathology involved in how the androgen-dependent cancer 
cells were transformed to androgen-independent or castration resistant cells is not fully 
understood. Currently several hypothesized mechanisms were proposed to explain this 
transition, and the most common theory to explain this transition is the androgen receptor 
(AR) sensitivity amplification theory 
320, 321
. This hypothesis proposed that when the cancer 
cells is deprived of androgen supply in the initial round of therapy, cells try to maximise their 
survival ability by increasing the sensitivity of AR to make use the small amount of androgen 
escaped from the blockage and thus some survived cells with an increased ability of using 
micro-quantity of androgen become dominant and castration resistant 
322, 323
. Some studies 
also suggested that mutations of AR gene could increase sensitivity to androgen stimulation 
324, 325
. Although each current theory can explain certain aspects of this complicated 
molecular pathology process, no single theory can satisfactorily explain every aspects of the 
process of transition in the cancer cells from androgen-dependent to androgen-independent 
form. For example, if AR amplification theory is true, then re-expression of AR in AR-
negative cells should increase the malignancy, but several studies on the highly malignant 
PC3 cells showed that the forced re-expression of AR in PC3 cells actually reduced the 
malignancy of cells 
326-328
. 
In previous study, an important molecular mechanism involved in VEGF regulation was the 
androgen-AR initiated Specificity-protein-1 or Specificity-protein-3 (Sp1/Sp3) pathways in 
androgen-dependent prostate cancer cells.  Sp1/Sp3 binding sites are located in the promoter 
region of VEGF and their regulatory effect on VEGF activity was shown in breast cancer 
235
, 
retinoblastoma cancer 
329
, bronchiolo-alveolar cancer 
330
 and pancreatic cancer 
331
. Oestrogen 
has been reported to up-regulate the expression of VEGF in breast cancer cells via acting 
with Sp1/Sp3 transcription sites in the core VEGF promoter 
235
. Similarly, androgen could 
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mediate the up-regulation of VEGF expression in androgen-dependent prostate cancer cells 
through Sp1/Sp3 binding sites in the VEGF core promoter region 
236
. 
To investigate the possible regulatory effect of Sp1 transcription binding site on VEGF 
activity in androgen-dependent prostate cancer cells in comparison with androgen-
independent cells, 22RV1 cells and PC3-M cells were transiently transfected with the three 
luciferase gene constructs. After treating 22RV1 co-transfectants (transfected with Wild type) 
with GW9662 and Mithramycin A, levels of luciferase activity were reduced by 21% and 
34%, respectively (Fig. 3.31, A). Comparing with GW9662, Mithramycin A produced more 
than 1.6-times reduction in luciferase activity. Subjecting them to a combination of both 
treatments could reduce the level of luciferase activity to only 36% (Fig. 3.32). Thus level of 
luciferase activity in 22RV1 co-transfectants significantly reduced after treating with Sp1 
inhibitor and PPARγ antagonist. These results indicated that in androgen-dependent 22RV1 
cells, both the C-FABP-PPARγ and the androgen-Sp1 pathways played important roles in up-
regulating the expression level of VEGF and the androgen-Sp1 route appeared to be even 
more important than the C-FABP-PPARγ route. Alternatively, when PC3-M co-transfectants 
(transfected with Wild type) was treated with the Sp1 inhibitor (Mithramycin A), the level of 
luciferase activity was hardly reduced by only 3% (Fig. 3.31, B). While level of luciferase 
activity in 22RV1 co-transfectants (transfected with Mutant1) was decreased by 51% after 
Mithramycin A treatment (Fig. 3.31, A); level in PC3-M co-transfectants (transfected with 
Mutant1) were only reduced by 15% after the same treatment (Fig. 3.31, B). While 
significant reduction in luciferase activity in PC3-M co-transfectants was achieved by 
GW9662 treatment (Fig. 3.28, B), no significant reduction was detected in the level of 
luciferase activity in PC3-M co-transfectants after treating with Sp1 inhibitor. These results 
suggested that in the androgen-independent PC3-M cells, the androgen-Sp1 pathway is not 
important anymore in up-regulating VEGF expression. The extremely high level of VEGF 
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expression in these cells was caused mainly through C-FABP-PPARγ route. It seemed that in 
the early stage of prostate cancer when the cancer cells are still responsive to androgen 
stimulation, the androgen-Sp1 pathway played a dominant role in promoting VEGF 
expression. As the cells gradually reduced their dependency on androgen supply and until 
ultimately loss responsive ability to androgen, the role of androgen-Sp1 pathway is gradually 
reduced and ultimately disappeared completely in AR-negative, androgen-independent cells 
(Fig. 4.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure  4.2: Schematic illustration of inter-relationship between androgen-Sp1/Sp3 and C-
FABP (fatty acids)-PPARγ signalling route in up-regulating VEGF in androgen-dependant 
and androgen-independent prostate cancer cells. 
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VEGF is a potent angiogenic factor which promotes vasculature formation of vessel network 
that is essential for growing and expansion of the cancer cells. VEGF can also directly 
promote malignancy of the cancer cells through an autocrine mechanism to simulate the 
receptor highly expressed on the surface of the prostate cancer cells (VEGFR-2)
332, 333
. Based 
on the results in this study and relevant results from other studies, I propose the following 
alternative hypothesis to explain the molecular mechanism involved in the crucial transition 
of the prostate cancer cells from androgen-dependant to androgen-independent state: When 
the cancer cells are deprived of androgen supply in the initial round of chemotherapy, the 
cells are desperate to seek for new sources of energy supply and under the heavy selection 
pressure, most of the cancer cells died due to starvation. However, some of the cancer cells 
may have survived under the heavy selection pressure by switching their reliance on 
androgen to fatty acids (transported by C-FABP) as an alternative energy source. These cells 
may be the so-called castration resistant cells. Although these cells can still use androgen, and 
although further androgen blockade will kill some more cells, it can also make some other 
cells more resistant to androgen deprivation by increasing and eventually, completely relying 
on fatty acids as their energy source. As the consequence of the increased demand of fatty 
acids and hence the high level of C-FABP during this process, the C-FABP-PPARγ-VEGF 
axis gradually increases its functional activity and eventually replace the androgen-Sp1/Sp3 
pathway to become the dominant route to promote further malignant progression. 
Consequentially, cancer cells will ultimately become totally androgen-independent after their 
androgen supply is repeatedly blocked. This hypothesis is further supported by the fact that a 
fatty acid synthase (FASN) greatly increased in prostate cancer cells 
334-337
. Based on this 
alternative hypothesis, disrupting the C-FABP-PPARγ-VEGF axis and cutting off the 
alternative energy supply of the cancer cells, rather than only blocking the last drop of 
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androgen, should be the correct way to kill the AR-negative androgen-independent cancer 
cells.  
4.7 Conclusion 
Based on the data achieved in this study, several important finding have been established: 
1- Overexpression of C-FABP and PPARγ in highly malignant prostate cancer cells and 
poorly differentiated tissues suggest that increased C-FABP may interact with PPARγ in a co-
ordinated mechanism to facilitate malignant progression in prostate carcinoma. 
2- Association the elevated levels of C-FABP and PPARγ with shorten patient survival and 
related statistical studies suggest that prognostic value of PPARγ is dependent to C-FABP in 
prostate carcinomas and they may employ as prognostic biomarkers in prostatic cancer 
patients. 
3- Suppression of PPARγ can inhibit the growth rate, invasiveness and anchorage-
independent growth in prostate cancer cells, in vitro. 
4- Suppression of PPARγ expression can reduced the incidence, volume and growth rate of 
prostate carcinoma in vivo which suggested that PPARγ can be used as a therapeutic target in 
prostate cancer.  
5- Both C-FABP and PPARγ regulate the VEGF expression and biological activity in 
prostate cancer in co-ordinated manner; which suggest that may be both C-FABP and PPARγ 
are involved in the same signalling network which integrated in the regulation of the VEGF 
activity in prostate cancer cells. 
6- C-FABP-PPARγ axis affects on VEGF promoter activity through PPRE elemants in 
prostate cancer cells. Although regulatury effects of androgen on VEGF activity has been 
shown to undergo through Sp1/Sp3 on VEGF promoter in androgen-dependent prostate 
cancer cells, it has been suggested that C-FABP-PPARγ axis may compensate this role in 
androgen-independent prosate carcinoma. 
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Last but not least, it was suggested that C-FABP, together with fatty acids, PPARγ and 
VEGF should be considered as key factors in a proposed fatty acid signalling pathway that 
promotes metastasis of prostatic cancer cells. Therefore, the C-FABP-PPARγ axis may be a 
novel therapeutic target for prostatic cancer. 
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6.1 APPENDIX A: REAGENTS 
 
Reagents                                                                             Supplier 
……………………………………………………………..………………….… 
6.1.1 Reagents for cell culture 
DMSO Sigma-Aldrich, Germany 
Foetal calf serum Biosera, East Sussex, UK 
L-Glutamine Lonza, Belgium 
Opti-MEM I medium Gibco, Invitrogen, Paisley, UK 
Penicillin/ Streptomycin Lonza, Belgium 
Phosphate buffered saline (tablet) Gibco, Invitrogen, Paisley, UK 
RPMI 1640 PAA, Pasching, Austria 
Sodium pyruvate   Sigma, USA 
Trypsin Gibco, Invitrogen, Paisley, UK 
Versene Gibco, Invitrogen, Paisley, UK 
X-tremeGENE HP DNA Transfection Reagent Roche, Germany 
X-tremeGENE siRNA Transfection Reagent Roche, Germany 
Zeocin    Invitrogen, CA, USA 
6.1.2 Reagents for Western blot 
β-mercaptoethanol Sigma, USA 
Ammonium persulfate (APS) Sigma, USA 
Bradford reagent Sigma, USA 
Bromophenol blue Sigma, USA 
CelLytic-M Sigma, USA 
Coomassie brilliant blue Bio-Rad GmbH, Munchen, Germany 
ECL detection kit GE Healthcare, Buckinghamshire, UK 
Glycine Melford, UK 
Kodak Developer Sigma, USA 
Kodak film GE Healthcare, Buckinghamshire, UK 
Kodak Fixer Sigma, USA 
Methanol Fisher scientific, Loughborough, UK 
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Reagents                                                                            Supplier 
……………………………………………………………..………………….… 
Next Gel 12.5% Amresco, OH, USA 
Ponceau S solution Sigma, USA 
PVDF membrane (Immobilon-P) Millipore, USA 
TEMED (NNN’N’-tetramethylethylenediamine) Sigma, USA 
Tris base ultrapure Melford, UK 
Tween-20 Sigma-Aldrich, Germany 
6.1.3 Reagents for Immunohistochemistry 
Acetone Sigma, USA 
DPX    Bios, Lancashire, UK 
EDTA Sigma, USA 
EnVision
TM
 FLEX/DAB+ Chromogen DakoCytomation, Ely, UK   
EnVision
TM
 FLEX/HRP DakoCytomation, Ely, UK 
Ethanol (IMS) GENTA, Tockwith, UK 
Formaldehyde Sigma, USA 
Haematoxylin   Sigma, USA 
Hydrogen peroxide 30% (w/w) BDH, England, UK 
Linker (Anti-gout IgG) (AI 5000) Vector, USA 
Scott’s tap water Sigma, USA 
Sodium citrate   Sigma, USA 
Sodium chloride Melford, UK 
Tris base ultrapure Melford, UK 
Tween-20   Sigma-Aldrich, Germany 
Xylene   GENTA, Tockwith, UK 
6.1.4 Reagents for RT-PCR 
dNTPs Thermo scientific, UK 
DTT Invitrogen, Paisley, UK 
Oligo (dT)20 Agilent Technologies, CA, USA 
PCR primers Invitrogen, Paisley, UK 
Platinum 
®
PCR SuperMix High Fidelity Invitrogen, Paisley, UK 
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Reagents                                                                          Supplier 
……………………………………………………………..………………….… 
QIAGEN RNeasy Mini Kit   QIAGEN, CA, USA 
SuperScript II Reverse Transcriptase Agilent Technologies, CA, USA 
5× First strand buffer Agilent Technologies, CA, USA 
6.1.5 Reagents for general molecular biology 
Ampicillin Sigma, USA 
Absolute ethanol BDH, England, UK 
Agarose Genflow, Fradley, UK 
DNA marker III Roche, England, UK 
DNA marker XIV Roche, England, UK 
E. coli GT116 cell InvivoGen, USA 
Glucose Sigma, USA 
Glycerol Sigma, USA 
Isopropanol BDH, England, UK 
LB agar Sigma, USA 
LB broth Sigma, USA 
Magnesium chloride Sigma, USA 
Magnesium sulphate Sigma, USA 
MOPS Sigma, USA 
psiRNA-h7SKGFPzeo plasmid   InvivoGen, USA 
QIAGEN Plasmid midi-preparation kit   QIAGEN, CA, USA 
QIAGEN Plasmid mini-preparation kit    QIAGEN, CA, USA 
Restriction enzymes New England BioLabs, MA, USA 
Restriction enzymes buffers New England BioLabs, MA, USA 
Safe View (Nucleic Acid Stain) NBS Biological, Cambridgeshire, UK 
Tryptone Sigma, USA 
Wizard
®
 DNA Clean-Up System Promega, WI, USA 
Yeast extract Fisher scientific, Loughborough, UK 
Zeocin   Invitrogen, CA, USA 
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Reagents                                                                          Supplier 
……………………………………………………………..………………….… 
6.1.6 Reagents for cell proliferation assay 
MTT Sigma, USA 
6.1.7 Reagents for cell invasion assay 
Crystal violet Sigma, USA 
6.1.8 Reagents for soft agar assay  
Low melting point agarose Genflow, Fradley, UK 
MTT Sigma, USA 
6.1.9 Reagents for measurement of VEGF 
Charcoal stripped FCS Gibco, Invitrogen, Paisley, UK 
Human VEGF ELISA Kit RayBiotech, GA, USA 
Phenol red-free RPMI 1640 Gibco, Invitrogen, Paisley, UK 
Recombinant Human VEGF RayBiotech, GA, USA 
TMB RayBiotech, GA, USA 
6.1.10 Reagents for in vitro angiogenesis assay 
EndoGRO basal medium Millipore, USA 
EndoGRO LS supplement kit Millipore, USA 
In Vitro Angiogenesis Assay Kit Millipore, USA 
MTT Sigma, USA 
Recombinant Human VEGF RayBiotech, GA, USA 
6.1.11 Reagents for dual luciferase reporter assay 
Dual Luciferase Reporter Kit Promega, WI, USA 
GW9662 Sigma, USA 
Mithramycin A Sigma, USA 
Rosiglitazone Sigma, USA 
X-treme GENE HP DNA Transfection Reagent Roche, Germany   
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6.2 APPENDIX B: BUFFERS 
6.2.1 Cell Culture 
Routine cell culture medium 
RPMI medium 1640                            500ml 
Foetal calf serum                                 10% (v/v) 
Pen-Strep (5000 U/ml)                         5ml 
L-Glutamine (20mM)                           5ml 
Sodium pyruvate (100mM)                  5ml 
 
Selective medium 
Routine medium with Zeocin
TM
 (100μg/ml) 
 
Culture medium for evaluation the expression level of VEGF 
Phenol red-free RPMI 1640 medium    500ml 
Charcoal stripped FCS                          5% (v/v)  
Pen-Strep (5000 U/ml)                          5ml 
L-Glutamine (20mM)                           5ml 
 
Culture medium for HUVEC cells (angiogenesis assay) 
EndoGRO basal medium                      500ml 
EndoGRO LS supplement kit 
Charcoal stripped FCS                          5% (v/v)  
 
Freezing medium 
Routine cell culture medium              92.5% (v/v) 
DMSO                                                  7.5% (v/v) 
 
Trypsin/EDTA solution (T/E) (2.5%) 
1× Versene                                           100ml 
Trypsin                                                  2.5ml 
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MTT solution (5mg/ml) 
MTT                                                50mg 
PBS                                                 10ml 
 
PBS 
PBS                                           one tablet 
dH2O                                               500ml  
Autoclaved 
 
6.2.2 Western Blot 
1M Tris pH 6.8 
Tris base                                         12.1gr 
dH2O                                              100ml 
pH adjusted with HCl      
 
10% (w/v) SDS solution 
Sodium Dodecyl Sulfate                 10gr 
dH2O                                             100ml   
 
10% (w/v) APS solution 
Ammonium persulfate                    100mg 
dH2O                                                   1ml 
 
2× SDS-PAGE sample loading buffer (SLB) 
1M Tris-HCl (pH 6.8)                     2.5ml 
Glycerol 40% (v/v)                            4ml 
Bromophenol blue 0.5% (w/v)       0.8ml 
SDS 10%                                           2ml 
β-mercaptoethanol                          0.5ml 
dH2O                                               4.7ml 
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5× SDS-PAGE sample loading buffer (SLB) 
1M Tris-HCl (pH 6.8)                   1.25ml 
Glycerol 40% (v/v)                          15ml 
Bromophenol blue 0.5% (w/v)       2.5ml 
SDS 10%                                           5ml 
β-mercaptoethanol                        1.25ml 
 
Transfer buffer (pH 8.3) 
Glycine                                         14.4g (192mM) 
Methanol                                        20% (v/v) 
Tris base                                       3.03g (25mM) 
dH2O                                       up to 1Lit 
pH adjusted with HCl      
 
10× TBS buffer (pH 7.6) 
Sodium chloride                           87.66gr (1500mM) 
Tris base                                       60.58gr (500mM) 
dH2O                                         up to 1 Lit 
pH adjusted with HCl      
Autoclaved     
 
1×TBS-Tween 1%  
10× TBS buffer                             100ml 
Tween 20                                          1ml 
dH2O                                      up to 1 Lit 
 
TBS-T-milk 5% (protoblock) 
Dried milk                                        5gr 
1×TBS-T                                      100ml   
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6.2.3 Immunohistochemistry  
Hydrogen peroxide-Methanol solution 
Hydrogen peroxide 30% (w/w)    12ml 
Methanol                                     400ml  
 
Sodium citrate buffer (10mM)   
Tris sodium citrate                 29.41gr 
dH2O                                up to 10 Lit      
pH 6; adjusted with HCl   
 
EDTA buffer (pH 7) 
EDTA                                        37.2gr 
Sodium hydroxide                       3.2gr 
dH2O                                  up to 10 Lit 
 
TBS-Tween 5% 
Sodium chloride                            87.66gr (1500mM) 
Tris base                                         60.58gr (500mM)  
Tween 20                                            5ml 
dH2O                                       up to 10 Lit      
pH adjusted with HCl   
 
Acid/alcohol 1%    
HCl                                                 20ml 
IMS                                             1400ml 
dH2O                                               60ml 
 
Scott’s tap water 
MgSO4                                           20gr 
NaHCO3                                                            3.5gr 
dH2O                                     up to 1 Lit    
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6.2.4 Molecular Biology   
LB medium 
LB broth                                     20gr 
dH2O                                          1 Lit 
Autoclaved   
 
LB agar 
LB agar                                      35gr 
dH2O                                          1 Lit 
Autoclaved   
 
RF 1 buffer (pH 5.8) 
KCl                                         7.456gr (100mM) 
MgCl2.4H2O                              9.9gr (50mM) 
K-acetate                                  2.94gr (30mM) 
CaCl2                                         1.5gr (10mM)  
Glycerol (v/v)                          150ml (15%) 
dH2O                                up to 1 Lit 
Adjust the pH and sterilized by filtration 
 
RF 2 buffer (pH 6.8) 
MOPS                                     2.1gr (10mM)  
KCl                                     0.745gr (10mM) 
CaCl2                                        11gr (75mM) 
Glycerol (v/v)                        150ml (15%)                                        
dH2O                                up to 1 Lit 
Adjust the pH and sterilized by autoclave 
Glucose 20% 
Glucose                                   20gr 
dH2O                                      10ml 
Sterilized by filtration 
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Magnesium salt solution (2M) 
MgCl2                                2.033gr (1M) 
MgSO4                               2.465gr (1M) 
dH2O                                  10ml 
Sterilized by filtration 
 
SOB medium (pH 7) 
Tryptone                                20gr 
Yeast extracts                          5gr 
NaCl                                     0.5gr 
KCl                                   0.186gr 
dH2O                                up to 1 Lit 
Adjust the pH and sterilized by autoclave 
 
SOC medium 
SOB medium                   4.850ml 
Mg
2+
 salt solution (2M)       50µl 
Glucose 20%                      150µl 
 
Stock medium for bacteria 
Glycerol                               5ml 
LB medium                         4ml 
Bacteria culture                   3ml 
 
10× TBE stock solution  
Tris base                                108gr (890mM)  
Boric acid                                55gr (890mM) 
EDTA 0.5M, pH 8                  40ml (20mM) 
dH2O                              up to 1 Lit 
Adjust the pH and sterilized by autoclave 
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50× TBE stock solution  
Tris base                                242gr  
Glacial Acetic Acid              57.1gr  
EDTA 0.5M, pH 8                100ml  
dH2O                              up to 1 Lit 
Adjust the pH and sterilized by autoclave 
 
TE buffer (pH 7.6) 
Tris-HCl                          1.21gr (10mM) 
EDTA                            0.3722gr (1mM) 
dH2O                                up to 1 Lit 
Adjust the pH and sterilized by autoclave 
 
6×DNA loading buffer 
Bromophenol blue 0.5%                  0.5ml    
Xylene cyanol FF                            0.5ml 
Glycerol in sterile dH2O (60%)          1ml 
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6.3 APPENDIX C: EQUIPMENTS 
AccuWeigh, WA, USA 
Portable Lab Scale 
 
BD Microlance 3, Ireland  
Needle 
Syringes 
 
BD Biosciences, USA   
BD BioCoat
TM
 Growth Factor Reduced (GFR) Matrigel
TM
 Invasion Chamber 
                                                                           
BD Plastics, Sunderland, UK  
Syringes   
                                                                           
Beckman coulter, UK 
Microcentrifuge 
 
Becton Dikinson, USA                                                                                                                        
Falcon 2059 tube  
                                                             
Berthold detection system, Germany 
Sirius Luminometer  
 
Bio-Rad, Hemel, UK                                            
Gel electrophoresis rig  
Mini-protein 3 cell system                                                 
 
BioTec, Brigend, UK  
Spectrophotometer                                                             
                                           
Borolabs, Basingstoke, UK  
CO2 incubator Model TC2323 
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Flowgen, Nottingham, UK  
Gel drier 
Generier bio-one, UK 
Tissue culture pipettes (5-50 ml) 
Universal tube 
 
Grant Instruments, UK 
Water bath 
 
GMI, MJ Research, MN, USA 
Thermal cycler (Peltier Thermal Cycler PTC-200) 
 
Heraeus Holding GmbH, Germany 
Labofuge 400R (centrifuge)                                                                   
 
Labsystem, Finland 
Multiskan MS (plate reader)    
                                                                
Labtech International, Ringmer, UK  
NanoDrop spectrophotometer 
                                 
Leica, Germany  
Superior Adhesive slide                                                      
 
Leitz Labovert, Luton, UK  
Light microscope  
                                                             
Microm, Oxford, UK 
Microtome HM355                                                                       
                                                                      
Millipore, UK                                              
Immobilon, Transfer membrane                                       
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Nalgene, UK                                         
Cryobox DNA  
 
Nunc, Denmark 
Cell culture filter cap flasks   
Cell culture plates  
Cryogenic vial 
 
OXFORD OPTRONIX, Oxford, UK 
GelCount 
 
QIAGEN, Crawley, UK  
Qiagen tip                                                                         
QIA Shredder spin column 
                                                 
Shandon, UK 
Sequenza slide rack  
Coverslip (20×40mm) 
 
SLS Ltd., Nottingham, UK 
Haemocytometer 
Magnificent stirrer 
 
Starlab, Milton Keynes, UK 
Microtubes  
Pipette tips                                                                                                                                              
 
Surgipath, UK  
Microslide 
Tissue cassette                                                                    
                                                           
Swann-Morton, Sheffeild, UK 
Carbon steel surgical blades 
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Techne, England, UK                                                          
Hot plate (Ori-Block 08-3) 
 
Whatman, England, UK  
Whatman filter paper 
 
Weber scientific International, NJ, USA 
Haemocytometer slide                                                          
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6.4 APPENDIX D: LUCIFERASE CONSTRUCTS SEQUENCES 
 
Wild type 
       
5’         GGTACCACTTTGATGTCTGCAGGCCAGATGAGGGCTCCAGATGGCACATTGTCAG 
AGGGACACACTGTGGCCCCTGTGCCCAGCCCTGGGCTCTCTGTACATGAAGCAACTCCAG
TCCCAAATATGTAGCTGTTTGGGAGGTCAGAAATAGGGGGTCCAGGAGCAAACTCCCCC
CACCCCCTTTCCAAAGCCCATTCCCTCTTTAGCCAGAGCCGGGGTGTGCAGACGGCAGTC
ACTAGGGGGCGCTCGGCCACCACAGGGAAGCTGGGTGAATGGAGCGAGCAGCGTCTTCG
AGAGTGAGGACGTGTGTGTCTGTGTGGGTGAGTGAGTGTGTGCGTGTGGGGTTGAGGGC
GTTGGAGCGGGGAGAAGGCCAGGGGTCACTCCAGGATTCCAATAGATCTGTGTGTCCCT
CTCCCCACCCGTCCCTGTCCGGCTCTCCGCCTTCCCCTGCCCCCTTCAATATTCCTAGCAA
AGAGGGAACGGCTCTCAGGCCCTGTCCGCACGTAACCTCACTTTCCTGCTCCCTCCTCGC
CAATGCCCCGCGGGCGCGTGTCTCTGGACAGAGTTTCCGGGGGCGGATGGGTAATTTTCA
GGCTGTGAACCTTGGTGGGGGTCGAGCTTCCCCTTCATTGCGGCGGGCTGCGGGCCAGGC
TTCACTGAGCGTCCGCAGAGCCCGGGCCCGAGCCGCGTGTGGAAGGGCTGAGGCTCGCC
TGTCCCCGCCCCCCGGGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGAGCCATGCGCC
CCCCCCTTTTTTTTTTAAAAGTCGGCTGGTAGCGGGGAGGCTCGAG        3’   
Mutant1  
        
5’       GGTACCACTTTGATGTCTGCATGCATGATGAGGGCTCCAGATGGCACATTGTCAGA 
GGGACACACTGTGGCCCCTGTGCCCAGCCCTGGGCTCTCTGTACATGAAGCAACTCCAGT
CCCAAATATGTAGCTGTTTGGGAGGTCAGAAATAGGGGGTCCAGGAGCAAACTCCCCCC
ACCCCCTTTCCAAAGCCCATTCCCTCTTTAGCCAGAGCCGGGGTGTGCAGACGGCAGTCA
CTAGGGGGCGCTCGGCCACCACAGGGAAGCTGGGTGAATGGAGCGAGCAGCGTCTTCGA
GAGTGAGGACGTGTGTGTCTGTGTGGGTGAGTGAGTGTGTGCGTGTGGGGTTGAGGGCG
TTGGAGCGGGGAGAATGCATGGGGTCACTCCAGGATTCCAATAGATCTGTGTGTCCCTC
TCCCCACCCGTCCCTGTCCGGCTCTCCGCCTTCCCCTGCCCCCTTCAATATTCCTAGCAAA
GAGGGAACGGCTCTCAGGCCCTGTCCGCACGTAACCTCACTTTCCTGCTCCCTCCTCGCC
AATGCCCCGCGGGCGCGTGTCTCTGGACAGAGTTTCCGGGGGCGGATGGGTAATTTTCAG
GCTGTGAACCTTGGTGGGGGTCGAGCTTCCCCTTCATTGCGGCGGGCTGCGGGCCAGGCT
TCACTGAGCGTCCGCAGAGCCCGGGCCCGAGCCGCGTGTGGAAGGGCTGAGGCTCGCCT
GTCCCCGCCCCCCGGGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGAGCCATGCGCCC
CCCCCTTTTTTTTTTAAAAGTCGGCTGGTAGCGGGGAGGCTCGAG        3’ 
Mutant2 
 
5’        GGTACCCGTCCCTGTCCGGCTCTCCGCCTTCCCCTGCCCCCTTCAATATTCCTAGCA 
AAGAGGGAACGGCTCTCAGGCCCTGTCCGCACGTAACCTCACTTTCCTGCTCCCTCCTCG
CCAATGCCCCGCGGGCGCGTGTCTCTGGACAGAGTTTCCGGGGGCGGATGGGTAATTTTC
AGGCTGTGAACCTTGGTGGGGGTCGAGCTTCCCCTTCATTGCGGCGGGCTGCGGGCCAGG
CTTCACTGAGCGTCCGCAGAGCCCGGGCCCGAGCCGCGTGTGGAAGGGCTGAGGCTCGC
CTGTCCCCGCCCCCCGGGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGAGCCATGCGC
CCCCCCCTTTTTTTTTTAAAAGTCGGCTGGTAGCGGGGAGGCTCGAG      3’ 
 
Sequence map of three constructs based on human VEGF promoter 
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